



Swiss Society of Addiction Medicine
Schweizerische Gesellschaft für Suchtmedizin
Société Suisse de Médecine de l'Addiction
Società Svizzera di Medicina delle Dipendenze

Anhang zu „Medizinische Empfehlungen für substitutionsgestützte Behandlungen (SGB) bei Opioidabhängigkeit“

Referenzen

1. Effect of corticosteroids for fetal maturation on perinatal outcomes. NIH Consens Statement 1994; 12(2):1-24
2. Ritonavir (Norvir) and methadone. *Treat Rev* 1998; (No 28):15
3. Migration und Gesundheit, Perspektiven für Gesundheitssysteme und öffentliches Gesundheitswesen. Düsseldorf: Akademie für öffentliches Gesundheitswesen in Düsseldorf; 2000.
4. Stratégies thérapeutiques pour les personnes dépendantes des opiacés : place des traitements de substitution [Therapeutic strategies for opioid addiction: the role of substitution therapy]. *Presse Med* 2004; 33(18 Suppl):41-7
5. Torsades de pointes with methadone. *Prescrire Int* 2005; 14(76):61-2
6. Increase in poisoning deaths caused by non-illicit drugs—Utah, 1991-2003. *MMWR Morb Mortal Wkly Rep* 2005; 54(2):33-6
7. Buprenorphine replacement therapy: a confirmed benefit. *Prescrire Int* 2006; 15(82):64-70
8. Definition Gesundheit WHO. WHO. 2006.
9. Abdel-Latif ME, Pinner J, Clews S, Cooke F, Lui K, Oei J. Effects of breast milk on the severity and outcome of neonatal abstinence syndrome among infants of drug-dependent mothers. *Pediatrics* 2006; 117(6):e1163-e1169
10. Adelson M, Peles E, Bodner G, Kreek MJ. Correlation between high methadone doses and methadone serum levels in methadone maintenance treatment (MMT) patients. *J Addict Dis* 2007; 26(1):15-26
11. Agar M, Reisinger HS. A tale of two policies: the French connection, methadone, and heroin epidemics. *Cult Med Psychiatry* 2002; 26(3):371-96
12. Akerele EO, Levin F, Nunes E, Brady R, Kleber H. Effects of HIV triple therapy on methadone levels. *Am J Addict* 2002; 11(4):308-14
13. Al-Adwani A, Basu N. Methadone and excessive sweating. *Addiction* 2004; 99(2):259
14. Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM. What clinicians should know about the QT interval. *JAMA* 2003; 289(16):2120-7
15. Alexandre PK, Salome HJ, French MT, Rivers JE, McCoy CB. Consequences and costs of closing a publicly funded methadone maintenance clinic. *Social-science-quarterly* 2002; 83(2):519-36

16. Alford DP, Compton P, Samet JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. *Ann Intern Med* 2006; 144(2):127-34
17. Alford DP, LaBelle CT, Richardson JM, O'Connell JJ, Hohl CA, Cheng DM, Samet JH. Treating homeless opioid dependent patients with buprenorphine in an office-based setting. *J Gen Intern Med* 2007; 22(2):171-6
18. Alho H, Sinclair D, Vuori E, Holopainen A. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. *Drug Alcohol Depend* 2007; 88(1):75-8
19. Almeghi A, Malas AM, Yousufuddin M, Rosencrance JG. Methadone-induced torsade de pointes in a patient with normal baseline QT interval. *W V Med J* 2004; 100(4):147-8
20. Alonzo NC, Bayer BM. Opioids, immunology, and host defenses of intravenous drug abusers. *Infect Dis Clin North Am* 2002; 16(3):553-69
21. Alter MJ. Epidemiology of hepatitis C. *Hepatology* 1997; 26(3 Suppl 1):62S-5S
22. Alterman AI, Mulvaney FD, Cacciola JS, Cnaan A, McDermott PA, Brown LS, Jr. The validity of the interviewer severity ratings in groups of ASI interviewers with varying training. *Addiction* 2001; 96(9):1297-305
23. Altice FL, Sullivan LE, Smith-Rohrberg D, Basu S, Stancliff S, Eldred L. The Potential Role of Buprenorphine in the Treatment of Opioid Dependence in HIV-Infected Individuals and in HIV Infection Prevention. *Clin Infect Dis* 2006; 43 Suppl 4:S178-S183
24. Amass L, Bickel WK, Higgins ST, Badger GJ. Alternate-day dosing during buprenorphine treatment of opioid dependence. *Life Sci* 1994; 54(17):1215-28
25. Amass L, Bickel WK, Crean JP, Higgins ST, Badger GJ. Preferences for clinic privileges, retail items and social activities in an outpatient buprenorphine treatment program. *J Subst Abuse Treat* 1996; 13(1):43-9
26. Amass L, Bickel WK, Crean JP, Blake J, Higgins ST. Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans. *Psychopharmacology (Berl)* 1998; 136(3):217-25
27. Amass L, Ling W, Freese TE, Reiber C, Annon JJ, Cohen AJ, McCarty D, Reid MS, Brown LS, Clark C, Ziedonis DM, Krejci J, Stine S, Winhusen T, Brigham G, Babcock D, Muir JA, Buchan BJ, Horton T. Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. *Am J Addict* 2004; 13 Suppl 1:S42-S66
28. Amato L, Minozzi S, Davoli M, Vecchi S, Ferri M, Mayet S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. *Cochrane Database Syst Rev* 2004; (4):CD005031
29. Amato L, Minozzi S, Davoli M, Vecchi S, Ferri M, Mayet S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. *Cochrane Database Syst Rev* 2004; (4):CD004147
30. Amato L, Davoli M, Minozzi S, Ali R, Ferri M. Methadone at tapered doses for the management of opioid withdrawal. *Cochrane Database Syst Rev* 2005; (3):CD003409
31. Amato L, Davoli M, Perucci A, Ferri M, Faggiano F, Mattick P. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. *J Subst Abuse Treat* 2005; 28(4):321-9
32. AMERICAN ACADEMY OF PEDIATRICS CoD. The Transfer of Drugs and Other Chemicals Into Human Milk. *Pediatrics* 2001; 108(3):776-89

33. Andersen HT. Regelmessig forskrivning av A- og B-preparater til rusavhengige i allmennpraksis [Regular prescription of narcotics and sedatives to drug-addicted patients in general practice]. *Tidsskr Nor Laegeforen* 2002; 122(12):1202-4
34. Anderson IB, Kearney TE. Use of methadone. *West J Med* 2000; 172(1):43-6
35. Anderson ME, Al-Khatib SM, Roden DM, Califf RM. Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. *Am Heart J* 2002; 144(5):769-81
36. Andersson P, Eisemann M. Parental rearing and individual vulnerability to drug addiction: a controlled study in a Swedish sample. *Nord J Psychiatry* 2003; 57(2):147-56
37. Andresz V, Marcantoni N, Binder F, Velten M, Alt M, Weber JC, Stephan D. Puffy hand syndrome due to drug addiction: a case-control study of the pathogenesis. *Addiction* 2006; 101(9):1347-51
38. Anglin MD, Kao CF, Harlow LL, Peters K, Booth MW. Similarity of behavior within addict couples. Part I. Methodology and narcotics patterns. *Int J Addict* 1987; 22(6):497-524
39. Anglin MD, Booth MW, Kao CF, Harlow LL, Peters K. Similarity of behavior within addict couples. Part II. Addiction-related variables. *Int J Addict* 1987; 22(7):583-607
40. Anglin MD, Hser YI, Booth MW. Sex differences in addict careers. 4. Treatment. *Am J Drug Alcohol Abuse* 1987; 13(3):253-80
41. Anglin MD, Ryan TM, Booth MW, Hser YI. Ethnic differences in narcotics addiction. I. Characteristics of Chicano and Anglo methadone maintenance clients. *Int J Addict* 1988; 23(2):125-49
42. Anglin MD, Booth MW, Ryan TM, Hser YI. Ethnic differences in narcotics addiction. II. Chicano and Anglo addiction career patterns. *Int J Addict* 1988; 23(10):1011-27
43. Anglin MD, Speckart GR, Booth MW, Ryan TM. Consequences and costs of shutting off methadone. *Addict Behav* 1989; 14(3):307-26
44. Arroyo E, Valenzuela B, Portilla J, Climent-Grana E, Perez-Ruixo JJ, Merino E. Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily. *Eur J Clin Pharmacol* 2007;
45. Ashwath ML, Ajjan M, Culclasure T. Methadone-induced bradycardia. *J Emerg Med* 2005; 29(1):73-5
46. Assadi SM, Hafezi M, Mokri A, Razzaghi EM, Ghaeli P. Opioid detoxification using high doses of buprenorphine in 24 hours: a randomized, double blind, controlled clinical trial. *J Subst Abuse Treat* 2004; 27(1):75-82
47. Ator NA, Griffiths RR, Weerts EM. Self-injection of flunitrazepam alone and in the context of methadone maintenance in baboons. *Drug Alcohol Depend* 2005; 78(2):113-23
48. Auriacombe M, Notz N, Franques P. Neuroelectric stimulation for the management of opioid withdrawal. Auriacombe M, Notz N, Franques P Neuroelectric stimulation for the management of opioid withdrawal The Cochrane Database of Systematic Reviews : Protocols 2001 Issue 1 John Wiley & Sons, Ltd Chichester, UK DOI : 10.1002/14651858.CD003025 2001;
49. Auriacombe M, Fatseas M, Dubernet J, Daulouede JP, Tignol J. French field experience with buprenorphine. *Am J Addict* 2004; 13 Suppl 1:S17-S28
50. Avants SK, Margolin A, Kosten TR, Rounsaville BJ, Schottenfeld RS. When is less treatment better? The role of social anxiety in matching methadone patients to psychosocial treatments. *Journal of consulting and clinical psychology* 1998; 66:924-31

51. Axelrod DJ, Reville B. Using methadone to treat opioid-induced hyperalgesia and refractory pain. *J Opioid Manag* 2007; 3(2):113-4
52. Baker JR, Best AM, Pade PA, Cance-Katz EF. Effect of Buprenorphine and Antiretroviral Agents on the QT Interval in Opioid-Dependent Patients. *Ann Pharmacother* 2006; 40(3):392-6
53. Baker R, Bowers M. Ritonavir and ecstasy. *BETA* 1997; :5::5
54. Bakker A, Fazey C. Methadone tolerance testing in drug misusers. *BMJ* 2006; 333(7577):1056-9
55. Ball JC, Ross A. *The Effectiveness of Methadone Maintenance Treatment: Patients, Programs, Services, and Outcome*. Springer; 1991.
56. Ballard JL. Treatment of neonatal abstinence syndrome with breast milk containing methadone. *J Perinat Neonatal Nurs* 2002; 15(4):76-85
57. Bandettini Di PA, Fornai F, Paparelli A, Pacini M, Perugi G, Maremmani I. Comparison between heroin and heroin-cocaine polyabusers: a psychopathological study. *Ann N Y Acad Sci* 2006; 1074:438-45
58. Banys P, Clark HW, Tusel DJ, Sees K, Stewart P, Mongan L, Delucchi K, Callaway E. An open trial of low dose buprenorphine in treating methadone withdrawal. *J Subst Abuse Treat* 1994; 11(1):9-15
59. Barnett PG. The cost-effectiveness of substance abuse treatment. *Curr Psychiatry Rep* 1999; 1(2):166-71
60. Barnett PG. The cost-effectiveness of methadone maintenance as a health care intervention. *Addiction* 1999; 94(4):479-88
61. Barnett PG, Hui SS. The cost-effectiveness of methadone maintenance. *Mt Sinai J Med* 2000; 67(5-6):365-74
62. Barnett PG, Zaric GS, Brandeau ML. The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. *Addiction* 2001; 96(9):1267-78
63. Barnett PG, Rodgers JH, Bloch DA. A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. *Addiction* 2001; 96(5):683-90
64. Barrau K, Thirion X, Micallef J, Chuniaud-Louche C, Bellemin B, San-Marco JL. Comparison of methadone and high dosage buprenorphine users in French care centres. *Addiction* 2001; 96(10):1433-41
65. Barry J, Bourke M, Buckley M, Coughlan B, Crowley D, Cullen W, Dooley S, Keating S, Kelleher D, Moloney J, Murray F, McCormick PA, MacMathuna P, O'Connor J, O'Grady J, O'Sullivan C, O'Sullivan P, Quinn C, Smyth B, Sweeney B. Hepatitis C among drug users: consensus guidelines on management in general practice. *Ir J Med Sci* 2004; 173(3):145-50
66. Bart G, Borg L, Schluger JH, Green M, Ho A, Kreek MJ. Suppressed prolactin response to dynorphin A1-13 in methadone-maintained versus control subjects. *The Journal of pharmacology and experimental therapeutics* 2003; 306:581-7
67. Batel P, Reynaud-Maurupt C, Lavignasse P, Constant MV, Kopp P, Jourdain JJ, Videau B, Mucchielli A, Riff B, Lowenstein W. Facteurs de risques de rupture précoce de prise en charge lors de l'induction d'un traitement substitutif par buprénorphine haut dosage [Risk factors of early drop-out during induction of high-dose buprenorphine substitution therapy. A study of 1085 opiate addicts]. *Presse Med* 2004; 33(18 Suppl):5-9

68. Batki SL, Manfredi LB, Jacob P, III, Jones RT. Fluoxetine for cocaine dependence in methadone maintenance: quantitative plasma and urine cocaine/benzoylecgonine concentrations. *J Clin Psychopharmacol* 1993; 13(4):243-50
69. Bauman JL, DiDomenico RJ. Cocaine-induced channelopathies: emerging evidence on the multiple mechanisms of sudden death. *J Cardiovasc Pharmacol Ther* 2002; 7(3):195-202
70. Beatty WW, Borrell GK. Forms of knowledge, cognitive impairment and drug abuse: a demonstration. *Prog Neuropsychopharmacol Biol Psychiatry* 2000; 24(1):17-22
71. Beaumont B. Survey of injectable methadone prescribing in general practice in England and Wales. *Int J Drug Policy* 2001; 12(1):91-101
72. Becker AB, Strain EC, Bigelow GE, Stitzer ML, Johnson RE. Gradual dose taper following chronic buprenorphine. *Am J Addict* 2001; 10(2):111-21
73. Begg EJ, Malpas TJ, Hackett LP, Ilett KF. Distribution of R- and S-methadone into human milk during multiple, medium to high oral dosing. *Br J Clin Pharmacol* 2001; 52(6):681-5
74. Belding MA, Iguchi MY, Morral AR, McLellan AT. Assessing the helping alliance and its impact in the treatment of opiate dependence. *Drug and alcohol dependence* 1997; 48:51-9
75. Bell J, Caplehorn JR, McNeil DR. The effect of intake procedures on performance in methadone maintenance. *Addiction* 1994; 89(4):463-71
76. Bell J, Mattick R, Hay A, Chan J, Hall W. Methadone maintenance and drug-related crime. *J Subst Abuse* 1997; 9:15-25
77. Bell J. Quality improvement for methadone maintenance treatment. *Subst Use Misuse* 2000; 35(12-14):1735-56
78. Bell J, Zador D. A risk-benefit analysis of methadone maintenance treatment. *Drug Saf* 2000; 22(3):179-90
79. Bell J, Dru A, Fischer B, Levit S, Sarfraz MA. Substitution therapy for heroin addiction. *Subst Use Misuse* 2002; 37(8-10):1149-78
80. Bell J, Mutch C. Treatment retention in adolescent patients treated with methadone or buprenorphine for opioid dependence: a file review. *Drug Alcohol Rev* 2006; 25(2):167-71
81. Bell J, Burrell T. Retention and attendance with supervised buprenorphine treatment: a case-note review. *Drug Alcohol Rev* 2006; 25(2):161-5
82. Bell J, Burrell T, Indig D, Gilmour S. Cycling in and out of treatment; participation in methadone treatment in NSW, 1990-2002. *Drug Alcohol Depend* 2006; 81(1):55-61
83. Belle DJ, Callaghan JT, Gorski JC, Maya JF, Mousa O, Wrighton SA, Hall SD. The effects of an oral contraceptive containing ethinylloestradiol and norgestrel on CYP3A activity. *Br J Clin Pharmacol* 2002; 53(1):67-74
84. Bennett J, Whale R. Galactorrhoea may be associated with methadone use. *BMJ* 2006; 332(7549):1071
85. Berg ML, Idrees U, Ding R, Nesbit SA, Liang HK, McCarthy ML. Evaluation of the use of buprenorphine for opioid withdrawal in an emergency department. *Drug Alcohol Depend* 2006;
86. Berger LJ, Westermeyer J. "World Traveler" addicts in Asia: II. Comparison with "Stay at home" addicts. *Am J Drug Alcohol Abuse* 1977; 4(4):495-503

87. Bergeron H, Kopp P. Policy paradigms, ideas, and interests: the case of the French public health policy toward drug abuse. *Annals-of-the-American-Academy-of-Political-and-Social-Science* 2002; 582(pp.37-48 U):-48
88. Bergschmidt VB. Pleasure, power and dangerous substances: applying Foucault to the study of 'heroin dependence' in Germany. *Anthropology-and-medicine* 2004; 11(1):59-74
89. Berson A, Gervais A, Cazals D, Boyer N, Durand F, Bernuau J, Marcellin P, Degott C, Valla D, Pessayre D. Hepatitis after intravenous buprenorphine misuse in heroin addicts. *J Hepatol* 2001; 34(2):346-50
90. Bertisch B, Meili D, Huber M. Nachweis von Hepatitis-C-Viruslast in gebrauchten Heroinspritzen. *Suchttherapie* 2002; Sup 1
91. Bickel WK, Johnson RE, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR. A clinical trial of buprenorphine: I. Comparison with methadone in the detoxification of heroin addicts. II. Examination of its opioid blocking properties. *NIDA Res Monogr* 1987; 76:182-8
92. Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE. Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans. *J Pharmacol Exp Ther* 1988; 247(1):47-53
93. Bickel WK, Amass L, Crean JP, Badger GJ. Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients. *Psychopharmacology (Berl)* 1999; 146(2):111-8
94. Bigelow GE, Preston KL. Assessment of buprenorphine in a drug discrimination procedure in humans. *NIDA Res Monogr* 1992; 121:28-37
95. Bilban M, Bilban C, Jakopin. Methadone maintenance treatment and drugs. *Collegium-antropologicum* 2002; 26(1):107-18
96. Blahoutova V, Zajicova A, Wilczek H, Holan V. [Opioids and their immunomodulatory properties]. *Cas Lek Cesk* 2003; 142(4):244-7
97. Bliesener N, Albrecht S, Schwager A, Weckbecker K, Lichtermann D, Klingmuller D. Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence. *J Clin Endocrinol Metab* 2005; 90(1):203-6
98. Bloms-Funke P, Gillen C, Schuettler AJ, Wnendt S. Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor. *Peptides* 2000; 21(7):1141-6
99. Bloor RN, McAuley R, Smallldridge N. Safe storage of methadone in the home--an audit of the effectiveness of safety information giving. *Harm Reduct J* 2005; 2:9
100. Bodkin JA, Zornberg GL, Lukas SE, Cole JO. Buprenorphine treatment of refractory depression. *J Clin Psychopharmacol* 1995; 15(1):49-57
101. Boissonnas A. [How to treat a patient with AIDS and drug dependence unwilling and/or unable to withdraw? Give substitution drugs at the hospital? Should substitution be continued after discharge? Is substitution a useful adjuvant to programs designed to prevent opportunistic diseases?] *opportunisticinfections?]. Ann Med Interne (Paris)* 1994; 145(Suppl 3):54-5
102. Borg L, Kreek MJ. Clinical problems associated with interactions between methadone pharmacotherapy and medications used in the treatment of HIV-1-positive and AIDS patients. *Current Opinion Psychiatry* 1995; 8:199-202

103. Bouhnik AD, Chesney M, Carrieri P, Gallais H, Moreau J, Moatti JP, Obadia Y, Spire B. Nonadherence among HIV-infected injecting drug users: the impact of social instability. *J Acquir Immune Defic Syndr* 2002; 31 Suppl 3:S149-53.:S149-S153
104. Bourgois P. Anthropology and epidemiology on drugs: the challenges of cross-methodological and theoretical dialogue. *International-journal-of-drug-policy* 2002; 13(4):259-69
105. Bovasso G, Cacciola J. The long-term outcomes of drug use by methadone maintenance patients. *J Behav Health Serv Res* 2003; 30(3):290-303
106. Boyle RK. Intra- and postoperative anaesthetic management of an opioid addict undergoing caesarean section. *Anaesth Intensive Care* 1991; 19(2):276-9
107. Brady TM, Salvucci S, Sverdlov LS, Male A, Kyeyune H, Sikali E, DeSale S, Yu P. Methadone dosage and retention: an examination of the 60 mg/day threshold. *J Addict Dis* 2005; 24(3):23-47
108. Bramness JG, Kornor H. Benzodiazepine prescription for patients in opioid maintenance treatment in Norway. *Drug Alcohol Depend* 2007;
109. Brands B, Blake J, Marsh D. Changing patient characteristics with increased methadone maintenance availability. *Drug Alcohol Depend* 2002; 66(1):11-20
110. Brands B, Blake J, Marsh D. Impact of methadone program philosophy changes on early treatment outcomes. *J Addict Dis* 2003; 22(3):19-38
111. Breen CL, Harris SJ, Lintzeris N, Mattick RP, Hawken L, Bell J, Ritter AJ, Lenné M, Mendoza E. Cessation of methadone maintenance treatment using buprenorphine: transfer from methadone to buprenorphine and subsequent buprenorphine reductions. *Drug and alcohol dependence* 2003; 71:49-55
112. Breese GR, Chu K, Dayas CV, Funk D, Knapp DJ, Koob GF, Le DA, O'Dell LE, Overstreet DH, Roberts AJ, Sinha R, Valdez GR, Weiss F. Stress enhancement of craving during sobriety: a risk for relapse. *Alcohol Clin Exp Res* 2005; 29(2):185-95
113. Brewster D, Humphrey MJ, McLeavy MA. Biliary excretion, metabolism and enterohepatic circulation of buprenorphine. *Xenobiotica* 1981; 11(3):189-96
114. Bridge TP, Fudala PJ, Herbert S, Leiderman DB. Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence. *Drug Alcohol Depend* 2003; 70(2 Suppl):S79-S85
115. Brooks DJ, Vosburg SK, Evans SM, Levin FR. Assessment of Cognitive Functioning of Methadone-Maintenance Patients: Impact of Adult ADHD and Current Cocaine Dependence. *J Addict Dis* 2006; 25(4):15-25
116. Brooner RK, Kidorf MS, King VL, Stoller KB, Peirce JM, Bigelow GE, Kolodner K. Behavioral contingencies improve counseling attendance in an adaptive treatment model. *J Subst Abuse Treat* 2004; 27(3):223-32
117. Brown BS, Joe GW, Thompson P. Minority group status and treatment retention. *Int J Addict* 1985; 20(2):319-35
118. Brown R, Balousek S, Mundt M, Fleming M. Methadone maintenance and male sexual dysfunction. *J Addict Dis* 2005; 24(2):91-106
119. Bruce RD, Cance-Katz E, Kharasch ED, Moody DE, Morse GD. Pharmacokinetic Interactions between Buprenorphine and Antiretroviral Medications. *Clin Infect Dis* 2006; 43 Suppl 4:S216-S223

120. Bruce RD, Altice FL, Gourevitch MN, Friedland GH. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. *J Acquir Immune Defic Syndr* 2006; 41(5):563-72
121. Brugal MT, Domingo-Salvany A, Puig R, Barrio G, Garcia de OP, de la FL. Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain. *Addiction* 2005; 100(7):981-9
122. Bruggmann P, Seidenberg A, Meili D, Kesseli B, Huber M. Hepatitis C- and HIV-Prevalence and Antiretroviral Therapy in a Low Threshold Opiate Maintenance Program. *Suchttherapie* 2005; 2:78-82
123. Bryant WK, Galea S, Tracy M, Piper TM, Tardiff KJ, Vlahov D. Overdose deaths attributed to methadone and heroin in New York city, 1990-1998. *Addiction* 2004; 99(7):846-54
124. Bullingham RE, McQuay HJ, Moore A, Bennett MR. Buprenorphine kinetics. *Clin Pharmacol Ther* 1980; 28(5):667-72
125. Buster MCA, Brussel GHA, van den Brink W. An increase in overdose mortality during the first 2 weeks after entering or re-entering methadone treatment in Amsterdam. *Addiction* 2002; 97(8):993-1001
126. Buydens-Branchey L, Branchey M, Reel-Brander C. Efficacy of buspirone in the treatment of opioid withdrawal. *J Clin Psychopharmacol* 2005; 25(3):230-6
127. Byrne A, Dolan K. Methadone treatment is widely accepted in prisons in New South Wales. *BMJ* 1998; 316(7146):1744-5
128. Cafilisch C, Figner B, Eich D. Biperiden for excessive sweating from methadone. *Am J Psychiatry* 2003; 160(2):386-7
129. Calsyn DA, Saxon AJ. An innovative approach to reducing cannabis use in a subset of methadone maintenance clients. *Drug Alcohol Depend* 1999; 53(2):167-9
130. Calvo R, Lukas JC, Rodriguez M, Carlos MA, Suarez E. Pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase efavirenz. *Br J Clin Pharmacol* 2002; 53(2):212-4
131. Cance-Katz EF, Rainey PM, Friedland G, Kosten TR, Jatlow P. Effect of opioid dependence pharmacotherapies on zidovudine disposition. *Am J Addict* 2001; 10(4):296-307
132. Cance-Katz EF, Gourevitch MN, Arnsten J, Sarlo J, Rainey P, Jatlow P. Modified directly observed therapy (MDOT) for injection drug users with HIV disease. *Am J Addict* 2002; 11(4):271-8
133. Cance-Katz EF, Rainey PM, Smith P, Morse G, Friedland G, Gourevitch M, Jatlow P. Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and nelfinavir. *Am J Addict* 2004; 13(2):163-80
134. Cance-Katz EF. Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiretroviral agents. *Clin Infect Dis* 2005; 41 Suppl 1:S89-S95
135. Cance-Katz EF, Moody DE, Smith PF, Morse GD, Friedland G, Pade P, Baker J, Alvanzo A, Jatlow P, Rainey PM. Interactions between Buprenorphine and Antiretrovirals. II. The Protease Inhibitors Nelfinavir, Lopinavir/Ritonavir, and Ritonavir. *Clin Infect Dis* 2006; 43 Suppl 4:S235-S246
136. Cance-Katz EF, Moody DE, Morse GD, Friedland G, Pade P, Baker J, Alvanzo A, Smith P, Ogundele A, Jatlow P, Rainey PM. Interactions between Buprenorphine and Antiretrovirals. I. The

- Nonnucleoside Reverse-Transcriptase Inhibitors Efavirenz and Delavirdine. *Clin Infect Dis* 2006; 43 Suppl 4:S224-S234
137. Caplehorn J, Deeks JJ. A critical appraisal of the Australian comparative trial of methadone and buprenorphine maintenance. *Drug Alcohol Rev* 2006; 25(2):157-60
 138. Caplehorn JR, Bell J. Methadone dosage and retention of patients in maintenance treatment. *Med J Aust* 1991; 154(3):195-9
 139. Caplehorn JR, Dalton MS, Cluff MC, Petrenas AM. Retention in methadone maintenance and heroin addicts' risk of death. *Addiction* 1994; 89(2):203-9
 140. Caplehorn JR, Ross MW. Methadone maintenance and the likelihood of risky needle-sharing. *Int J Addict* 1995; 30(6):685-98
 141. Caplehorn JR, Irwig L, Saunders JB. Physicians' attitudes and retention of patients in their methadone maintenance programs. *Subst Use Misuse* 1996; 31(6):663-77
 142. Caplehorn JR, Dalton MS, Haldar F, Petrenas AM, Nisbet JG. Methadone maintenance and addicts' risk of fatal heroin overdose. *Subst Use Misuse* 1996; 31(2):177-96
 143. Caplehorn JR, Hartel DM, Irwig L. Measuring and comparing the attitudes and beliefs of staff working in New York methadone maintenance clinics. *Subst Use Misuse* 1997; 32(4):399-413
 144. Caplehorn JR, Lumley TS, Irwig L. Staff attitudes and retention of patients in methadone maintenance programs. *Drug Alcohol Depend* 1998; 52(1):57-61
 145. Caplehorn JR. Deaths in the first two weeks of maintenance treatment in NSW in 1994: identifying cases of iatrogenic methadone toxicity. *Drug Alcohol Rev* 1998; 17(1):9-17
 146. Caplehorn JR, Drummer OH. Mortality associated with New South Wales methadone programs in 1994: lives lost and saved. *Med J Aust* 1999; 170(3):104-9
 147. Caplehorn JR, Drummer OH. Methadone dose and post-mortem blood concentration. *Drug Alcohol Rev* 2002; 21(4):329-33
 148. Caplehorn JR, Drummer OH. Fatal methadone toxicity: signs and circumstances, and the role of benzodiazepines. *Aust N Z J Public Health* 2002; 26(4):358-62
 149. Carballo-Dieguez A, Sahs J, Goetz R, el SW, Sorell S, Gorman J. The effect of methadone on immunological parameters among HIV-positive and HIV-negative drug users. *Am J Drug Alcohol Abuse* 1994; 20(3):317-29
 150. Carnwath T. Prescribing heroin. *Am J Addict* 2005; 14(4):311-8
 151. Carpenter KM, Aharonovich E, Smith JL, Iguchi MY, Nunes EV. Behavior Therapy for Depression in Drug Dependence (BTDD): Results of a Stage Ia Therapy Development Pilot. *Am J Drug Alcohol Abuse* 2006; 32(4):541-8
 152. Carpentier J, Bloch-Laine JF, Hefez S. [Value and limitations of substitution treatments in the care of drug addicts]. *Ann Med Interne (Paris)* 1994; 145(Suppl 3):50-1
 153. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, Morand P, Goujard C, Pialoux G, Piroth L, Salmon-Ceron D, Degott C, Cacoub P, Perronne C. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. *JAMA* 2004; 292(23):2839-48

154. Carrieri MP, Vlahov D, Dellamonica P, Gallais H, Lepeu G, Spire B, Obadia Y. Use of buprenorphine in HIV-infected injection drug users: negligible impact on virologic response to HAART. The Manif-2000 Study Group. *Drug Alcohol Depend* 2000; 60(1):51-4
155. Carrieri MP, Chesney MA, Spire B, Loundou A, Sobel A, Lepeu G, Moatti JP. Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting drug users. *Int J Behav Med* 2003; 10(1):1-14
156. Carrieri MP, Amass L, Lucas GM, Vlahov D, Wodak A, Woody GE. Buprenorphine use: the international experience. *Clin Infect Dis* 2006; 43 Suppl 4:S197-S215
157. Carroll CP, Walsh SL, Bigelow GE, Strain EC, Preston KL. Assessment of agonist and antagonist effects of tramadol in opioid-dependent humans. *Exp Clin Psychopharmacol* 2006; 14(2):109-20
158. Cassidy B, Cyna AM. Challenges that opioid-dependent women present to the obstetric anaesthetist. *Anaesth Intensive Care* 2004; 32(4):494-501
159. Cazorla C, Grenier de CD, Schuhmacher H, Thomas L, Wack A, May T, Rabaud C. Complications infectieuses et mésusage de la buprénorphine à haut dosage [Infectious complications and misuse of high-dose buprenorphine]. *Presse Med* 2005; 34(10):719-24
160. Celentano DD, Galai N, Sethi AK, Shah NG, Strathdee SA, Vlahov D, Gallant JE. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. *AIDS* 2001; 15(13):1707-15
161. Celerier E, Laulin JP, Corcuff JB, Le MM, Simonnet G. Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: a sensitization process. *J Neurosci* 2001; 21(11):4074-80
162. Chang Y, Moody DE. Effect of benzodiazepines on the metabolism of buprenorphine in human liver microsomes. *Eur J Clin Pharmacol* 2005; 60(12):875-81
163. Chang Y, Moody DE, Cance-Katz EF. Novel metabolites of buprenorphine detected in human liver microsomes and human urine. *Drug Metab Dispos* 2006; 34(3):440-8
164. Chawarski MC, Moody DE, Pakes J, O'Connor PG, Schottenfeld RS. Buprenorphine tablet versus liquid: a clinical trial comparing plasma levels, efficacy, and symptoms. *J Subst Abuse Treat* 2005; 29(4):307-12
165. Chiriboga CA. Fetal alcohol and drug effects. *Neurologist* 2003; 9(6):267-79
166. Chua SM, Lee TS. Abuse of prescription buprenorphine, regulatory controls and the role of the primary physician. *Ann Acad Med Singapore* 2006; 35(7):492-5
167. Chutuape MA, Silverman K, Stitzer ML. Survey assessment of methadone treatment services as reinforcers. *Am J Drug Alcohol Abuse* 1998; 24(1):1-16
168. Chutuape MA, Silverman K, Stitzer ML. Use of methadone take-home contingencies with persistent opiate and cocaine abusers. *J Subst Abuse Treat* 1999; 16(1):23-30
169. Chutuape MA, Silverman K, Stitzer M. Contingent reinforcement sustains post-detoxification abstinence from multiple drugs: a preliminary study with methadone patients. *Drug Alcohol Depend* 1999; 54(1):69-81
170. Chutuape MA, Silverman K, Stitzer ML. Effects of urine testing frequency on outcome in a methadone take-home contingency program. *Drug Alcohol Depend* 2001; 62(1):69-76

171. Ciccocioppo R, Economidou D, Rimondini R, Sommer W, Massi M, Heilig M. Buprenorphine Reduces Alcohol Drinking Through Activation of the Nociceptin/Orphanin FQ-NOP Receptor System. *Biol Psychiatry* 2006;
172. Clark N, Lintzeris N, Gijsbers A, Whelan G, Dunlop A, Ritter A, Ling W. LAAM maintenance vs methadone maintenance for heroin dependence. *Cochrane Database Syst Rev* 2002; (2):CD002210
173. Clarke H. Economic analysis of public policies for controlling heroin use. *Australian-economic-papers* 2003; 42(2):234-52
174. Clarke S, Mulcahy F, Bergin C, Reynolds H, Boyle N, Barry M, Back DJ. Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir. *Clin Infect Dis* 2002; 34(8):1143-5
175. Clarke SM, Mulcahy FM, Tjia J, Reynolds HE, Gibbons SE, Barry MG, Back DJ. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. *Br J Clin Pharmacol* 2001; 51(3):213-7
176. Clarke SM, Mulcahy FM, Tjia J, Reynolds HE, Gibbons SE, Barry MG, Back DJ. Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. *Clin Infect Dis* 2001; 33(9):1595-7
177. Cobb MN, Desai J, Brown LS, Zannikos PN, Rainey PM. The effect of fluconazole on the clinical pharmacokinetics of methadone. *Clinical pharmacology and therapeutics* 1998; 63:655-62
178. Coid J, Carvell A, Kittler Z, Healey A, Henderson J. The impact of methadone treatment on drug misuse and crime. London: Home Office Research, Development and Statistics Directorate; 2000.
179. Collett BJ. Opioid tolerance: the clinical perspective. *Br J Anaesth* 1998; 81(1):58-68
180. Collins ED, Kleber HD, Whittington RA, Heitler NE. Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial. *JAMA* 2005; 294(8):903-13
181. Comer SD, Collins ED, Fischman MW. Buprenorphine sublingual tablets: effects on IV heroin self-administration by humans. *Psychopharmacology (Berl)* 2001; 154(1):28-37
182. Comer SD, Collins ED, Fischman MW. Intravenous buprenorphine self-administration by detoxified heroin abusers. *J Pharmacol Exp Ther* 2002; 301(1):266-76
183. Comer SD, Sullivan MA, Walker EA. Comparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individuals. *J Pharmacol Exp Ther* 2005; 315(3):1320-30
184. Compton MA. Cold-pressor pain tolerance in opiate and cocaine abusers: correlates of drug type and use status. *J Pain Symptom Manage* 1994; 9(7):462-73
185. Compton P. Pain tolerance in opioid addicts on and off naltrexone pharmacotherapy: a pilot study. *J Pain Symptom Manage* 1998; 16(1):21-8
186. Compton P, Charuvastra VC, Kintaudi K, Ling W. Pain responses in methadone-maintained opioid abusers. *Journal of pain and symptom management* 2000; 20:237-45
187. Compton P, Charuvastra VC, Ling W. Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent. *Drug Alcohol Depend* 2001; 63(2):139-46
188. Compton P, Miotto K, Elashoff D. Precipitated opioid withdrawal across acute physical dependence induction methods. *Pharmacol Biochem Behav* 2004; 77(2):263-8

189. Compton P, Ling W, Moody D, Chiang N. Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine. *Drug Alcohol Depend* 2006; 82(1):25-31
190. Compton PA, Ling W, Charuvastra VC, Wesson DR. Buprenorphine as a pharmacotherapy for cocaine abuse: a review of the evidence. *J Addict Dis* 1995; 14(3):97-114
191. Cone EJ, Gorodetzky CW, Yousefnejad D, Buchwald WF, Johnson RE. The metabolism and excretion of buprenorphine in humans. *Drug Metab Dispos* 1984; 12(5):577-81
192. Cone EJ, Preston KL. Toxicologic aspects of heroin substitution treatment. *Ther Drug Monit* 2002; 24(2):193-8
193. Conner KR, Britton PC, Sworts LM, Joiner TE, Jr. Suicide attempts among individuals with opiate dependence: The critical role of belonging. *Addict Behav* 2006;
194. Cook S, Indig D, Gray J, McGrath D. Opiate overdose and health treatment options for opiate users in New South Wales, 1999-2002. *N S W Public Health Bull* 2004; 15(7-8):125-31
195. Corkery JM, Schifano F, Ghodse AH, Oyefeso A. The effects of methadone and its role in fatalities. *Hum Psychopharmacol* 2004; 19(8):565-76
196. Correia CJ, Walsh SL, Bigelow GE, Strain EC. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period. *Psychopharmacology (Berl)* 2006; 189(3):297-306
197. Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. *Clin Pharmacokinet* 2005; 44(1):33-60
198. Cournot M, Glibert A, Castel F, Druart F, Imani K, Lauwers-Cances V, Morin T. Management of hepatitis C in active drugs users: experience of an addiction care hepatology unit. *Gastroenterol Clin Biol* 2004; 28(6-7 Pt 1):533-9
199. Cowan A, Lewis JW, Macfarlane IR. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. *Br J Pharmacol* 1977; 60(4):537-45
200. Cowan A. Buprenorphine: new pharmacological aspects. *Int J Clin Pract Suppl* 2003; (133):3-8
201. Cozzolino E, Guglielmino L, Vigezzi P, Marzorati P, Silenzio R, De CM, Corrado F, Cocchi L. Buprenorphine treatment: a three-year prospective study in opioid-addicted patients of a public out-patient addiction center in Milan. *Am J Addict* 2006; 15(3):246-51
202. Crettol S, Deglon JJ, Besson J, Croquette-Krokkar M, Gothuey I, Hammig R, Monnat M, Huttemann H, Baumann P, Eap CB. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. *Clin Pharmacol Ther* 2005; 78(6):593-604
203. Crettol S, Monnat M, Eap CB. Could pharmacogenetic data explain part of the interindividual sensitivity to methadone-induced respiratory depression? *Crit Care* 2007; 11(1):119
204. Cropsey KL, Villalobos GC, St Clair CL. Pharmacotherapy treatment in substance-dependent correctional populations: a review. *Subst Use Misuse* 2005; 40(13-14):1983-8
205. Crouch MA, Limon L, Cassano AT. Clinical relevance and management of drug-related QT interval prolongation. *Pharmacotherapy* 2003; 23(7):881-908
206. Cruciani RA, Sekine R, Homel P, Lussier D, Yap Y, Suzuki Y, Schweitzer P, Yancovitz SR, Lapin JA, Shaiova L, Sheu RG, Portenoy RK. Measurement of QTc in patients receiving chronic methadone therapy. *J Pain Symptom Manage* 2005; 29(4):385-91

207. Cullen W, Kelly Y, Stanley J, Langton D, Bury G. Experience of hepatitis C among current or former heroin users attending general practice. *Ir Med J* 2005; 98(3):73-4
208. Cullen W, Stanley J, Langton D, Kelly Y, Staines A, Bury G. Hepatitis C infection among injecting drug users in general practice: a cluster randomised controlled trial of clinical guidelines' implementation. *Br J Gen Pract* 2006; 56(532):848-56
209. Cunningham CO, Sohler NL, McCoy K, Kunins HV. Attending physicians' and residents' attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital. *Fam Med* 2006; 38(5):336-40
210. Curran HV, Bolton J, Wanigaratne S, Smyth C. Additional methadone increases craving for heroin: a double-blind, placebo-controlled study of chronic opiate users receiving methadone substitution treatment. *Addiction* 1999; 94(5):665-74
211. Curran HV, Kleckham J, Bearn J, Strang J, Wanigaratne S. Effects of methadone on cognition, mood and craving in detoxifying opiate addicts: a dose-response study. *Psychopharmacology* 2001; 154:153-60
212. D'Apolito K. Methadone maintenance and breast feeding: do they mix? *Neonatal Netw* 1994; 13(8):64-5
213. D'Apolito K. Methadone maintenance and breast feeding continued.. *Neonatal Netw* 1995; 14(4):77-8
214. Dahan A, Yassen A, Bijl H, Romberg R, Sarton E, Teppema L, Olofsen E, Danhof M. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. *Br J Anaesth* 2005; 94(6):825-34
215. Dahan A. Opioid-induced respiratory effects: new data on buprenorphine. *Palliat Med* 2006; 20 Suppl 1:s3-s8
216. Dahan A, Yassen A, Romberg R, Sarton E, Teppema L, Olofsen E, Danhof M. Buprenorphine induces ceiling in respiratory depression but not in analgesia. *Br J Anaesth* 2006;
217. Dale O, Hoffer C, Sheffels P, Kharasch ED. Disposition of nasal, intravenous, and oral methadone in healthy volunteers. *Clinical pharmacology and therapeutics* 2002; 72:536-45
218. Dale O, Sheffels P, Kharasch ED. Bioavailabilities of rectal and oral methadone in healthy subjects. *British journal of clinical pharmacology* 2004; 58:156-62
219. Dalgard O, Bjoro K, Hellum K, Myrvang B, Skaug K, Gutigard B, Bell H. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. *Eur Addict Res* 2002; 8(1):45-9
220. Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. *J Pain* 2002; 3(5):377-84
221. Daniell HW. Opioid osteoporosis. *Arch Intern Med* 2004; 164(3):338
222. Darke S, Kaye S, Finlay-Jones R. Drug use and injection risk-taking among prison methadone maintenance patients. *Addiction* 1998; 93(8):1169-75
223. Darke S, Sims J, McDonald S, Wickes W. Cognitive impairment among methadone maintenance patients. *Addiction* 2000; 95(5):687-95
224. Darke S, Ross J. The relationship between suicide and heroin overdose among methadone maintenance patients in Sydney, Australia. *Addiction* 2001; 96(10):1443-53

225. Darke S, Hetherington K, Ross J, Lynskey M, Teesson M. Non-injecting routes of administration among entrants to three treatment modalities for heroin dependence. *Drug Alcohol Rev* 2004; 23(2):177-83
226. Davids E, Gastpar M. Buprenorphine in the treatment of opioid dependence. *Eur Neuropsychopharmacol* 2004; 14(3):209-16
227. Davis PE, Liddiard H, McMillan TM. Neuropsychological deficits and opiate abuse. *Drug Alcohol Depend* 2002; 67(1):105-8
228. Davstad I, Stenbacka M, Leifman A, Beck O, Korkmaz S, Romelsjo A. Patterns of illicit drug use and retention in a methadone program: a longitudinal study. *J Opioid Manag* 2007; 3(1):27-34
229. Dawe S, Harnett PH, Staiger P, Dadds MR. Parent training skills and methadone maintenance: clinical opportunities and challenges. *Drug Alcohol Depend* 2000; 60(1):1-11
230. Day E, Ison J, Strang J. Inpatient versus other settings for detoxification for opioid dependence. *Cochrane Database Syst Rev* 2005; (2):CD004580
231. Day E, Ison J, Strang J. Inpatient versus other settings for detoxification for opioid dependence. Day E, Ison J, Strang J Inpatient versus other settings for detoxification for opioid dependence *The Cochrane Database of Systematic Reviews : Reviews* 2005 Issue 2 John Wiley & Sons , Ltd Chichester, UK DOI : 10 1002 /14651858 CD004580 pub2 2005;
232. De Bie J, Robaey G, Buntinx F. Hepatitis C, interferon alpha and psychiatric co-morbidity in intravenous drug users (IVDU) : guidelines for clinical practice. *Acta Gastroenterol Belg* 2005; 68(1):68-80
233. De Jong CA, Laheij RJ, Krabbe PF. General anaesthesia does not improve outcome in opioid antagonist detoxification treatment: a randomized controlled trial. *Addiction* 2005; 100(2):206-15
234. De Klerk G, Mattie H, Spierdijk J. Comparative study on the circulatory and respiratory effects of buprenorphine and methadone. *Acta Anaesthesiologica Belgica* 1981; 32:131-9
235. de la Rosa RE, Hennessey JV. Hypogonadism and methadone: Hypothalamic hypogonadism after long-term use of high-dose methadone. *Endocr Pract* 1996; 2(1):4-7
236. de Vos JW, Ufkes JG, van Brussel GH, van den Brink W. Craving despite extremely high methadone dosage. *Drug Alcohol Depend* 1996; 40(3):181-4
237. de Vos JW, Ufkes JG, Kaplan CD, Tursch M, Krause JK, van Wilgenburg H, Woodcock BG, Staib AH. L-Methadone and D,L-methadone in methadone maintenance treatment: a comparison of therapeutic effectiveness and plasma concentrations. *Eur Addict Res* 1998; 4(3):134-41
238. de Vos JW, Ufkes JG, Van den BW, van Brussel GH, de Wolff FA. Craving patterns in methadone maintenance treatment with dextromoramide as adjuvant. *Addict Behav* 1999; 24(5):707-13
239. De Waal EJ, Van Der Laan JW, Van LH. Effects of prolonged exposure to morphine and methadone on in vivo parameters of immune function in rats. *Toxicology* 1998; 129(2-3):201-10
240. de Wet CJ, Reed LJ, Bearn J. The rise of buprenorphine prescribing in England: analysis of NHS regional data, 2001-03. *Addiction* 2005; 100(4):495-9
241. Dean AJ, Bell J, Christie MJ, Mattick RP. Depressive symptoms during buprenorphine vs. methadone maintenance: findings from a randomised, controlled trial in opioid dependence. *Eur Psychiatry* 2004; 19(8):510-3

242. Decerf JA, Gressens B, Brohet C, Liolios A, Hantson P. Can methadone prolong the QT interval? *Intensive Care Med* 2004; 30(8):1690-1
243. Degenhardt L, Black E, Breen C, Bruno R, Kinner S, Roxburgh A, Fry C, Jenkinson R, Ward J, Fetherston J, Weekley J, Fischer J. Trends in morphine prescriptions, illicit morphine use and associated harms among regular injecting drug users in Australia. *Drug Alcohol Rev* 2006; 25(5):403-12
244. Delwaide J, Bourgeois N, Gerard C, De MS, Mokaddem F, Wain E, Bastens B, Fevery J, Geheot M, Le MO, Martinet JP, Robaey G, Servais B, Van GM, Van VH. Treatment of acute hepatitis C with interferon alpha-2b: early initiation of treatment is the most effective predictive factor of sustained viral response. *Aliment Pharmacol Ther* 2004; 20(1):15-22
245. Department of Health Scottish Office Department of Health Welsh Office Department of Health and Social Services NI. Drug Misuse and Dependence - Guidelines on Clinical Management. Department of Health Scottish Office Department of Health Welsh Office Department of Health and Social Services, Northern Ireland; 1999.
246. DGS, DGPPN. Postakutbehandlung bei Störungen durch Opiode. *DG Sucht*; 2004.
247. Dickinson GL, Rostami-Hodjegan A, Lagundoye O, Seivewright N, Pratt P, Lennard MS. A six-year evaluation of methadone prescribing practices at a substance misuse treatment centre in the UK. *J Clin Pharm Ther* 2006; 31(5):477-84
248. Dieperink E, Ho SB, Thuras P, Willenbring ML. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. *Psychosomatics* 2003; 44(2):104-12
249. Digiusto E, Shakeshaft A, Ritter A, O'Brien S, Mattick RP, NEPOD-Research-Group (Corp. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). *Addiction* 2004; 99(4):450-60
250. DiMartini A, Weinrieb R, Fireman M. Liver transplantation in patients with alcohol and other substance use disorders. *Psychiatr Clin North Am* 2002; 25(1):195-209
251. DiPaula BA, Schwartz R, Montoya ID, Barrett D, Tang C. Heroin detoxification with buprenorphine on an inpatient psychiatric unit. *J Subst Abuse Treat* 2002; 23(3):163-9
252. Dittert S, Naber D, Soyka M. "Methadonsubstitution und Fahrtauglichkeit" Ergebnisse einer experimentellen Studie ['Methadone substitution therapy and driving']. Results of an experimental study]. *Nervenarzt* 1999; 70(5):457-62
253. Doab A, Treloar C, Dore GJ. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. *Clin Infect Dis* 2005; 40 Suppl 5:S313-S320
254. Dolan K, Hall W, Wodak A. Methadone maintenance reduces injecting in prison. *BMJ* 1996; 312(7039):1162
255. Dolan KA, Wodak AD, Hall WD. Methadone maintenance treatment reduces heroin injection in New South Wales prisons. *Drug Alcohol Rev* 1998; 17(2):153-8
256. Dolan KA, Wodak A. HIV transmission in a prison system in an Australian State. *Med J Aust* 1999; 171(1):14-7
257. Dolan KA, Shearer J, MacDonald M, Mattick RP, Hall W, Wodak AD. A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. *Drug Alcohol Depend* 2003; 72(1):59-65

258. Dolan KA, Shearer J, White B, Zhou J, Kaldor J, Wodak AD. Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. *Addiction* 2005; 100(6):820-8
259. Dole VP, Nyswander ME, Kreek MJ. Narcotic blockade—a medical technique for stopping heroin use by addicts. *Trans Assoc Am Physicians* 1966; 79:122-36
260. Donaher PA, Welsh C. Managing opioid addiction with buprenorphine. *Am Fam Physician* 2006; 73(9):1573-8
261. Donny EC, Walsh SL, Bigelow GE, Eissenberg T, Stitzer ML. High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans. *Psychopharmacology (Berl)* 2002; 161(2):202-12
262. Donny EC, Brassler SM, Bigelow GE, Stitzer ML, Walsh SL. Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. *Addiction* 2005; 100(10):1496-509
263. Doran CM, Shanahan M, Mattick RP, Ali R, White J, Bell J. Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. *Drug Alcohol Depend* 2003; 71(3):295-302
264. Doran CM, Shanahan M, Bell J, Gibson A. A cost-effectiveness analysis of buprenorphine-assisted heroin withdrawal. *Drug Alcohol Rev* 2004; 23(2):171-5
265. Dore GM, Walker JD, Paice JR, Clarkson S. Methadone maintenance treatment: outcomes from the Otago methadone programme. *N Z Med J* 1999; 112(1100):442-5
266. Douglas SD. Methadone may promote HIV replication: study. *AIDS Alert* 2001; 16(9):120
267. Doherty M, White JM, Somogyi AA, Bochner F, Ali R, Ling W. Hyperalgesic responses in methadone maintenance patients. *Pain* 2001; 90(1-2):91-6
268. Doherty M, Somogyi AA, White JM, Bochner F, Beare CH, Menelaou A, Ling W. Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine. *Pain* 2001; 93(2):155-63
269. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. *Clin Pharmacokinet* 2000; 38(1):41-57
270. Dressler FA, Roberts WC. Modes of death and types of cardiac diseases in opiate addicts: analysis of 168 necropsy cases. *Am J Cardiol* 1989; 64(14):909-20
271. Drozdick J, III, Berghella V, Hill M, Kaltenbach K. Methadone trough levels in pregnancy. *Am J Obstet Gynecol* 2002; 187(5):1184-8
272. Duburcq A, Charpak Y, Blin P, Madec L. Suivi à 2 ans d'une cohorte de patients sous buprénorphine haut dosage. Résultats de l'étude SPESUB (suivi pharmaco-épidémiologique du Subutex en médecine de ville) [Two years follow-up of a heroin users cohort treated with high dosage buprenorphine. Results of the SPESUB study (pharmacoepidemiologic follow-up of general practice Subutex)]. *Rev Epidemiol Sante Publique* 2000; 48(4):363-73
273. Ducharme LJ, Luckey JW. Implementation of the methadone treatment quality assurance system. findings from the feasibility study. *Eval Health Prof* 2000; 23(1):72-90
274. Ducharme LJ, Knudsen HK, Roman PM. Evidence-based treatment for opiate-dependent clients: availability, variation, and organizational correlates. *Am J Drug Alcohol Abuse* 2006; 32(4):569-76

275. Duran S, Solas C, Spire B, Carrieri MP, Fuzibet JG, Costagliola D, Lacarelle B, Moatti JP. 'Do HIV-infected injecting drug users over-report adherence to highly active antiretroviral therapy?' A comparison between patients' self-reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study. *AIDS* 2001; 15(8):1075-7
276. Durst P, Palazzolo J, Peyrelong JP, Berger M, Chalabreysse M, Billiard M, Vialle A. Méthadone et Syndrome d'Apnées du Sommeil [Methadone and sleep apnea syndrome]. *Can J Psychiatry* 2005; 50(3):153-8
277. Dyer KR, White JM. Patterns of symptom complaints in methadone maintenance patients. *Addiction* 1997; 92(11):1445-55
278. Eap CB, Bourquin M, Martin J, Spagnoli J, Livoti S, Powell K, Baumann P, Deglon J. Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment. *Drug Alcohol Depend* 2000; 61(1):47-54
279. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. *Clin Pharmacokinet* 2002; 41(14):1153-93
280. Ebner N, Rohrmeister K, Winklbaaur B, Baewert A, Jagsch R, Peternell A, Thau K, Fischer G. Management of neonatal abstinence syndrome in neonates born to opioid maintained women. *Drug Alcohol Depend* 2006;
281. Ebner R, Schreiber W, Zierer C. Buprenorphin oder Methadon im Entzug junger Opiatabhängiger? [Buprenorphine or methadone for detoxification of young opioid addicts?]. *Psychiatr Prax* 2004; 31(Suppl 1):S108-S110
282. Eder H, Fischer G, Gombas W, Jagsch R, Haberler B, Rössler B, Kasper S. Methadone and buprenorphine in maintenance therapy for opioid dependence. 11th.European.College.of Neuropsychopharmacology Congress.Paris, France.31st.October 4th.November.1998. 1998. Ref Type: Abstract
283. Eder H, Fischer C, Gombas W, Jagsch R, Peternell A, Stuhlinger G, Aschauer HN, Kasper S. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. *NIDA Research Monograph* 2000; 180:159
284. Eder H, Jagsch R, Kraigher D, Primorac A, Ebner N, Fischer G. Comparative study of the effectiveness of slow-release morphine and methadone for opioid maintenance therapy. *Addiction* 2005; 100(8):1101-9
285. Edlin BR, Seal KH, Lorvick J, Kral AH, Ciccarone DH, Moore LD, Lo B. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? *N Engl J Med* 2001; 345(3):211-5
286. Edlin BR, Kresina TF, Raymond DB, Carden MR, Gourevitch MN, Rich JD, Cheever LW, Cargill VA. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. *Clin Infect Dis* 2005; 40 Suppl 5:S276-S285
287. Ehret GB, Desmeules JA, Broers B. Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology. *Expert Opin Drug Saf* 2007; 6(3):289-303
288. Eiber R, Puel M, Schmitt L. [Heroin abuse, autobiographical memory and depression]. *Encephale* 1999; 25(6):549-57
289. Eissenberg T, Greenwald MK, Johnson RE, Liebson IA, Bigelow GE, Stitzer ML. Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans. *J Pharmacol Exp Ther* 1996; 276(2):449-59

290. Eissenberg T, Johnson RE, Bigelow GE, Walsh SL, Liebson IA, Strain EC, Stitzer ML. Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients. *Drug Alcohol Depend* 1997; 45(1-2):81-91
291. el Bassel N, Chen DR, Cooper D. Social support and social network profiles among women on methadone. *Social-service-review* 1998; 72(3):379-401
292. el Bassel N, Gilbert L, Wu E, Go H, Hill J. HIV and intimate partner violence among methadone-maintained women in New York City. *Social-science-and-medicine* 2005; 61(1):171-83
293. Elhassan AM, Lindgren JU, Hultenby K, Bergstrom J, Adem A. Methionine-enkephalin in bone and joint tissues. *J Bone Miner Res* 1998; 13(1):88-95
294. Elkader A, Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. *Clin Pharmacokinet* 2005; 44(7):661-80
295. Emmanuelli J, Desenclos JC. Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003. *Addiction* 2005; 100(11):1690-700
296. Ensrud KE, Blackwell T, Mangione CM, Bowman PJ, Bauer DC, Schwartz A, Hanlon JT, Nevitt MC, Whooley MA. Central nervous system active medications and risk for fractures in older women. *Arch Intern Med* 2003; 163(8):949-57
297. Epstein DH, Preston KL. Does cannabis use predict poor outcome for heroin-dependent patients on maintenance treatment? Past findings and more evidence against. *Addiction* 2003; 98(3):269-79
298. Epstein DH, Hawkins WE, Covi L, Umbricht A, Preston KL. Cognitive-behavioral therapy plus contingency management for cocaine use: findings during treatment and across 12-month follow-up. *Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors* 2003; 17:73-82
299. Erriator I. Narcotic analgesics for chronic pain management. *Current Review of Pain* 1998; (2):193-200
300. Escaffre N, Morin M, Bouhnik AD, Fuzibet JG, Gastaut JA, Obadia Y, Moatti JP. Injecting drug users' adherence to HIV antiretroviral treatments: physicians' beliefs. *AIDS Care* 2000; 12(6):723-30
301. Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. Methadone maintenance at different dosages for opioid dependence. *Cochrane Database Syst Rev* 2003; (3):CD002208
302. Fajemirokun-Odudeyi O, Sinha C, Tutty S, Paireudeau P, Armstrong D, Phillips T, Lindow SW. Pregnancy outcome in women who use opiates. *Eur J Obstet Gynecol Reprod Biol* 2006; 126(2):170-5
303. Falcato L, Stohler R, Dürsteler-MacFarland KM, Eichenberger A, Eich D, Rössler W. Closure of an open drug scene - a case register-based analysis of the impact on the demand for methadone maintenance treatment. *Addiction* 2001; 96(4):623-8
304. Fanoë S, Hvidt C, Ege P, Jensen GB. Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen. *Heart* 2007;
305. Farre M, Mas A, Torrens M, Moreno V, Cami J. Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis. *Drug Alcohol Depend* 2002; 65(3):283-90
306. Farre M, Torrens M. Maintenance buprenorphine for opioid users. *Lancet* 2003; 361(9372):1906-7
307. FDA, CDER, CBER. E6 Guideline for good clinical practice: consolidated guidance. Rockville MD: ICH; 1996.

308. Ferrari A, Coccia CP, Bertolini A, Sternieri E. Methadone--metabolism, pharmacokinetics and interactions. *Pharmacol Res* 2004; 50(6):551-9
309. Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroin dependents. *Cochrane Database Syst Rev* 2005; (2):CD003410
310. Fiellin DA, O'Connor PG, Chawarski M, Pakes JP, Pantalon MV, Schottenfeld RS. Methadone maintenance in primary care: a randomized controlled trial. *JAMA : the journal of the American Medical Association* 2001; 286:1724-31
311. Fiellin DA, Barthwell AG. Guideline development for office-based pharmacotherapies for opioid dependence. *J Addict Dis* 2003; 22(4):109-20
312. Fiellin DA, O'Connor PG, Chawarski M, Schottenfeld RS. Processes of care during a randomized trial of office-based treatment of opioid dependence in primary care. *Am J Addict* 2004; 13 Suppl 1:S67-S78
313. Fiellin DA, Pantalon MV, Chawarski MC, Moore BA, Sullivan LE, O'Connor PG, Schottenfeld RS. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. *N Engl J Med* 2006; 355(4):365-74
314. Fiellin DA, Friedland GH, Gourevitch MN. Opioid dependence: rationale for and efficacy of existing and new treatments. *Clin Infect Dis* 2006; 43 Suppl 4:S173-S177
315. Fischer B, Cape D, Daniel N, Gliksman L. Methadone treatment in Ontario after the 1996 regulation reforms. Results of a physician survey. *Ann Med Interne (Paris)* 2002; 153(7 Suppl):2S11-21
316. Fischer B, Haydon E, Kim G, Rehm J, El-Guebaly N. Screening for antisocial personality disorder in drug users--a qualitative exploratory study on feasibility. *Int J Methods Psychiatr Res* 2003; 12(3):151-6
317. Fischer B, Rehm J, Kim G, Kirst M. Eyes wide shut?--A conceptual and empirical critique of methadone maintenance treatment. *Eur Addict Res* 2005; 11(1):1-9
318. Fischer G, Gombas W, Eder H, Jagsch R, Peternell A, Stuhlinger G, Pezawas L, Aschauer HN, Kasper S. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. *Addiction* 1999; 94(9):1337-47
319. Fischer G, Gombas W, Eder H, Jagsch R, Stühlinger G, Aschauer HN, Kasper S. Vergleichsuntersuchung von Buprenorphin und Methadon im Rahmen der Erhaltungstherapie Opiatkranker [Buprenorphine vs. methadone as maintenance treatment for opioid dependence]. *Der Nervenarzt* 1999; 70(9):795-802
320. Fischer G, Ortner R, Rohrmeister K, Jagsch R, Baewert A, Langer M, Aschauer H. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. *Addiction* 2006; 101(2):275-81
321. Fischman MW, Foltin RW. Stimulant-Opiate Interactions in Humans. *XXth.Collegium.Internationale.Neuro.psychopharmacologicum.Melbourne., Australia.* 23rd.27th.June., 1996. 1996. Ref Type: Abstract
322. Foltin RW, Christiansen I, Levin FR, Fischman MW. Effects of single and multiple intravenous cocaine injections in humans maintained on methadone. *J Pharmacol Exp Ther* 1995; 275(1):38-47
323. Fountain J, Strang J, Gossop M, Farrell M, Griffiths P. Diversion of prescribed drugs by drug users in treatment: analysis of the UK market and new data from London. *Addiction* 2000; 95(3):393-406

324. Fredheim OM, Borchgrevink PC, Klepstad P, Kaasa S, Dale O. Long term methadone for chronic pain: A pilot study of pharmacokinetic aspects. *Eur J Pain* 2006;
325. Freedman RR, Czertko G. A comparison of thrice weekly LAAM and daily methadone in employed heroin addicts. *Drug Alcohol Depend* 1981; 8(3):215-22
326. Frei A, Rehm J. Die Prävalenz psychischer Komorbidität unter Opiatabhängigen (eine Metaanalyse bisheriger Studien). *Psychiatrische Praxis* 2002; 29:258-62
327. Frei A, Rehm J. Komorbidität: Psychische Störungen bei Opiatabhängigen zu Beginn einer heroingestützten Behandlung. *Psychiatrische Praxis* 2002; 29:251-7
328. Friedland G, Andrews L, Schreibman T, Agarwala S, Daley L, Child M, Shi J, Wang Y, O'Mara E. Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. *AIDS* 2005; 19(15):1635-41
329. Friedman J, Alicea M, Fox KJ. Surviving heroin: interviews with women in methadone clinics. *American-journal-of-sociology* 2002; 108(3):710-3
330. Friedmann PD, Alexander JA, D'Aunno TA. Organizational correlates of access to primary care and mental health services in drug abuse treatment units. *J Subst Abuse Treat* 1999; 16(1):71-80
331. Friedmann PD, Alexander JA, Jin L, D'Aunno TA. On-site primary care and mental health services in outpatient drug abuse treatment units. *J Behav Health Serv Res* 1999; 26(1):80-94
332. Fudala PJ, Jaffe JH, Dax EM, Johnson RE. Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. *Clin Pharmacol Ther* 1990; 47(4):525-34
333. Galski T, Williams JB, Ehle HT. Effects of opioids on driving ability. *J Pain Symptom Manage* 2000; 19(3):200-8
334. Galynker II, Eisenberg D, Matochik JA, Gertmenian-King E, Cohen L, Kimes AS, Contoreggi C, Kurian V, Ernst M, Rosenthal RN, Prosser J, London ED. Cerebral metabolism and mood in remitted opiate dependence. *Drug Alcohol Depend* 2007;
335. Garrett ER, Chandran VR. Pharmacokinetics of morphine and its surrogates VI: Bioanalysis, solvolysis kinetics, solubility, pK'a values, and protein binding of buprenorphine. *J Pharm Sci* 1985; 74(5):515-24
336. Garrido MJ, Troconiz IF. Methadone: a review of its pharmacokinetic/pharmacodynamic properties. *J Pharmacol Toxicol Methods* 1999; 42(2):61-6
337. Gelkopf M, Bleich A, Hayward R, Adelson M. Patient outcomes after initiation of Sabbath closure of a methadone maintenance clinic in Israel. *Psychiatr Serv* 1998; 49(11):1483-5
338. Geraghty B, Graham EA, Logan B, Weiss EL. Methadone levels in breast milk. *J Hum Lact* 1997; 13(3):227-30
339. Gerber JG, Rosenkranz S, Segal Y, Aberg J, D'Amico R, Mildvan D, Gulick R, Hughes V, Flexner C, Aweeka F, Hsu A, Gal J. Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401. *J Acquir Immune Defic Syndr* 2001; 27(2):153-60
340. Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, Schraut WW, Schirren CA, Waechtler M, Backmund M, Pape GR. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. *Gastroenterology* 2003; 125(1):80-8

341. Gerra G, Ferri M, Polidori E, Santoro G, Zaimovic A, Sternieri E. Long-term methadone maintenance effectiveness: psychosocial and pharmacological variables. *J Subst Abuse Treat* 2003; 25(1):1-8
342. Gerra G, Borella F, Zaimovic A, Moi G, Bussandri M, Bubici C, Bertacca S. Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. *Drug Alcohol Depend* 2004; 75(1):37-45
343. Gerra G, Zaimovic A, Raggi MA, Moi G, Branchi B, Moroni M, Brambilla F. Experimentally induced aggressiveness in heroin-dependent patients treated with buprenorphine: Comparison of patients receiving methadone and healthy subjects. *Psychiatry Res* 2006;
344. Gerra G, Leonardi C, D'Amore A, Strepparola G, Fagetti R, Assi C, Zaimovic A, Lucchini A. Buprenorphine treatment outcome in dually diagnosed heroin dependent patients: A retrospective study. *Prog Neuropsychopharmacol Biol Psychiatry* 2006; 30(2):265-72
345. Gerra G, Fantoma A, Zaimovic A. Naltrexone and buprenorphine combination in the treatment of opioid dependence. *J Psychopharmacol* 2006;
346. Gerstein DR. The structure of heroin communities (in relation to methadone maintenance). *Am J Drug Alcohol Abuse* 1976; 3(4):571-87
347. Gerstein DR. Cultural action and heroin addiction. *Sociol Inq* 1981; 51(3-4):355-70
348. Giacomuzzi S, Haaser W, Pilsz L, Riemer Y. Driving impairment on buprenorphine and slow-release oral morphine in drug-dependent patients. *Forensic Sci Int* 2005; 152(2-3):323-4
349. Giacomuzzi SM, Riemer Y, Kemmler G, Ertl M, Richter R, Rossler H, Hinterhuber H. Subjektives Wohlbefinden und somatische Merkmale bei Methadonsubstitution. Evaluierung bei 61 Heroinabhängigen. [Subjective wellbeing and somatic markers in methadone substitution. Evaluation of 61 heroin addicts]. *Fortschr Med Orig* 2001; 119(3-4):103-8
350. Giacomuzzi SM, Riemer Y, Kemmler G, Ertl M, Richter R, Rossler H, Hinterhuber H. Subjektives Wohlbefinden und somatische Merkmale bei Methadonsubstitution [Subjective wellbeing and somatic markers in methadone substitution. Evaluation of 61 heroin addicts]. *MMW Fortschr Med* 2001; 119(3-4):103-8
351. Giacomuzzi SM, Riemer Y, Kemmler G, Ertl M, Richter R, Rossler H, Hinterhuber H. [Subjective wellbeing in heroin withdrawal. With methadone the patient feels better]. *MMW Fortschr Med* 2001; 143(37):53
352. Giacomuzzi SM, Riemer Y, Ertl M, Kemmler G, Rossler H, Hinterhuber H, Kurz M. Buprenorphine versus methadone maintenance treatment in an ambulant setting: a health-related quality of life assessment. *Addiction* 2003; 98(5):693-702
353. Giacomuzzi SM, Ertl M, Riemer Y, Rossler H, Vigl A, Hinterhuber H, Kurz M. [Current consumer conditions among opioid addicts--implications for maintenance-treatment programmes provided by ambulatory drug treatment centers and physicians]. *Wien Klin Wochenschr* 2004; 116(4):119-27
354. Giacomuzzi SM, Ertl M, Kemmler G, Riemer Y, Vigl A. Sublingual buprenorphine and methadone maintenance treatment: a three-year follow-up of quality of life assessment. *ScientificWorldJournal* 2005; 5:452-68
355. Giacomuzzi SM, Riemer Y, Ertl M, Kemmler G, Rossler H, Hinterhuber H, Kurz M. Gender differences in health-related quality of life on admission to a maintenance treatment program. *Eur Addict Res* 2005; 11(2):69-75
356. Gibson AE, Doran CM, Bell JR, Ryan A, Lintzeris N. A comparison of buprenorphine treatment in clinic and primary care settings: a randomised trial. *Med J Aust* 2003; 179(1):38-42

357. Gil M, Sala M, Anguera I, Chapinal O, Cervantes M, Guma JR, Segura F. QT prolongation and Torsades de Pointes in patients infected with human immunodeficiency virus and treated with methadone. *Am J Cardiol* 2003; 92(8):995-7
358. Gilbert L, El-Bassel N, Manuel J, Wu E, Go H, Golder S, Seewald R, Sanders G. An integrated relapse prevention and relationship safety intervention for women on methadone: testing short-term effects on intimate partner violence and substance use. *Violence Vict* 2006; 21(5):657-72
359. Gill AC, Oei J, Lewis NL, Younan N, Kennedy I, Lui K. Strabismus in infants of opiate-dependent mothers. *Acta Paediatr* 2003; 92(3):379-85
360. Glasper A, Reed LJ, de Wet CJ, Gossop M, Bearn J. Induction of patients with moderately severe methadone dependence onto buprenorphine. *Addict Biol* 2005; 10(2):149-55
361. Goff M, O'Connor M. Perinatal care of women maintained on methadone. *J Midwifery Womens Health* 2007; 52(3):e23-e26
362. Goldstein A, Herrera J. Heroin addicts and methadone treatment in Albuquerque: a 22-year follow-up. *Drug Alcohol Depend* 1995; 40(2):139-50
363. Goldstein A, Brown BW. Urine testing in methadone maintenance treatment: applications and limitations. *J Subst Abuse Treat* 2003; 25(2):61-3
364. Gomart E. Methadone: six effects in search of a substance. *Social-studies-of-science* 2002; 32(1):93-136
365. Gonzalez G, Sevarino K, Sofuoglu M, Poling J, Oliveto A, Gonsai K, George TP, Kosten TR. Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study. *Addiction* 2003; 98(11):1625-32
366. Gonzalez M, Cebrian S, Nadal C, Sala L, Vall-Llosera A, Delas J. Ciudadanos del este de Europa consumidores de drogas en Barcelona [Injecting drug users from Eastern Europe in Barcelona, Spain]. *Gac Sanit* 2003; 17(3):256-8
367. Goodnick PJ, Jerry J, Parra F. Psychotropic drugs and the ECG: focus on the QTc interval. *Expert Opin Pharmacother* 2002; 3(5):479-98
368. Gorazd M, Kamenczak A, Pach J, Schmager J, Wronka I. [Preliminary research on opioid mutagenicity]. *Przegl Lek* 2003; 60(4):245-8
369. Gossop M, Marsden J, Stewart D, Kidd T. The National Treatment Outcome Research Study (NTORS): 4-5 year follow-up results. *Addiction* 2003; 98(3):291-303
370. Gossop M, Stewart D, Marsden J. Treatment process components and heroin use outcome among methadone patients. *Drug Alcohol Depend* 2003; 71(1):93-102
371. Gossop M, Stewart D, Browne N, Marsden J. Methadone treatment for opiate dependent patients in general practice and specialist clinic settings: Outcomes at 2-year follow-up. *J Subst Abuse Treat* 2003; 24(4):313-21
372. Gossop M, Marsden J, Stewart D. Remission of psychiatric symptoms among drug misusers after drug dependence treatment. *J Nerv Ment Dis* 2006; 194(11):826-32
373. Gourevitch MN, Friedland GH. Methadone and antiretroviral medications, part II. *AIDS Clin Care* 1999; 11(5):37, 43, 45-37, 43, 46
374. Gowing L, Ali R, White J. Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. *Cochrane Database Syst Rev* 2002; (2):CD002022

375. Gowing L, Ali R, White J. Buprenorphine for the management of opioid withdrawal. *Cochrane Database Syst Rev* 2004; (4):CD002025
376. Gowing L, Farrell M, Bornemann R, Ali R. Substitution treatment of injecting opioid users for prevention of HIV infection. *Cochrane Database Syst Rev* 2004; (4):10.1002./14651858.
377. Gowing L, Farrell M, Ali R, White J. Alpha2 adrenergic agonists for the management of opioid withdrawal. *Cochrane Database Syst Rev* 2004; (4):CD002024
378. Gowing L, Ali R, White J. Buprenorphine for the management of opioid withdrawal. *Cochrane Database Syst Rev* 2006; (2):CD002025
379. Gowing L, Ali R, White J. Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. *Cochrane Database Syst Rev* 2006; (2):CD002022
380. Gowing L, Ali R, White J. Opioid antagonists with minimal sedation for opioid withdrawal. *Cochrane Database of Syst Rev* 2006; (1):CD002021
381. Gowing LR, Farrell M, Bornemann R, Sullivan LE, Ali RL. Brief report: Methadone treatment of injecting opioid users for prevention of HIV infection. *J Gen Intern Med* 2006; 21(2):193-5
382. Gowing LR, Ali RL. The place of detoxification in treatment of opioid dependence. *Curr Opin Psychiatry* 2006; 19(3):266-70
383. Greenhalgh T. *Einführung in die Evidence-based Medicine*. Bern: Verlag Hans Huber; 2003.
384. Greenwald M, Johanson CE, Bueller J, Chang Y, Moody DE, Kilbourn M, Koeppe R, Zubieta JK. Buprenorphine Duration of Action: Mu-opioid Receptor Availability and Pharmacokinetic and Behavioral Indices. *Biol Psychiatry* 2006;
385. Greenwald MK, Johanson CE, Schuster CR. Opioid reinforcement in heroin-dependent volunteers during outpatient buprenorphine maintenance. *Drug Alcohol Depend* 1999; 56(3):191-203
386. Greenwald MK. Heroin craving and drug use in opioid-maintained volunteers: effects of methadone dose variations. *Exp Clin Psychopharmacol* 2002; 10(1):39-46
387. Greenwald MK, Schuh KJ, Hopper JA, Schuster CR, Johanson CE. Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans. *Psychopharmacology (Berl)* 2002; 160(4):344-52
388. Greenwald MK. Maximizing Suppression of Heroin Craving: A Randomized-Group, Double-Blind Comparison of Two Methadone Induction Schedules. *Drug and alcohol dependence* 2002; 66 Suppl 1:68-9
389. Greenwald MK, Schuh KJ, Stine SM. Transferring methadone-maintained outpatients to the buprenorphine sublingual tablet: a preliminary study. *Am J Addict* 2003; 12(4):365-74
390. Greenwald MK, Johanson CE, Moody DE, Woods JH, Kilbourn MR, Koeppe RA, Schuster CR, Zubieta JK. Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. *Neuropsychopharmacology* 2003; 28(11):2000-9
391. Greenwald MK. Opioid craving and seeking behavior in physically dependent volunteers: effects of acute withdrawal and drug reinforcement opportunity. *Exp Clin Psychopharmacol* 2005; 13(1):3-14
392. Greenwald MK. Early impact of methadone induction for heroin dependence: differential effects of two dose sequences in a randomized controlled study. *Exp Clin Psychopharmacol* 2006; 14(1):52-67

393. Greenwald MK, Hursh SR. Behavioral economic analysis of opioid consumption in heroin-dependent individuals: Effects of unit price and pre-session drug supply. *Drug Alcohol Depend* 2006;
394. Gruber SA, Tzilos GK, Silveri MM, Pollack M, Renshaw PF, Kaufman MJ, Yurgelun-Todd DA. Methadone maintenance improves cognitive performance after two months of treatment. *Exp Clin Psychopharmacol* 2006; 14(2):157-64
395. Guichard A, Lert F, Calderon C, Gaigi H, Maguet O, Soletti J, Brodeur JM, Richard L, Benigeri M, Zunzunegui MV. Illicit drug use and injection practices among drug users on methadone and buprenorphine maintenance treatment in France. *Addiction* 2003; 98(11):1585-97
396. Gunderson EW, Fiellin DA, Levin FR, Sullivan LE, Kleber HD. Evaluation of a combined online and in person training in the use of buprenorphine. *Subst Abus* 2006; 27(3):39-45
397. Gunne LM, Grönbladh L. The Swedish methadone maintenance program: a controlled study. *Drug and alcohol dependence* 1981; 7:249-56
398. Haasen C, Van den BW. Innovations in agonist maintenance treatment of opioid-dependent patients. *Curr Opin Psychiatry* 2006; 19(6):631-6
399. Habrat B, Chmielewska K, Baran-Furga H, Keszycka B, Taracha E. [Subjective Quality of Life in opiate-dependent patients before admission after six months and one-year participation in methadone program]. *Przegl Lek* 2002; 59(4-5):351-4
400. Haddad M, Inch C, Glazier RH, Wilkins AL, Bayoumi A, Rourke S. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. Haddad M , Inch C , Glazier RH , Wilkins AL, Bayoumi A, Rourke S Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV /AIDS The Cochrane Database of Systematic Reviews : Reviews 2000 Issue 3 John Wiley & 2000;
401. Hagan H, Strauss SM, Astone JM, Des J. Medical examinations at entry to treatment for drug abuse as an opportunity to initiate care for hepatitis C virus infection. *Clin Infect Dis* 2005; 40 Suppl 5:S297-S303
402. Haig T. Randomized controlled trial proves effectiveness of methadone maintenance treatment in prison. *Can HIV AIDS Policy Law Rev* 2003; 8(3):48
403. Hallinan R, Byrne A, Amin J, Dore GJ. Hepatitis C virus incidence among injecting drug users on opioid replacement therapy. *Aust N Z J Public Health* 2004; 28(6):576-8
404. Hallinan R, Byrne A, Amin J, Dore GJ. Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy. *J Gastroenterol Hepatol* 2005; 20(7):1082-6
405. Hallinan R, Ray J, Byrne A, Agho K, Attia J. Therapeutic thresholds in methadone maintenance treatment: A receiver operating characteristic analysis. *Drug Alcohol Depend* 2006; 81(2):129-36
406. Hamilton SP, Nunes EV, Janal M, Weber L. The effect of sertraline on methadone plasma levels in methadone-maintenance patients. *Am J Addict* 2000; 9(1):63-9
407. Hand CW, Sear JW, Uppington J, Ball MJ, McQuay HJ, Moore RA. Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. *Br J Anaesth* 1990; 64(3):276-82
408. Hansen GR. The drug-seeking patient in the emergency room. *Emerg Med Clin North Am* 2005; 23(2):349-65

409. Hao W, Zhao M. A comparative clinical study of the effect of WeiniCom, a Chinese herbal compound, on alleviation of withdrawal symptoms and craving for heroin in detoxification treatment. *J Psychoactive Drugs* 2000; 32(3):277-84
410. Haro G, Martinez-Raga J, Castellano M, Bolinches F, de VP, Valderrama JC. Prescripción médica de heroína: existe evidencia científica de su eficacia en el tratamiento de la dependencia de la misma? [Heroin prescribing: Is there scientific evidence of its efficacy for the treatment of its dependence?]. *Actas Esp Psiquiatr* 2001; 29(5):343-8
411. Harris AH, Gospodarevskaya E, Ritter AJ. A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting. *Pharmacoeconomics* 2005; 23:77-91
412. Harris KA, Jr., Arnsten JH, Joseph H, Hecht J, Marion I, Juliana P, Gourevitch MN. A 5-year evaluation of a methadone medical maintenance program. *J Subst Abuse Treat* 2006; 31(4):433-8
413. Haug NA, Svikis DS, Diclemente C. Motivational enhancement therapy for nicotine dependence in methadone-maintained pregnant women. *Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors* 2004; 18:289-92
414. Haug NA, Sorensen JL, Lollo ND, Gruber VA, Delucchi KL, Hall SM. Gender differences among HIV-positive methadone maintenance patients enrolled in a medication adherence trial. *AIDS Care* 2005; 17(8):1022-9
415. Hawkinson JE, costa-Burrueal M, Espitia SA. Opioid activity profiles indicate similarities between the nociceptin/orphanin FQ and opioid receptors. *Eur J Pharmacol* 2000; 389(2-3):107-14
416. Healey A, Knapp M, Marsden J, Gossop M, Stewart D. Criminal outcomes and costs of treatment services for injecting and non-injecting heroin users: evidence from a national prospective cohort survey. *J Health Serv Res Policy* 2003; 8(3):134-41
417. Heel RC, Brogden RN, Speight TM, Avery GS. Buprenorphine: a review of its pharmacological properties and therapeutic efficacy. *Drugs* 1979; 17(2):81-110
418. Heilig M, Kakko J. Dämpat drogsuch och bättre social funktion med buprenorfinterapi. Kombinationsbehandling alternativ till metadon vid heroinmissbruk [Reduced drug craving and better social function with buprenorphine therapy. Combination therapy as an alternative to methadone therapy in heroin addiction]. *Lakartidningen* 2003; 100(32-33):2526-7
419. Heimer R, Catania H, Newman RG, Zambrano J, Brunet A, Ortiz AM. Methadone maintenance in prison: Evaluation of a pilot program in Puerto Rico. *Drug Alcohol Depend* 2006; 83(2):122-9
420. Heinemann A, Iwersen-Bergmann S, Stein S, Schmoldt A, Puschel K. Methadone-related fatalities in Hamburg 1990-1999: implications for quality standards in maintenance treatment? *Forensic Sci Int* 2000; 113(1-3):449-55
421. Hendrix CW, Wakeford J, Wire MB, Lou Y, Bigelow GE, Martinez E, Christopher J, Fuchs EJ, Snidow JW. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects. *Pharmacotherapy* 2004; 24(9):1110-21
422. Henry-Edwards S, Gowing L, White J, Ali R, Bell J, Brough R, Lintzeris N, Ritter A, Quigley A. Clinical Guidelines and Procedures for the Use of Methadone in the Maintenance Treatment of Opioid Dependence. Canberra: Commonwealth of Australia; 2003 Aug.
423. Hepner IJ, Homewood J, Taylor AJ. Methadone disrupts performance on the working memory version of the Morris water task. *Physiol Behav* 2002; 76(1):41-9

424. Herve S, Riachi G, Noblet C, Guillement N, Tanasescu S, Gorla O, Thuillez C, Tranvouez JL, Ducrotte P, Lerebours E. Acute hepatitis due to buprenorphine administration. *Eur J Gastroenterol Hepatol* 2004; 16(10):1033-7
425. Hill JL, Zacny JP. Comparing the subjective, psychomotor, and physiological effects of intravenous hydromorphone and morphine in healthy volunteers. *Psychopharmacology (Berl)* 2000; 152(1):31-9
426. Hoffmann M. Anzahl der Klient/innen in Beratung und Betreuung und Anteil der Migranten. Lippe Detmold: Drogenberatung e.V.; 2001.
427. Hopfer CJ, Khuri E, Crowley TJ, Hooks S. Adolescent heroin use: a review of the descriptive and treatment literature. *J Subst Abuse Treat* 2002; 23(3):231-7
428. Hopwood M, Southgate E, Kippax S, Bammer G, Isaac-Toua G, MacDonald M. The injection of methadone syrup in New South Wales: patterns of use and increased harm after partial banning of injecting equipment. *Aust N Z J Public Health* 2003; 27(5):551-5
429. Hosek M. Substitutionsbehandlungen in der Schweiz: Fortsetzung einer Erfolgsgeschichte. *SuchtMagazin* 2006; 06(1):3-9
430. Hotham E, Roche A, Skinner N, Dollman B. The general practitioner pharmacotherapy prescribing workforce: examining sustainability from a systems perspective. *Drug Alcohol Rev* 2005; 24(5):393-400
431. Hou Y, Tan Y, Belcheva MM, Clark AL, Zahm DS, Coscia CJ. Differential effects of gestational buprenorphine, naloxone, and methadone on mesolimbic mu opioid and ORL1 receptor G protein coupling. *Brain Res Dev Brain Res* 2004; 151(1-2):149-57
432. Houtsmuller EJ, Walsh SL, Schuh KJ, Johnson RE, Stitzer ML, Bigelow GE. Dose-response analysis of opioid cross-tolerance and withdrawal suppression during LAAM maintenance. *J Pharmacol Exp Ther* 1998; 285(2):387-96
433. Hrovatin E, Zardo F, Brieda M, Dametto E, Piazza R, ntonini-Canterin F, Cassin M, Meneguzzo N, Viel E, Lestuzzi C, Di Gennaro G, Nicolosi GL. Allungamento del QT e torsione di punta in un paziente con immunodeficienza virale acquisita in multiterapia con farmaci utilizzatori del citocromo P450 [Long QT and torsade de pointes in a patient with acquired human immunodeficiency virus infection in multitherapy with drugs affecting cytochrome P450]. *Ital Heart J Suppl* 2004; 5(9):735-40
434. Hser YI, Anglin MD, Booth MW. Sex differences in addict careers. 3. *Addiction. Am J Drug Alcohol Abuse* 1987; 13(3):231-51
435. Hser YI, Hoffman V, Grella CE, Anglin MD. A 33-year follow-up of narcotics addicts. *Arch Gen Psychiatry* 2001; 58(5):503-8
436. Hser YI, Evans E, Huang D, Anglin DM. Relationship between drug treatment services, retention, and outcomes. *Psychiatr Serv* 2004; 55(7):767-74
437. Hsyu PH, Lillibridge J, Daniels E, Kerr BM. Pharmacokinetic interaction of nelfinavir and methadone in intravenous drug users. *Biopharm Drug Dispos* 2005; 27(2):61-8
438. Huang P, Kehner GB, Cowan A, Liu-Chen LY. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. *J Pharmacol Exp Ther* 2001; 297(2):688-95
439. Huber M, Schmid P, Vernazza P, Meili D. Reasons for the lack of treatment of hepatitis C infection in drug dependent patients in opiate substitution. *Suchttherapie* 2002; (3(Suppl)):27-30

440. Huber M, Weber R, Oppliger R, Vernazza P, Schmid P, Schönbucher P, Bertisch B, Meili D, Renner EL. Interferon alpha-2a plus ribavirin 1000/1200mg versus Interferon alpha-2a plus ribavirin 600mg for chronic hepatitis c infection in patients on opiate maintenance treatment: an open-label randomized multicenter trial. *Infection* 2005; 33:25-9
441. Hulse GK, Milne E, English DR, Holman CD. Assessing the relationship between maternal opiate use and antepartum haemorrhage. *Addiction* 1998; 93(10):1553-8
442. Hulse GK, Milne E, English DR, Holman CD. Assessing the relationship between maternal opiate use and neonatal mortality. *Addiction* 1998; 93(7):1033-42
443. Humeniuk R, Ali R, McGregor C, Darke S. Prevalence and correlates of intravenous methadone syrup administration in Adelaide, Australia. *Addiction* 2003; 98(4):413-8
444. Hussain T, Ewer AK. Maternal methadone may cause arrhythmias in neonates. *Acta Paediatr* 2007; 96(5):768-9
445. Hutchinson MR, Somogyi AA. (S)-(+)-methadone is more immunosuppressive than the potent analgesic (R)-(-)-methadone. *Int Immunopharmacol* 2004; 4(12):1525-30
446. Hutchinson SJ, Taylor A, Gruer L, Barr C, Mills C, Elliott L, Goldberg DJ, Scott R, Gilchrist G. One-year follow-up of opiate injectors treated with oral methadone in a GP-centred programme. *Addiction* 2000; 95(7):1055-68
447. Ibrahim RB, Wilson JG, Thorsby ME, Edwards DJ. Effect of buprenorphine on CYP3A activity in rat and human liver microsomes. *Life Sci* 2000; 66(14):1293-8
448. Inturrisi CE, Verebely K. The levels of methadone in the plasma in methadone maintenance. *Clin Pharmacol Ther* 1972; 13(5):633-7
449. Inturrisi CE. Clinical pharmacology of opioids for pain. *Clin J Pain* 2002; 18(4 Suppl):S3-13
450. Inturrisi CE. Pharmacology of methadone and its isomers. *Minerva Anesthesiol* 2005; 71(7-8):435-7
451. Iribarne C, Picart D, Dreano Y, Bail JP, Berthou F. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. *Life Sci* 1997; 60(22):1953-64
452. Iribarne C, Berthou F, Carlhant D, Dreano Y, Picart D, Lohezic F, Riche C. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. *Drug Metab Dispos* 1998; 26(3):257-60
453. Iskandar SB, bi-Saleh BS, Mechleb BK, Fahrig SA. Methadone and torsade de pointes: case report and review of the literature. *Tenn Med* 2007; 100(2):35-7, 42
454. Jaeckel E, Wedemeyer H, Wiegand J, Manns MP. Acute hepatitis C virus infection: to treat or not to treat? *Gastroenterology* 2004; 126(4):1219-20
455. Jaffe JH, O'Keeffe C. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States. *Drug Alcohol Depend* 2003; 70(2 Suppl):S3-S11
456. Jamieson Beals Lalonde and Associates Inc. Best Practices - Methadone Maintenance Treatment. Ottawa: Office of Canada's Drug Strategy Health Canada; 2002.
457. Janiri L, Martinotti G, Dario T, Reina D, Paparello F, Pozzi G, Addolorato G, Di GM, De RS. Anhedonia and substance-related symptoms in detoxified substance-dependent subjects: a correlation study. *Neuropsychobiology* 2005; 52(1):37-44

458. Jansson LM, Dipietro J, Elko A. Fetal response to maternal methadone administration. *Am J Obstet Gynecol* 2005; 193(3 Pt 1):611-7
459. Jansson LM, Choo RE, Harrow C, Velez M, Schroeder JR, Lowe R, Huestis MA. Concentrations of methadone in breast milk and plasma in the immediate perinatal period. *J Hum Lact* 2007; 23(2):184-90
460. Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. *Arch Gen Psychiatry* 1978; 35(4):501-16
461. Jasinski DR. Human pharmacology of narcotic antagonists. *Br J Clin Pharmacol* 1979; 7 Suppl 3:287S-90S
462. Jasinski DR. Clinical pharmacology of mixed agonist-antagonist drugs [proceedings]. *Psychopharmacol Bull* 1981; 17(1):85-6
463. Jasinski DR, Fudala PJ, Johnson RE. Sublingual versus subcutaneous buprenorphine in opiate abusers. *Clin Pharmacol Ther* 1989; 45(5):513-9
464. Jasinski DR. Tolerance and dependence to opiates. *Acta Anaesthesiol Scand* 1997; 41(1 Pt 2):184-6
465. Johnson K, Greenough A, Gerada C. Maternal drug use and length of neonatal unit stay. *Addiction* 2003; 98(6):785-9
466. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. First randomized controlled trial of methadone, Levomethadyl Acetate, Buprenorphine in Opioid Dependence. *Clinical Pharmacology & Therapeutics* 1999; 65:145
467. Johnson RE, McCagh JC. Buprenorphine and naloxone for heroin dependence. *Curr Psychiatry Rep* 2000; 2(6):519-26
468. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. *N Engl J Med* 2000; 343(18):1290-7
469. Johnson RE, Strain EC, Amass L. Buprenorphine: how to use it right. *Drug Alcohol Depend* 2003; 70(2 Suppl):S59-S77
470. Johnson RE, Fudala PJ, Payne R. Buprenorphine: considerations for pain management. *J Pain Symptom Manage* 2005; 29(3):297-326
471. Jones BE, Prada JA. Drug-seeking behavior during methadone maintenance. *Psychopharmacologia* 1975; 41(1):7-10
472. Jones HE, Johnson RE, Jasinski DR, O'Grady KE, Chisholm CA, Choo RE, Crocetti M, Dudas R, Harrow C, Huestis MA, Jansson LM, Lantz M, Lester BM, Milio L. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. *Drug Alcohol Depend* 2005; 79(1):1-10
473. Jones HE, Suess P, Jasinski DR, Johnson RE. Transferring methadone-stabilized pregnant patients to buprenorphine using an immediate release morphine transition: an open-label exploratory study. *Am J Addict* 2006; 15(1):61-70
474. Joseph H, Stancliff S, Langrod J. Methadone maintenance treatment (MMT): a review of historical and clinical issues. *Mt Sinai J Med* 2000; 67(5-6):347-64

475. Joseph R, Moselhy HF. National survey of methadone prescribing for maintenance treatment: 'opiophobia' among substance misuse services? *Psychiatr Bull* 2005; 29(12):459-61
476. Jowett SL, Agarwal K, Smith BC, Craig W, Hewett M, Bassendine DR, Gilvarry E, Burt AD, Bassendine MF. Managing chronic hepatitis C acquired through intravenous drug use. *QJM* 2001; 94(3):153-8
477. Justo D. Methadone-induced long QT syndrome vs methadone-induced torsades de pointes. *Arch Intern Med* 2006; 166(20):2288-90
478. Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. *Lancet* 2003; 361(9358):662-8
479. Kakko J, Gronbladh L, Svanborg KD, von WJ, Ruck C, Rawlings B, Nilsson LH, Heilig M. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. *Am J Psychiatry* 2007; 164(5):797-803
480. Kamal F, Flavin S, Campbell F, Behan C, Fagan J, Smyth R. Factors affecting the outcome of methadone maintenance treatment in opiate dependence. *Ir Med J* 2007; 100(3):393-7
481. Kantor TG, Cantor R, Tom E. A study of hospitalized surgical patients on methadone maintenance. *Drug Alcohol Depend* 1980; 6(3):163-73
482. Kaplan JE, Parham DL, Soto-Torres L, van DK, Greaves JA, Rauch K, Ellis B, Amandus HE. Adherence to guidelines for antiretroviral therapy and for preventing opportunistic infections in HIV-infected adults and adolescents in Ryan White-funded facilities in the United States. *J Acquir Immune Defic Syndr* 1999; 21(3):228-35
483. Karasz A, Zallman L, Berg K, Gourevitch M, Selwyn P, Arnsten JH. The experience of chronic severe pain in patients undergoing methadone maintenance treatment. *J Pain Symptom Manage* 2004; 28(5):517-25
484. Karch SB, Stephens BG. Toxicology and pathology of deaths related to methadone: retrospective review. *West J Med* 2000; 172(1):11-4
485. Kashiwagi M, Arlettaz R, Lauper U, Zimmermann R, Hebisch G. Methadone maintenance program in a Swiss perinatal center: (I): Management and outcome of 89 pregnancies. *Acta Obstet Gynecol Scand* 2005; 84(2):140-4
486. Katchman AN, McGroary KA, Kilborn MJ, Kornick CA, Manfredi PL, Woosley RL, Ebert SN. Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents. *J Pharmacol Exp Ther* 2002; 303(2):688-94
487. Kayemba-Kay's S, Lacllyde JP. Buprenorphine withdrawal syndrome in newborns: a report of 13 cases. *Addiction* 2003; 98(11):1599-604
488. Keen J, Rowse G, Mathers N, Campbell M, Seivewright N. Can methadone maintenance for heroin-dependent patients retained in general practice reduce criminal conviction rates and time spent in prison? *Br J Gen Pract* 2000; 50(450):48-9
489. Keen J, Oliver P, Mathers N. Methadone maintenance treatment can be provided in a primary care setting without increasing methadone-related mortality: the Sheffield experience 1997-2000. *Br J Gen Pract* 2002; 52(478):387-9
490. Keen J, Oliver P, Rowse G, Mathers N. Does methadone maintenance treatment based on the new national guidelines work in a primary care setting? *Br J Gen Pract* 2003; 53(491):461-7

491. Kell MJ. Utilization of plasma and urine methadone concentrations to optimize treatment in maintenance clinics: I. Measurement techniques for a clinical setting. *J Addict Dis* 1994; 13(1):5-26
492. Kenna GA, Nielsen DM, Mello P, Schiesl A, Swift RM. Pharmacotherapy of dual substance abuse and dependence. *CNS Drugs* 2007; 21(3):213-37
493. Kerr T, Wodak A, Elliott R, Montaner JS, Wood E. Opioid substitution and HIV/AIDS treatment and prevention. *Lancet* 2004; 364(9449):1918-9
494. Khalsa J, Vocci F, Altice F, Fiellin D, Miller V. Buprenorphine and HIV Primary Care: New Opportunities for Integrated Treatment. *Clin Infect Dis* 2006; 43 Suppl 4:S169-S172
495. Kharasch ED, Mautz D, Senn T, Lentz G, Cox K. Menstrual cycle variability in midazolam pharmacokinetics. *J Clin Pharmacol* 1999; 39(3):275-80
496. Kharasch ED, Hoffer C, Whittington D. The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. *British journal of clinical pharmacology* 2004; 57:600-10
497. Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. *Clinical pharmacology and therapeutics* 2004; 76:250-69
498. Khawaja IS, Feinstein RE. Cardiovascular effects of selective serotonin reuptake inhibitors and other novel antidepressants. *Heart Dis* 2003; 5(2):153-60
499. Kidorf M, Stitzer ML, Brooner RK, Goldberg J. Contingent methadone take-home doses reinforce adjunct therapy attendance of methadone maintenance patients 38. *Drug Alcohol Depend* 1994; 36(3):221-6
500. Kidorf M, King VL, Neufeld K, Stoller KB, Peirce J, Brooner RK. Involving significant others in the care of opioid-dependent patients receiving methadone. *J Subst Abuse Treat* 2005; 29(1):19-27
501. Kilicarslan T, Sellers EM. Lack of interaction of buprenorphine with flunitrazepam metabolism. *Am J Psychiatry* 2000; 157(7):1164-6
502. King CD, Rios GR, Green MD, MacKenzie PI, Tephly TR. Comparison of stably expressed rat UGT1.1 and UGT2B1 in the glucuronidation of opioid compounds. *Drug Metab Dispos* 1997; 25(2):251-5
503. King VL, Kidorf MS, Stoller KB, Schwartz R, Kolodner K, Brooner RK. A 12-month controlled trial of methadone medical maintenance integrated into an adaptive treatment model. *J Subst Abuse Treat* 2006; 31(4):385-93
504. Kinjo M, Setoguchi S, Schneeweiss S, Solomon DH. Bone mineral density in subjects using central nervous system-active medications. *Am J Med* 2005; 118(12):1414
505. Kinlock TW, Battjes RJ, Schwartz RP. A novel opioid maintenance program for prisoners: report of post-release outcomes. *Am J Drug Alcohol Abuse* 2005; 31(3):433-54
506. Kintz P. A new series of 13 buprenorphine-related deaths. *Clin Biochem* 2002; 35(7):513-6
507. Kissin W, McLeod C, Sonnefeld J, Stanton A. Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. *J Addict Dis* 2006; 25(4):91-103
508. Knight DK, Cross DR, Giles-Sims J, Simpson DD. Psychosocial functioning among adult drug users: the role of parental absence, support, and conflict. *Int J Addict* 1995; 30(10):1271-88

509. Knudsen HK, Ducharme LJ, Roman PM, Link T. Buprenorphine diffusion: the attitudes of substance abuse treatment counselors. *J Subst Abuse Treat* 2005; 29(2):95-106
510. Knudsen HK, Ducharme LJ, Roman PM. Early adoption of buprenorphine in substance abuse treatment centers: data from the private and public sectors. *J Subst Abuse Treat* 2006; 30(4):363-73
511. Kobayashi K, Yamamoto T, Chiba K, Tani M, Shimada N, Ishizaki T, Kuroiwa Y. Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. *Drug Metab Dispos* 1998; 26(8):818-21
512. Koch M, Banys P. Liver transplantation and opioid dependence. *JAMA* 2001; 285(8):1056-8
513. Kocheril AG, Bokhari SA, Batsford WP, Sinusas AJ. Long QTc and torsades de pointes in human immunodeficiency virus disease. *Pacing Clin Electrophysiol* 1997; 20(11):2810-6
514. Kolarzyk E, Jenner B, Szpanowska-Wohn A, Pach D, Szurkowska M. The changes in taste preferences during 4 years period of methadone maintenance treatment. *Przegl Lek* 2005; 62(6):378-81
515. Kolpe M, Carlson GA. Influence of attention-deficit/hyperactivity disorder symptoms on methadone treatment outcome. *Am J Addict* 2007; 16(1):46-8
516. Kornick CA, Kilborn MJ, Santiago-Palma J, Schulman G, Thaler HT, Keefe DL, Katchman AN, Pezzullo JC, Ebert SN, Woosley RL, Payne R, Manfredi PL. QTc interval prolongation associated with intravenous methadone. *Pain* 2003; 105(3):499-506
517. Kornor H, Waal H. [Methadone dose, treatment duration and heroin use in drug-assisted rehabilitation]. *Tidsskr Nor Laegeforen* 2004; 124(3):332-4
518. Kornor H, Waal H. From opioid maintenance to abstinence: a literature review. *Drug Alcohol Rev* 2005; 24(3):267-74
519. Kornor H, Waal H. From opioid maintenance to abstinence: a literature review. *Drug Alcohol Rev* 2005; 24(3):267-74
520. Kornor H, Waal H, Ali RL. Abstinence-orientated buprenorphine replacement therapy for young adults in out-patient counselling. *Drug Alcohol Rev* 2006; 25(2):123-30
521. Kornor H, Waal H, Ali RL. Abstinence-orientated buprenorphine replacement therapy for young adults in out-patient counselling. *Drug Alcohol Rev* 2006; 25(2):123-30
522. Kosten T, Falcioni J, Oliveto A, Feingold A. Depression predicts higher rates of heroin use on desipramine with buprenorphine than with methadone. *Am J Addict* 2004; 13(2):191-201
523. Kosten TR, Rayford BS. Effects of ethnicity on low-dose opiate stabilization. *J Subst Abuse Treat* 1995; 12(2):111-6
524. Kraigher D, Ortner R, Eder H, Schindler S, Fischer G. Retardiertes Morphinhydrochlorid in der Erhaltungstherapie Opioidabhängiger [Slow-release morphine hydrochloride for maintenance therapy of opioid dependence]. *Wien Klin Wochenschr* 2002; 114(21-22):904-10
525. Kranke P, Koetter K. Interventions for the treatment of opioid-induced pruritus (itching). Kranke P, Koetter K Interventions for the treatment of opioid induced pruritus The Cochrane Database of Systematic Reviews : Protocols 2004 Issue 1 John Wiley & Sons , Ltd Chichester, UK DOI : 10 1002 /14651858 CD004841 2004;

526. Krantz MJ, Lewkowicz L, Hays H, Woodroffe MA, Robertson AD, Mehler PS. Torsade de pointes associated with very-high-dose methadone. *Ann Intern Med* 2002; 137(6):501-4
527. Krantz MJ, Kutinsky IB, Robertson AD, Mehler PS. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. *Pharmacotherapy* 2003; 23(6):802-5
528. Krantz MJ, Mehler PS. Synthetic opioids and QT prolongation. *Arch Intern Med* 2003; 163(13):1615
529. Krantz MJ, Martell BA, Arnsten JH, Gourevitch MN. Medications that prolong the QT interval. *JAMA* 2003; 290(8):1025
530. Krantz MJ, Mehler PS. Methadone and QT prolongation: a dose-dependent effect? *Am J Cardiol* 2004; 93(7):952
531. Krantz MJ, Garcia JA, Mehler PS. Effects of buprenorphine on cardiac repolarization in a patient with methadone-related torsade de pointes. *Pharmacotherapy* 2005; 25(4):611-4
532. Krantz MJ, Lowery CM, Martell BA, Gourevitch MN, Arnsten JH. Effects of methadone on QT-interval dispersion. *Pharmacotherapy* 2005; 25(11):1523-9
533. Krantz MJ, Rowan SB, Mehler PS. Cocaine-related torsade de pointes in a methadone maintenance patient. *J Addict Dis* 2005; 24(1):53-60
534. Krantz MJ, Baker WA, Schmittner J. Cocaine and methadone: parallel effects on the QTc interval. *Am J Cardiol* 2006; 98(8):1121
535. Krausz M, Vertheim U, Degkwitz P. Prevalence of psychiatric disorders in opiate dependent patients in contact with the drug treatment system. *Nervenarzt* 1998; 69(7):557-67
536. Krausz M, Vertheim U, Degkwitz P. Psychiatric Comorbidity in Opiate Addicts. *Eur Addict Res* 1999; 5:55-62
537. Kreek MJ. Plasma and urine levels of methadone. Comparison following four medication forms used in chronic maintenance treatment. *N Y State J Med* 1973; 73(23):2773-7
538. Kreek MJ, Khuri E, Flomenberg N, Albeck H, Ochshorn M. Immune status of unselected methadone maintained former heroin addicts. *Prog Clin Biol Res* 1990; 328:445-8
539. Kreek MJ, Vocci FJ. History and current status of opioid maintenance treatments: blending conference session. *J Subst Abuse Treat* 2002; 23(2):93-105
540. Krejci J, Ziedonis D. Medications in the treatment of addiction: workplace issues. *Occup Med* 2002; 17(1):91-104, v
541. Kresina TF, Eldred L, Bruce RD, Francis H. Integration of pharmacotherapy for opioid addiction into HIV primary care for HIV/hepatitis C virus-co-infected patients. *AIDS* 2005; 19 Suppl 3:S221-S226
542. Kristensen O, Espegren O, Asland R, Jakobsen E, Lie O, Seiler S. Buprenorfin og metadon til opiatavhengige - en randomisert studie [Buprenorphine and methadone to opiate addicts - a randomized trial]. *Tidsskr Nor Laegeforen* 2005; 125(2):148-51
543. Kristensen O, Lolandsmo T, Isaksen A, Vederhus JK, Clausen T. Treatment of polydrug-using opiate dependents during withdrawal: towards a standardisation of treatment. *BMC Psychiatry* 2006; 6:54
544. Krook AL, Waal H, Hansteen V. EKG som rutine for metadonassistert rehabilitering er feil prioritering [Routine ECG in methadone-assisted rehabilitation is wrong prioritization]. *Tidsskr Nor Laegeforen* 2004; 124(22):2940-1

545. Kuhlman JJ, Jr., Lalani S, Maglulio J, Jr., Levine B, Darwin WD. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. *J Anal Toxicol* 1996; 20(6):369-78
546. Kuschel CA, Austerberry L, Cornwell M, Couch R, Rowley RS. Can methadone concentrations predict the severity of withdrawal in infants at risk of neonatal abstinence syndrome? *Arch Dis Child Fetal Neonatal Ed* 2004; 89(5):F390-F393
547. La Harpe R, Fryc O. [Fatalities associated with methadone administration in the Geneva canton (1987-1993)]. *Arch Kriminol* 1995; 196(1-2):24-9
548. Lacroix I, Berrebi A, Chaumerliac C, Lapeyre-Mestre M, Montastruc JL, mase-Michel C. Buprenorphine in pregnant opioid-dependent women: first results of a prospective study. *Addiction* 2004; 99(2):209-14
549. Lai SH, Yao YJ, Lo DS. A survey of buprenorphine related deaths in Singapore. *Forensic Sci Int* 2006;
550. Lai SH, Teo CE. Buprenorphine-associated deaths in Singapore. *Ann Acad Med Singapore* 2006; 35(7):508-11
551. Lamont P, Hunt SC. A twist on torsade: a prolonged QT interval on methadone. *J Gen Intern Med* 2006; 21(11):C9-C12
552. Lancon C, Jaquet I, Labrune N, Bartolo K, De SC, Auquier P. Données qualitatives d'une cohorte traitée par méthadone ou buprénorphine haut dosage à Marseille, entre 1996 et 2001 [The profile of drug addicts attending the Sainte Marguerite University Hospital in Marseille analysis of the active file from 1996 to 2001]. *Presse Med* 2004; 33(18 Suppl):11-7
553. Lange RA, Hillis LD. Cardiovascular complications of cocaine use. *N Engl J Med* 2001; 345(5):351-8
554. Langendam MW, van Brussel GH, Coutinho RA, van Ameijden EJ. The impact of harm-reduction-based methadone treatment on mortality among heroin users. *Am J Public Health* 2001; 91(5):774-80
555. Langrod J, Lowinson J, Ruiz P. Methadone treatment and physical complaints: a clinical analysis. *Int J Addict* 1981; 16(5):947-52
556. Langrod J, Alksne L, Lowinson J, Ruiz P. Rehabilitation of the Puerto Rican addict: a cultural perspective. *Int J Addict* 1981; 16(5):841-7
557. Langton D, Hickey A, Bury G, Smith M, O'Kelly F, Barry J, Sweeney B, Bourke M. Methadone maintenance in general practice: impact on staff attitudes. *Ir J Med Sci* 2000; 169(2):133-6
558. Latowsky M. Methadone death, dosage and torsade de pointes: risk-benefit policy implications. *J Psychoactive Drugs* 2006; 38(4):513-9
559. Laulin JP, Celerier E, Larcher A, Le MM, Simonnet G. Opiate tolerance to daily heroin administration: an apparent phenomenon associated with enhanced pain sensitivity. *Neuroscience* 1999; 89(3):631-6
560. Lawrie T, Matheson C, Bond CM, Roberts K. Pharmacy customers' views and experiences of using pharmacies which provide drug misuse services. *Drug Alcohol Rev* 2004; 23(2):195-202
561. Layson-Wolf C, Goode JV, Small RE. Clinical use of methadone. *J Pain Palliat Care Pharmacother* 2002; 16(1):29-59
562. Leavitt SB, Shinderman M, Maxwell S, Eap CB, Paris P. When "enough" is not enough: new perspectives on optimal methadone maintenance dose. *Mt Sinai J Med* 2000; 67(5-6):404-11

563. Lehotay DC, George S, Etter ML, Graybiel K, Eichhorst JC, Fern B, Wildenboer W, Selby P, Kapur B. Free and bound enantiomers of methadone and its metabolite, EDDP in methadone maintenance treatment: Relationship to dosage? *Clin Biochem* 2005; 38(12):1088-94
564. Lejeune C, Simmat-Durand L, Gourarier L, Aubisson S. Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenorphine substitution. *Drug Alcohol Depend* 2006; 82(3):250-7
565. Lenne M, Lintzeris N, Breen C, Harris S, Hawken L, Mattick R, Ritter A. Withdrawal from methadone maintenance treatment: prognosis and participant perspectives. *Aust N Z J Public Health* 2001; 25(2):121-5
566. Lenné MG, Dietze P, Rumbold GR, Redman JR, Triggs TJ. The effects of the opioid pharmacotherapies methadone, LAAM and buprenorphine, alone and in combination with alcohol, on simulated driving. *Drug and alcohol dependence* 2003; 72:271-8
567. Lepere B, Gourarier L, Sanchez M, Adda C, Peyret E, Nordmann F, Ben Soussen P, Gisselbrecht M, Lowenstein W. Diminution du nombre de surdoses mortelles à l'héroïne, en France, depuis 1994. À propos du rôle des traitements de substitution. [Reduction in the number of lethal heroin overdoses in France since 1994. Focus on substitution treatments]. *Ann Med Interne (Paris)* 2001; 152(Suppl 3):IS5-IS12
568. Leri F, Bruneau J, Stewart J. Understanding polydrug use: review of heroin and cocaine co-use. *Addiction* 2003; 98(1):7-22
569. LeVier DG, Brown RD, Musgrove DL, Butterworth LF, McCay JA, White KL, Jr., Fuchs BA, Harris LS, Munson AE. The effect of methadone on the immune status of B6C3F1 mice. *Fundam Appl Toxicol* 1995; 24(2):275-84
570. Li Y, Wang X, Tian S, Guo CJ, Douglas SD, Ho WZ. Methadone enhances human immunodeficiency virus infection of human immune cells. *J Infect Dis* 2002; 185(1):118-22
571. Ling W, Wesson DR, Charuvastra C, Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. *Arch Gen Psychiatry* 1996; 53(5):401-7
572. Ling W, Charuvastra C, Collins JF, Batki S, Brown LS, Jr., Kintaudi P, Wesson DR, McNicholas L, Tusel DJ, Malkernek U, Renner JA, Jr., Santos E, Casadonte P, Fye C, Stine S, Wang RI, Segal D. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. *Addiction* 1998; 93(4):475-86
573. Ling W, Smith D. Buprenorphine: blending practice and research. *J Subst Abuse Treat* 2002; 23(2):87-92
574. Ling W, Wesson DR. Clinical efficacy of buprenorphine: comparisons to methadone and placebo. *Drug Alcohol Depend* 2003; 70(2 Suppl):S49-S57
575. Ling W, Amass L, Shoptaw S, Annon JJ, Hillhouse M, Babcock D, Brigham G, Harrer J, Reid M, Muir J, Buchan B, Orr D, Woody G, Krejci J, Ziedonis D. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. *Addiction* 2005; 100(8):1090-100
576. Lintzeris N, Bell J, Bammer G, Jolley DJ, Rushworth L. A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal. *Addiction* 2002; 97(11):1395-404
577. Lintzeris N, Ritter A, Dunlop A, Muhleisen P. Training primary health care professionals to provide buprenorphine and LAAM treatment. *Subst Abus* 2002; 23(4):245-54

578. Lintzeris N, Mitchell T, Bond A, Nestor L, Strang J. Pharmacodynamic interactions between diazepam with methadone, and diazepam with buprenorphine in opioid-dependent individuals. Sixty Eight Annual Scientific Meeting of the College on Problems of Drug Dependence 2005;
579. Lintzeris N, Mitchell TB, Bond A, Nestor L, Strang J. Interactions on mixing diazepam with methadone or buprenorphine in maintenance patients. *J Clin Psychopharmacol* 2006; 26(3):274-83
580. Lintzeris N, Strang J, Metrebian N, Byford S, Hallam C, Lee S, Zador D. Methodology for the Randomised Injecting Opioid Treatment Trial (RIOTT): evaluating injectable methadone and injectable heroin treatment versus optimised oral methadone treatment in the UK. *Harm Reduct J* 2006; 3:28
581. Liu P, Foster G, Labadie R, Somoza E, Sharma A. Pharmacokinetic interaction between voriconazole and methadone at steady-state in patients on methadone therapy. *Antimicrob Agents Chemother* 2006;
582. Lofwall MR, Strain EC, Stitzer ML, Bigelow GE. Comparative safety and side-effect profiles of buprenorphine vs. methadone in the outpatient treatment of opioid dependence. Sixty Sixth Annual Scientific Meeting of College on Problems of Drug Dependence 2004;
583. Longwell B, Kestler RJ, Cox TJ. Side effects in methadone patients: a survey of self-reported complaints. *Int J Addict* 1979; 14(4):485-94
584. Lopatko OV, White JM, Huber A, Ling W. Opioid effects and opioid withdrawal during a 24 h dosing interval in patients maintained on buprenorphine. *Drug and alcohol dependence* 2003; 69:317-22
585. Lott DC, Strain EC, Brooner RK, Bigelow GE, Johnson RE. HIV risk behaviors during pharmacologic treatment for opioid dependence: A comparison of levomethadyl acetate hydrochloride, buprenorphine, and methadone. *J Subst Abuse Treat* 2006; 31(2):187-94
586. Lowenstein W, Haas C, Durand H. [Do substitution treatments reduce the incidence of human immunodeficiency virus infections in intravenous heroin addicts? Review of pertinent literature]. *Ann Med Interne (Paris)* 1994; 145(Suppl 3):75-8
587. Lucas GM, Weidle PJ, Hader S, Moore RD. Directly administered antiretroviral therapy in an urban methadone maintenance clinic: a nonrandomized comparative study. *Clin Infect Dis* 2004; 38 Suppl 5:S409-13.:S409-S413
588. Lucchini A, Barbaro G, Barbarini G. Methadone and QT prolongation in HIV-infected patients. *Am J Cardiol* 2004; 94(1):147-8
589. Luger L, Bathia N, Alcorn R, Power R. Involvement of community pharmacists in the care of drug misusers: pharmacy-based supervision of methadone consumption. *Int J Drug Policy* 2000; 11(3):227-34
590. Lugo RA, Satterfield KL, Kern SE. Pharmacokinetics of methadone. *J Pain Palliat Care Pharmacother* 2005; 19(4):13-24
591. Lum PJ, Tulskey JP. The medical management of opioid dependence in HIV primary care settings. *Curr HIV/AIDS Rep* 2006; 3(4):195-204
592. Lundgren LM, Amodeo M, Ferguson F, Davis K. Racial and ethnic differences in drug treatment entry of injection drug users in Massachusetts. *J Subst Abuse Treat* 2001; 21(3):145-53
593. Lundgren LM, Schilling RF, Fitzgerald T, Davis K, Amodeo M. Parental status of women injection drug users and entry to methadone maintenance. *Subst Use Misuse* 2003; 38(8):1109-31

594. Lutfy K, Eitan S, Bryant CD, Yang YC, Saliminejad N, Walwyn W, Kieffer BL, Takeshima H, Carroll FI, Maidment NT, Evans CJ. Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. *J Neurosci* 2003; 23(32):10331-7
595. Luthi B, Huttner A, Speck RF, Mueller NJ. Methadone-induced Torsade de pointes after stopping lopinavir-ritonavir. *Eur J Clin Microbiol Infect Dis* 2007; 26(5):367-9
596. Lyvers M, Yakimoff M. Neuropsychological correlates of opioid dependence and withdrawal. *Addict Behav* 2003; 28(3):605-11
597. Maag V. Estimated trends in the prevalence of heroin addiction in Switzerland. A multiple-indicator approach. *Eur Addict Res* 2003; 9(4):176-81
598. Macleod J, Whittaker A, Robertson JR. Changes in opiate treatment during attendance at a community drug service—findings from a clinical audit. *Drug Alcohol Rev* 1998; 17(1):19-25
599. Maddux JF, Desmond DP. Ethnic matching of caseworker and patient in methadone maintenance. *J Subst Abuse Treat* 1996; 13(3):233-9
600. Magura S, Nwakeze PC, Kang SY, Demsky S. Program quality effects on patient outcomes during methadone maintenance: a study of 17 clinics. *Subst Use Misuse* 1999; 34(9):1299-324
601. Magura S, Rosenblum A, Fong C, Villano C, Richman B. Treating cocaine-using methadone patients: predictors of outcomes in a psychosocial clinical trial. *Subst Use Misuse* 2002; 37(14):1927-55
602. Malpas TJ, Darlow BA. Neonatal abstinence syndrome following abrupt cessation of breastfeeding. *N Z Med J* 1999; 112(1080):12-3
603. Man LH, Best D, Gossop M, Stillwell G, Strang J. Relationship between prescribing and risk of opiate overdose among drug users in and out of maintenance treatment. *Eur Addict Res* 2004; 10(1):35-40
604. Manfredi PL, Gonzales GR, Cheville AL, Kornick C, Payne R. Methadone analgesia in cancer pain patients on chronic methadone maintenance therapy. *J Pain Symptom Manage* 2001; 21(2):169-74
605. Mannelli P, Janiri L, Tempesta E, Jones RT. Prediction in drug abuse: cocaine interactions with alcohol and buprenorphine. *Br J Psychiatry Suppl* 1993; (21):39-45
606. Mao J, Price DD, Mayer DJ. Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. *Pain* 1995; 62(3):259-74
607. Maremmani I, Pacini M, Cesaroni C, Lovrecic M, Perugi G, Tagliamonte A. QTc interval prolongation in patients on long-term methadone maintenance therapy. *Eur Addict Res* 2005; 11(1):44-9
608. Maremmani I, Pacini M, Pani PP. Effectiveness of buprenorphine in double diagnosed patients. Buprenorphine as psychothropic drug. *Heroin Add & Rel Clin Probl* 2006; 8(1):31-8
609. Maremmani I, Pani PP, Mellini A, Pacini M, Marini G, Lovrecic M, Perugi G, Shinderman M. Alcohol and cocaine use and abuse among opioid addicts engaged in a methadone maintenance treatment program. *J Addict Dis* 2007; 26(1):61-70
610. Margo K, Winn R. Testosterone treatments: why, when, and how? *Am Fam Physician* 2006; 73(9):1591-8
611. Margolin A, Avants SK, Warburton LA, Hawkins KA. Factors affecting cognitive functioning in a sample of human immunodeficiency virus-positive injection drug users. *AIDS Patient Care STDS* 2002; 16(6):255-67

612. Marquet P, Chevrel J, Lavignasse P, Merle L, Lachatre G. Buprenorphine withdrawal syndrome in a newborn. *Clin Pharmacol Ther* 1997; 62(5):569-71
613. Marsch LA. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis (Structured abstract). *Addiction* 1998; 93:515-32
614. Martell BA, Arnsten JH, Ray B, Gourevitch MN. The impact of methadone induction on cardiac conduction in opiate users. *Ann Intern Med* 2003; 139(2):154-5
615. Martell BA, Arnsten JH, Krantz MJ, Gourevitch MN. Impact of methadone treatment on cardiac repolarization and conduction in opioid users. *Am J Cardiol* 2005; 95(7):915-8
616. Martin E, Canavan A, Butler R. A decade of caring for drug users entirely within general practice. *Br J Gen Pract* 1998; 48(435):1679-82
617. Martyres RF, Clode D, Burns JM. Seeking drugs or seeking help? Escalating "doctor shopping" by young heroin users before fatal overdose. *Med J Aust* 2004; 180(5):211-4
618. Marzolini C, Troillet N, Telenti A, Baumann P, Decosterd LA, Eap CB. Efavirenz decreases methadone blood concentrations. *AIDS* 2000; 14(9):1291-2
619. Masson CL, Barnett PG, Sees KL, Delucchi KL, Rosen A, Wong W, Hall SM. Cost and cost-effectiveness of standard methadone maintenance treatment compared to enriched 180-day methadone detoxification. *Addiction* 2004; 99(6):718-26
620. Mathei C, Robaey G, Van RM, van DP, Buntinx F. The epidemiology of hepatitis C among injecting drug users in Belgium. *Acta Gastroenterol Belg* 2005; 68(1):50-4
621. Mathei C, Wollants E, Verbeeck J, Van RM, Robaey G, van DP, Buntinx F. Molecular epidemiology of hepatitis C among drug users in Flanders, Belgium: association of genotype with clinical parameters and with sex- and drug-related risk behaviours. *Eur J Clin Microbiol Infect Dis* 2005; 24(8):514-22
622. Mathei C, Robaey G, van DP, Buntinx F, Verrando R. Prevalence of hepatitis C in drug users in Flanders: determinants and geographic differences. *Epidemiol Infect* 2005; 133(1):127-36
623. Matheny CJ, Lamb MW, Brouwer KR, Pollack GM. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. *Pharmacotherapy* 2001; 21(7):778-96
624. Matheson C, Bond CM, Pitcairn J. Community pharmacy services for drug misusers in Scotland: what difference does 5 years make? *Addiction* 2002; 97(11):1405-11
625. Matheson C, Pitcairn J, Bond CM, van Teijlingen E, Ryan M. General practice management of illicit drug users in Scotland: a national survey. *Addiction* 2003; 98(1):119-26
626. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. *Cochrane Database Syst Rev* 2003; (2):CD002209
627. Mattick RP, Ali R, White JM, O'Brien S, Wolk S, Danz C. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. *Addiction* 2003; 98(4):441-52
628. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. *Cochrane Database Syst Rev* 2004; (3):CD002207
629. Mauss S, Berger F, Goelz J, Jacob B, Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. *Hepatology* 2004; 40(1):120-4

630. Mauss S, Valenti W, DePamphilis J, Duff F, Cupelli L, Passe S, Solsky J, Torriani FJ, Dieterich D, Larrey D. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. *AIDS* 2004; 18(13):F21-F25
631. Mawhinney S, Ashe RG, Lowry J. Substance abuse in pregnancy: opioid substitution in a northern Ireland maternity unit. *Ulster Med J* 2006; 75(3):187-91
632. Maxwell JC, Pullum TW, Tannert K. Deaths of clients in methadone treatment in Texas: 1994-2002. *Drug Alcohol Depend* 2005; 78(1):73-81
633. Maxwell S, Shinderman MS. Optimizing long-term response to methadone maintenance treatment: a 152-week follow-up using higher-dose methadone. *Journal of Addictive Diseases* 2002; 21:1-12
634. Mayet S, Farrell M, Ferri M, Amato, Langton-Hewer CD, Davoli, Mac DR. Psychosocial treatment for opiate abuse and dependence. Mayet S, Farrell M, Ferri M, Amato, Langton Hewer CD, Davoli, Mac Donald R Psychosocial treatment for opiate abuse and dependence *The Cochrane Database of Systematic Reviews* : Reviews 2004 Issue 4 John Wiley & Sons, Ltd Chichester, UK DOI : 10 100 2004;
635. Mazlan M, Schottenfeld RS, Chawarski MC. New challenges and opportunities in managing substance abuse in Malaysia. *Drug Alcohol Rev* 2006; 25(5):473-8
636. McCambridge J, Gossop M, Beswick T, Best D, Bearn J, Rees S, Strang J. In-patient detoxification procedures, treatment retention, and post-treatment opiate use: Comparison of lofexidine+naloxone, lofexidine+placebo, and methadone. *Drug Alcohol Depend* 2006;
637. McCarthy JJ, Flynn N. Hepatitis C in methadone maintenance patients: prevalence and public policy implications. *J Addict Dis* 2001; 20(1):19-31
638. McCarthy JJ, Leamon MH, Parr MS, Anania B. High-dose methadone maintenance in pregnancy: maternal and neonatal outcomes. *Am J Obstet Gynecol* 2005; 193(3 Pt 1):606-10
639. McCusker M. Influence of hepatitis C status on alcohol consumption in opiate users in treatment. *Addiction* 2001; 96(7):1007-14
640. McGonagle D. Methadone anonymous: a 12-step program. Reducing the stigma of methadone use. *J Psychosoc Nurs Ment Health Serv* 1994; 32(10):5-12
641. McNeely J, Drucker E, Hartel D, Tuchman E. Office-based methadone prescribing: acceptance by inner-city practitioners in New York. *J Urban Health* 2000; 77(1):96-102
642. McNicol E, Horowicz-Mehler N, Fisk RA, Bennett K, Gialeli-Goudas M, Chew PW, Lau J, Carr D. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. *J Pain* 2003; 4(5):231-56
643. Megarbane B, Hreiche R, Pirnay S, Marie N, Baud FJ. Does high-dose buprenorphine cause respiratory depression? : possible mechanisms and therapeutic consequences. *Toxicol Rev* 2006; 25(2):79-85
644. Mehta SH, Cox A, Hoover DR, Wang XH, Mao Q, Ray S, Strathdee SA, Vlahov D, Thomas DL. Protection against persistence of hepatitis C. *Lancet* 2002; 359(9316):1478-83
645. Meijler WJ. Ongefundeerd rijverbod bij chronisch gebruik van opioïden [Driving ban for patients on chronic opioid therapy unfounded]. *Ned Tijdschr Geneesk* 2000; 144(34):1644-5
646. Meili D, Marcinko J, Bertisch B, Huber M, Davatz F, Wang J. Possible Transmission Routes of Viral Diseases During Communal Preparation of Drugs for i. v. Use. *Suchttherapie* 2002; (3):20-6

647. Melichar JK, Hume SP, Williams TM, Daghli MR, Taylor LG, Ahmad R, Malizia AL, Brooks DJ, Myles JS, Lingford-Hughes A, Nutt DJ. Using [¹¹C]diprenorphine to image opioid receptor occupancy by methadone in opioid addiction: clinical and preclinical studies. *J Pharmacol Exp Ther* 2005; 312(1):309-15
648. Mello NK, Mendelson JH. Buprenorphine suppresses heroin use by heroin addicts. *Science* 1980; 207(4431):657-9
649. Mello NK, Mendelson JH. Behavioral pharmacology of buprenorphine. *Drug Alcohol Depend* 1985; 14(3-4):283-303
650. Mello NK, Mendelson JH, Lukas SE, Gastfriend DR, Teoh SK, Holman BL. Buprenorphine treatment of opiate and cocaine abuse: clinical and preclinical studies. *Harv Rev Psychiatry* 1993; 1(3):168-83
651. Mendelson J, Jones RT, Welm S, Brown J, Batki SL. Buprenorphine and naloxone interactions in methadone maintenance patients. *Biological psychiatry* 1997; 41:1095-101
652. Mercadante S, Arcuri E. Hyperalgesia and opioid switching. *Am J Hosp Palliat Care* 2005; 22(4):291-4
653. Merrill JO, Jackson TR, Schulman BA, Saxon AJ, Awan A, Kapitan S, Carney M, Brumback LC, Donovan D. Methadone medical maintenance in primary care. An implementation evaluation. *J Gen Intern Med* 2005; 20(4):344-9
654. Metrebian N, Carnwath T, Stimson GV, Storz T. Survey of doctors prescribing diamorphine (heroin) to opiate-dependent drug users in the United Kingdom. *Addiction* 2002; 97(9):1155-61
655. Meulenbeek PA. Addiction problems and methadone treatment. *J Subst Abuse Treat* 2000; 19(2):171-4
656. Michel L, Maguet O. Traitements de substitution en milieu carcéral : guide des bonnes pratiques. [Guidelines for substitution treatments in prison populations]. *Encephale* 2005; 31(1 Pt 1):92-7
657. Milekic MH, Brown SD, Castellini C, Alberini CM. Persistent disruption of an established morphine conditioned place preference. *J Neurosci* 2006; 26(11):3010-20
658. Miller V. Buprenorphine and HIV Primary Care: Report of a Forum for Collaborative HIV Research Workshop. *Clin Infect Dis* 2006; 43 Suppl 4:S254-S257
659. Miller WR, Rollnick S. *Motivierende Gesprächsführung*. 2nd ed. Freiburg im Breisgau: Lambertus; 2004.
660. Millery M, Kleinman BP, Polissar NL, Millman RB, Scimeca M. Detoxification as a gateway to long-term treatment: assessing two interventions. *Journal of substance abuse treatment* 2002; 23:183-90
661. Millson PE, Challacombe L, Villeneuve PJ, Fischer B, Strike CJ, Myers T, Shore R, Hopkins S, Raftis S, Pearson M. Self-perceived health among Canadian opiate users: a comparison to the general population and to other chronic disease populations. *Can J Public Health* 2004; 95(2):99-103
662. Milroy CM, Forrest AR. Methadone deaths: a toxicological analysis. *J Clin Pathol* 2000; 53(4):277-81
663. Mintzer MZ, Stitzer ML. Cognitive impairment in methadone maintenance patients. *Drug Alcohol Depend* 2002; 67(1):41-51
664. Mintzer MZ, Correia CJ, Strain EC. A dose-effect study of repeated administration of buprenorphine/naloxone on performance in opioid-dependent volunteers. *Drug Alcohol Depend* 2004; 74(2):205-9

665. Mintzer MZ, Copersino ML, Stitzer ML. Opioid abuse and cognitive performance. *Drug Alcohol Depend* 2005; 78(2):225-30
666. Mitchell TB, White JM, Somogyi AA, Bochner F. Slow-release oral morphine versus methadone: a crossover comparison of patient outcomes and acceptability as maintenance pharmacotherapies for opioid dependence. *Addiction* 2004; 99(8):940-5
667. Mitchell TB, Dyer KR, Peay ER. Patient and physician characteristics in relation to clinical decision making in methadone maintenance treatment. *Subst Use Misuse* 2006; 41(3):393-404
668. Mitra S, Sinatra RS. Perioperative management of acute pain in the opioid-dependent patient. *Anesthesiology* 2004; 101(1):212-27
669. Moatti JP, Carrieri MP, Spire B, Gastaut JA, Cassuto JP, Moreau J. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group. *AIDS* 2000; 14(2):151-5
670. Moggi F, Donati R. *Psychische Störungen und Sucht: Doppeldiagnosen*. Göttingen: Hogrefe; 2004.
671. Montagne M. Appreciating the user's perspective: listening to the "methadonians". *Subst Use Misuse* 2002; 37(4):565-70
672. Montastruc JL, Arnaud P, Barbier C, Berlin I, Gatignol C, Haramburu F, Lagier G, Lapeyre-Mestre M, Mallaret M, Micaleff J. [Pharmacologic criteria for medical substitution in opiate dependence]. *Therapie* 2003; 58(2):123-5
673. Montoya ID, Gorelick DA, Preston KL, Schroeder JR, Umbricht A, Cheskin LJ, Lange WR, Contoreggi C, Johnson RE, Fudala PJ. Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. *Clin Pharmacol Ther* 2004; 75(1):34-48
674. Moolchan ET, Umbricht A, Epstein D. Therapeutic drug monitoring in methadone maintenance: choosing a matrix. *J Addict Dis* 2001; 20(2):55-73
675. Moral MP, Rueda SJ, Tacias PM, Calbuig A, Jr. [Torsade de Pointes in patient infected with human immunodeficiency virus and treated with methadone]. *An Med Interna* 2006; 23(8):397-8
676. Morgan O, Griffiths C, Hickman M. Association between availability of heroin and methadone and fatal poisoning in England and Wales 1993-2004. *Int J Epidemiol* 2006;
677. Morgan OW, Johnson H, Rooney C, Seagroatt V, Griffiths C. Changes to the daily pattern of methadone-related deaths in England and Wales, 1993-2003. *J Public Health (Oxf)* 2006; 28(4):318-23
678. Morral AR, Belding MA, Iguchi MY. Identifying methadone maintenance clients at risk for poor treatment response: pretreatment and early progress indicators. *Drug and alcohol dependence* 1999; 55:25-33
679. Morrow K, Costello T. HIV, STD and hepatitis prevention among women in methadone maintenance: a qualitative and quantitative needs assessment. *AIDS Care* 2004; 16(4):426-33
680. Moss AJ. Long QT Syndrome. *JAMA* 2003; 289(16):2041-4
681. Murphy SL, Rounsaville BJ, Eyre S, Kleber HD. Suicide attempts in treated opiate addicts. *Compr Psychiatrie* 24 (1), 79-89. 1983.
Ref Type: Generic

682. Mutasa HC. Risk factors associated with noncompliance with methadone substitution therapy (MST) and relapse among chronic opiate users in an Outer London community. *J Adv Nurs* 2001; 35(1):97-107
683. Nanovskaya T, Deshmukh S, Brooks M, Ahmed MS. Transplacental transfer and metabolism of buprenorphine. *J Pharmacol Exp Ther* 2002; 300(1):26-33
684. Nanovskaya T, Nekhayeva I, Karunaratne N, Audus K, Hankins GD, Ahmed MS. Role of P-glycoprotein in transplacental transfer of methadone. *Biochem Pharmacol* 2005; 69(12):1869-78
685. Nantwi KD, Hicks S, Bradley D, Jr., Schoener EP. Interactions of buprenorphine and selective dopamine receptor antagonists in the rat nucleus accumbens. *Gen Pharmacol* 1998; 31(3):425-9
686. Negrin MA, Vazquez-Polo FJ. Bayesian cost-effectiveness analysis with two measures of effectiveness: the cost-effectiveness acceptability plane. *Health Econ* 2005;
687. Nekhayeva IA, Nanovskaya TN, Hankins GD, Ahmed MS. Role of human placental efflux transporter P-glycoprotein in the transfer of buprenorphine, levo-alpha-acetylmethadol, and paclitaxel. *Am J Perinatol* 2006; 23(7):423-30
688. Neri S, Bruno CM, Pulvirenti D, Malaguarnera M, Italiano C, Mauceri B, Abate G, Cilio D, Calvagno S, Tsami A, Ignaccolo L, Interlandi D, Prestianni L, Ricchena M, Noto R. Randomized clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers. *Psychopharmacology* 2005; 179:700-4
689. Neuman MG, Monteiro M, Rehm J. Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodeficiency and hepatitis viruses. *Subst Use Misuse* 2006; 41(10-12):1395-463
690. New York State Department of Health AI. Drug-Drug Interactions Between HAART, Medications Used in Substance Use Treatment, and Recreational Drugs. 2005.
Ref Type: Generic
691. Newcombe DA, Bochner F, White JM, Somogyi AA. Evaluation of levo-alpha-acetylmethadol (LAAM) as an alternative treatment for methadone maintenance patients who regularly experience withdrawal: a pharmacokinetic and pharmacodynamic analysis. *Drug and alcohol dependence* 2004; 76:63-72
692. Newman RG. Expansion of opiate agonist treatment: an historical perspective. *Harm Reduct J* 2006; 3:20-2
693. Nielsen S, Dietze P, Dunlop A, Muhleisen P, Lee N, Taylor D. Buprenorphine supply by community pharmacists in Victoria, Australia: perceptions, experiences and key issues identified. *Drug Alcohol Rev* 2007; 26(2):143-51
694. Nisse P, Cezard C, Peucelle D, Mathieu-Nolf M. [Accidental ingestion of methadone and buprenorphine by children 37 cases review of Lille Poison Centre between 1995 and 2005]. *Acta Clin Belg Suppl* 2006; (1):37-40
695. Nixon LN. Cannabis use and treatment outcome in methadone maintenance. *Addiction* 2003; 98(9):1321-2
696. Noyce PR. Providing patient care through community pharmacies in the UK: policy, practice, and research. *Ann Pharmacother* 2007; 41(5):861-8
697. Nunes EV, Sullivan MA, Levin FR. Treatment of depression in patients with opiate dependence. *Biol Psychiatry* 2004; 56(10):793-802

698. O'Brien CP, Woody GE, McLellan AT. Enhancing the effectiveness of methadone using psychotherapeutic interventions. *NIDA Res Monogr* 1995; 150:5-18
699. Ohtani M, Kotaki H, Uchino K, Sawada Y, Iga T. Pharmacokinetic analysis of enterohepatic circulation of buprenorphine and its active metabolite, norbuprenorphine, in rats. *Drug Metab Dispos* 1994; 22(1):2-7
700. Olsen Y, Alford DP, Horton NJ, Saitz R. Addressing smoking cessation in methadone programs. *J Addict Dis* 2005; 24(2):33-48
701. Oreskovich MR, Saxon AJ, Ellis ML, Malte CA, Reoux JP, Knox PC. A double-blind, double-dummy, randomized, prospective pilot study of the partial mu opiate agonist, buprenorphine, for acute detoxification from heroin. *Drug Alcohol Depend* 2005; 77(1):71-9
702. Ortner R, Jagsch R, Schindler SD, Primorac A, Fischer G. Buprenorphine maintenance: office-based treatment with addiction clinic support. *Eur Addict Res* 2004; 10(3):105-11
703. Osborn DA, Jeffery HE, Cole M. Opiate treatment for opiate withdrawal in newborn infants. Osborn DA, Jeffery HE, Cole M Opiate treatment for opiate withdrawal in newborn infants *The Cochrane Database of Systematic Reviews : Reviews* 2005 Issue 3 John Wiley & Sons, Ltd Chichester, UK DOI : 10.1002/14651858.CD002059.pub2 2005;
704. Ostvold C, Topper M. Metadonindusert hjerterytmeforstyrrelse [Methadone-induced heart arrhythmia]. *Tidsskr Nor Laegeforen* 2005; 125(15):2021-2
705. Oyefeso A, Clancy C, Ghodse H. Developing a quality of care index for outpatient methadone treatment programmes. *J Eval Clin Pract* 1998; 4(1):39-47
706. Padaiga Z, Subata E, Vanagas G. Outpatient methadone maintenance treatment program. Quality of life and health of opioid-dependent persons in Lithuania. *Medicina (Kaunas)* 2007; 43(3):235-41
707. Paetzold W, Eronat V, Seifert J, Holze I, Emrich HM, Schneider U. Detoxifikation polytoxikomaner Patienten mit Buprenorphin: Auswirkungen auf Affektivität, Angst und Entzugssymptomatik [Detoxification of poly-substance abusers with buprenorphine. Effects on affect, anxiety, and withdrawal symptoms]. *Nervenarzt* 2000; 71(9):722-9
708. Palepu A, Cheng DM, Kim T, Nunes D, Vidaver J, Alperen J, Saitz R, Samet JH. Substance abuse treatment and receipt of liver specialty care among persons coinfecting with HIV/HCV who have alcohol problems. *J Subst Abuse Treat* 2006; 31(4):411-7
709. Panda S, Saha U, Pahari S, Nathan M, Poddar S, Neogi D, Sarkar M, Pal NK, Mahalanabis D. Drug use among the urban poor in Kolkata: behaviour and environment correlates of low HIV infection. *Natl Med J India* 2002; 15(3):128-34
710. Pani PP, Pirastu R, Ricci A, Gessa GL. Prohibition of take-home dosages: negative consequences on methadone maintenance treatment. *Drug Alcohol Depend* 1996; 41(1):81-4
711. Passie T, Metzner C, Seifert J, Zedler M, Schneider U, Emrich HM, Karst M. Akzidentelle intraarterielle Injektion von Diacetylmorphin (Heroin) bei Drogenabhängigen [Accidental intraarterial injection of diacetylmorphine (heroin) in drug addicts – three case reports]. *Anesthesiol Intensivmed Notfallmed Schmerzther* 2005; 40(7):419-22
712. Passik SD, Kirsh KL. Opioid therapy in patients with a history of substance abuse. *CNS Drugs* 2004; 18(1):13-25
713. Pasternak GW. Multiple opiate receptors: deja vu all over again. *Neuropharmacology* 2004; 47 Suppl 1:312-23

714. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. *Ann Intern Med* 2000; 133(1):21-30
715. Paterson DL, Potoski B, Capitano B. Measurement of adherence to antiretroviral medications. *J Acquir Immune Defic Syndr* 2002; 31 Suppl 3:S103-6.:S103-S106
716. Paulozzi LJ. Opioid analgesic involvement in drug abuse deaths in American metropolitan areas. *Am J Public Health* 2006; 96(10):1755-7
717. Pearson EC, Woosley RL. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. *Pharmacoepidemiol Drug Saf* 2005; 14(11):747-53
718. Pedrazzoni M, Vescovi PP, Maninetti L, Michelini M, Zaniboni G, Pioli G, Costi D, Alfano FS, Passeri M. Effects of chronic heroin abuse on bone and mineral metabolism. *Acta Endocrinol (Copenh)* 1993; 129(1):42-5
719. Peh LH, Ng BY. Medicalising the treatment of opioid dependence. *Ann Acad Med Singapore* 2006; 35(7):447-9
720. Peles E, Schreiber S, Adelson M. Variables associated with perceived sleep disorders in methadone maintenance treatment (MMT) patients. *Drug Alcohol Depend* 2005;
721. Peles E, Schreiber S, Adelson M. Factors predicting retention in treatment: 10-year experience of a methadone maintenance treatment (MMT) clinic in Israel. *Drug Alcohol Depend* 2005;
722. Peles E, Kreek MJ, Kellogg S, Adelson M. High methadone dose significantly reduces cocaine use in methadone maintenance treatment (MMT) patients. *J Addict Dis* 2006; 25(1):43-50
723. Peles E, Schreiber S, Naumovsky Y, Adelson M. Depression in methadone maintenance treatment patients: Rate and risk factors. *J Affect Disord* 2006;
724. Pelet A, Doll S, Huissoud T, Resplendino J, Besson J, Favrat B. Methadone maintenance treatment in the Swiss Canton of Vaud: demographic and clinical data on 1,782 ambulatory patients. *Eur Addict Res* 2005; 11(2):99-106
725. Pelet A, Besson J, Pecoud A, Favrat B. Difficulties associated with out-patient management of drug abusers by general practitioners. A cross sectional survey of general practitioners with and without methadone patients in the french-speaking part of Switzerland. *BMC Fam Pract* 2005; 6(1):51
726. Pelletier LR, Hoffman JA. A framework for selecting performance measures for opioid treatment programs. *J Healthc Qual* 2002; 24(3):24-35
727. Perez-Castrillon JL, Olmos JM, Gomez JJ, Barrallo A, Riancho JA, Perera L, Valero C, Amado JA, Gonzalez-Macias J. Expression of opioid receptors in osteoblast-like MG-63 cells, and effects of different opioid agonists on alkaline phosphatase and osteocalcin secretion by these cells. *Neuroendocrinology* 2000; 72(3):187-94
728. Perlis TE, Jarlais DCD, Friedman SR, Arasteh K, Turner CF. Audio-computerized self-interviewing versus face-to-face interviewing for research data collection at drug abuse treatment programs. *Addiction* 2004; 99(7):885-96
729. Perneger TV, Mino A, Giner F, Broers B. Patterns of opiate use in a heroin maintenance programme. *Psychopharmacology (Berl)* 2000; 152(1):7-13
730. Perronne C. Antiviral hepatitis and antiretroviral drug interactions. *J Hepatol* 2006; 44(1 Suppl):S119-S125

731. Petitjean S, Stohler R, Deglon JJ, Livoti S, Waldvogel D, Uehlinger C, Ladewig D. Double-blind randomized trial of buprenorphine and methadone in opiate dependence. *Drug Alcohol Depend* 2001; 62(1):97-104
732. Petitjean S, von BU, Weber M, Ladewig D. Buprenorphine versus methadone in opiate detoxification. *Drug and alcohol dependence* 2002; 66 Suppl 1
733. Petry NM, Martin B, Simcic J. Prize reinforcement contingency management for cocaine dependence: integration with group therapy in a methadone clinic. *Journal-of-consulting-and-clinical-psychology* 2005; 73(2):354-9
734. Philipp BL, Merewood A, O'Brien S. Methadone and breastfeeding: new horizons. *Pediatrics* 2003; 111(6 Pt 1):1429-30
735. Phillips CD, Hubbard RL, Dunteman G, Fountain DL, Czechowicz D, Cooper JR. Measuring program performance in methadone treatment using in-treatment outcomes: an illustration. *J Ment Health Adm* 1995; 22(3):214-25
736. Picard N, Cresteil T, Djebli N, Marquet P. In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. *Drug Metab Dispos* 2005; 33(5):689-95
737. Piguet V, Desmeules J, Ehret G, Stoller R, Dayer P. QT interval prolongation in patients on methadone with concomitant drugs. *J Clin Psychopharmacol* 2004; 24(4):446-8
738. Pinzani V, Faucherre V, Peyriere H, Blayac JP. Methadone withdrawal symptoms with nevirapine and efavirenz. *Ann Pharmacother* 2000; 34(3):405-7
739. Pirnay S, Borron SW, Giudicelli CP, Tourneau J, Baud FJ, Ricordel I. A critical review of the causes of death among post-mortem toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone-associated deaths. *Addiction* 2004; 99(8):978-88
740. Polycarpou A, Papanikolaou P, Ioannidis JPA, Contopoulos-Ioannidis DG. Anticonvulsants for alcohol withdrawal. Polycarpou A, Papanikolaou P, Ioannidis JPA, Contopoulos Ioannidis DG Anticonvulsants for alcohol withdrawal *The Cochrane Database of Systematic Reviews : Reviews* 2005 Issue 3 John Wiley & Sons, Ltd Chichester, UK DOI : 10 1002 /14651858 CD005064 pub 2005;
741. Ponizovsky AM, Grinshpoon A, Margolis A, Cohen R, Rosca P. Well-being, psychosocial factors, and side-effects among heroin-dependent inpatients after detoxification using buprenorphine versus clonidine. *Addict Behav* 2006;
742. Pons D, Fremaux D, Duvauchelle B, Loas G, Compagnon M. Initialisation hospitalière d'un traitement substitutif par méthadone, recommandations de prescription [Initiation of methadone replacement therapy in the hospital, prescribing guidelines]. *Presse Med* 2004; 33(13):858-61
743. Portsmouth SD, Osorio J, McCormick K, Gazzard BG, Moyle GJ. Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules. *HIV Med* 2005; 6(3):185-90
744. Powell J, Dawe S, Richards D, Gossop M, Marks I, Strang J, Gray J. Can opiate addicts tell us about their relapse risk? Subjective predictors of clinical prognosis. *Addict Behav* 1993; 18(4):473-90
745. Prendergast ML, Podus D, Chang E. Program factors and treatment outcomes in drug dependence treatment: an examination using meta-analysis. *Subst Use Misuse* 2000; 35(12-14):1931-65
746. Preston A. *The Methadone Briefing*. UK: Island Press; 1996.
747. Preston KL, Griffiths RR, Stitzer ML, et al. Diazepam and methadone interactions in methadone maintenance. *Clin Pharmacol Ther* 1984; 36:534-41

748. Preston KL, Bigelow GE, Liebson IA. Buprenorphine and naloxone alone and in combination in opioid-dependent humans. *Psychopharmacology (Berl)* 1988; 94(4):484-90
749. Preston KL, Umbricht A, DeJesus A. Abstinence reinforcement and methadone dose increases for treatment of opioid dependence. *NIDA Research Monograph* 1999; 179:72
750. Preston KL, Umbricht A, Epstein DH. Methadone dose increase and abstinence reinforcement for treatment of continued heroin use during methadone maintenance. *Arch Gen Psychiatry* 2000; 57(4):395-404
751. Preston KL, Umbricht A, Epstein DH. Abstinence reinforcement maintenance contingency and one-year follow-up. *Drug and alcohol dependence* 2002; 67:125-37
752. Puigdollers E, Cots F, Brugal MT, Torralba L, Domingo-Salvany A. Programmas de mantenimiento de metadona con servicios auxiliares: un estudio de coste-efectividad [Methadone maintenance programs with supplementary services: a cost-effectiveness study]. *Gac Sanit* 2003; 17(2):123-30
753. Puigdollers E, Domingo-Salvany A, Brugal MT, Torrens M, Alvaros J, Castillo C, Magri N, Martin S, Vazquez JM. Characteristics of heroin addicts entering methadone maintenance treatment: quality of life and gender. *Subst Use Misuse* 2004; 39(9):1353-68
754. Quaglio G, Lugoboni F, Pattaro C, Investigators G, Montanari L, Lechi A, Mezzelani P, Jarlais DC. Patients in long-term maintenance therapy for drug use in Italy: analysis of some parameters of social integration and serological status for infectious diseases in a cohort of 1091 patients. *BMC Public Health* 2006; 6(1):216
755. Quang-Cantagrel ND, Wallace MS, Ashar N, Mathews C. Long-term methadone treatment: effect on CD4+ lymphocyte counts and HIV-1 plasma RNA level in patients with HIV infection. *Eur J Pain* 2001; 5(4):415-20
756. Rabl W, Sigrist T, Sutter K. [Iatrogenic methadone poisoning]. *Schweiz Rundsch Med Prax* 1993; 82(8):217-9
757. Rademacher S, Dietz R, Haverkamp W. QT prolongation and syncope with methadone, doxepin, and a beta-blocker. *Ann Pharmacother* 2005; 39(10):1762-3
758. Radkowski M, Werezynska T, Kopicz-Kaminska E, Kuligowski S, Slusarczyk J. [The effect of discontinuing intravenous opiate injections and methadone treatment on the status of the immune system in narcotic abusers with HIV]. *Pol Tyg Lek* 1996; 51(23-26):334-5, 339
759. Ragni G, De Lauretis L, Gambaro V, Di PR, Bestetti O, Recalcati F, Papetti C. Semen evaluation in heroin and methadone addicts. *Acta Eur Fertil* 1985; 16(4):245-9
760. Rainey PM, Friedland G, Cance-Katz EF, Andrews L, Mitchell SM, Charles C, Jatlow P. Interaction of methadone with didanosine and stavudine. *Journal of Acquired Immune Deficiency Syndromes* 2000; 24:241-8
761. Rainey PM, Friedland GH, Snidow JW, Cance-Katz EF, Mitchell SM, Andrews L, Lane B, Jatlow P. The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. *Am J Addict* 2002; 11(1):66-74
762. Raisch DW, Fye CL, Boardman KD, Sather MR. Opioid dependence treatment, including buprenorphine/naloxone. *Ann Pharmacother* 2002; 36(2):312-21
763. Rajs J, Petersson A, Thiblin I, Olsson-Mortlock C, Fredriksson A, Eksborg S. Nutritional status of deceased illicit drug addicts in Stockholm, Sweden—a longitudinal medicolegal study. *J Forensic Sci* 2004; 49(2):320-9

764. Ramirez-Cacho WA, Flores S, Schrader RM, McKay J, Rayburn WF. Effect of chronic maternal methadone therapy on intrapartum fetal heart rate patterns. *J Soc Gynecol Investig* 2006; 13(2):108-11
765. Rance MJ, Shillingford JS. The metabolism of phenolic opiates by rat intestine. *Xenobiotica* 1977; 7(9):529-36
766. Rao SR, Broome KM, Simpson DD. Depression and hostility as predictors of long-term outcomes among opiate users. *Addiction* 2004; 99(5):579-89
767. Rathod NH, Addenbrooke WM, Rosenbach AF. Heroin dependence in an English town: 33-year follow-up. *Br J Psychiatry* 2005; 187:421-5
768. Rayburn WF, Bogenschutz MP. Pharmacotherapy for pregnant women with addictions. *Am J Obstet Gynecol* 2004; 191(6):1885-97
769. Rea F, Bell JR, Young MR, Mattick RP. A randomised, controlled trial of low dose naltrexone for the treatment of opioid dependence. *Drug Alcohol Depend* 2004; 75(1):79-88
770. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. *Lancet* 2000; 355(9209):1048-52
771. Reisinger M. Buprenorphine as new treatment for heroin dependence. *Drug Alcohol Depend* 1985; 16(3):257-62
772. Remien RH, Hirky AE, Johnson MO, Weinhardt LS, Whittier D, Le GM. Adherence to medication treatment: a qualitative study of facilitators and barriers among a diverse sample of HIV+ men and women in four US cities. *AIDS Behav* 2003; 7(1):61-72
773. Renzelli CM, Capretto NA. Less pain, more gain: buprenorphine-naloxone and patient retention in treatment. *J Addict Dis* 2006; 25(3):97-104
774. Resnick RB, Galanter M, Pycha C, Cohen A, Grandison P, Flood N. Buprenorphine: an alternative to methadone for heroin dependence treatment. *Psychopharmacol Bull* 1992; 28(1):109-13
775. Rhoades HM, Creson D, Elk R, Schmitz J, Grabowski J. Retention, HIV risk, and illicit drug use during treatment: methadone dose and visit frequency. *Am J Public Health* 1998; 88(1):34-9
776. Rhodes T. Risk Theory in Epidemic Times: Sex, Drugs and the Social Organisation of 'Risk Behaviour'. *Sociology of Health and Illness* 1997; 19(2):227
777. Rhodin A, Gronbladh L, Nilsson LH, Gordh T. Methadone treatment of chronic non-malignant pain and opioid dependence - A long-term follow-up. *Eur J Pain* 2005;
778. Richards ML, Sadee W. In vivo opiate receptor binding of oripavines to mu, delta and kappa sites in rat brain as determined by an ex vivo labeling method. *Eur J Pharmacol* 1985; 114(3):343-53
779. Rico H, Costales C, Cabranes JA, Escudero M. Lower serum osteocalcin levels in pregnant drug users and their newborns at the time of delivery. *Obstet Gynecol* 1990; 75(6):998-1000
780. Riker RR, Fraser GL. Adverse events associated with sedatives, analgesics, and other drugs that provide patient comfort in the intensive care unit. *Pharmacotherapy* 2005; 25(5 Pt 2):85-185
781. Robaey G, Buntinx F, Bottieau E, Bourgeois S, Brenard R, Colle I, De BJ, Mathei C, Mulkay JP, van DP, Van RM, Verrando R, Michielsen P, Bourgeois N, Brenard R, de GC, Delwaide J, Henrion J, Horsmans Y, Michielsen P, Reynaert H, Robaey G, Sprengers D. Guidelines for the management of chronic hepatitis C in patients infected after substance use. *Acta Gastroenterol Belg* 2005; 68(1):38-45

782. Robaey G, Buntinx F. Treatment of hepatitis C viral infections in substance abusers. *Acta Gastroenterol Belg* 2005; 68(1):55-67
783. Robaey G, Van VH, Mathei C, Van RM, Bruckers L, Buntinx F. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. *Eur J Gastroenterol Hepatol* 2006; 18(2):159-66
784. Robinson SE. Buprenorphine: an analgesic with an expanding role in the treatment of opioid addiction. *CNS Drug Rev* 2002; 8(4):377-90
785. Robinson SE. Buprenorphine-containing treatments: place in the management of opioid addiction. *CNS Drugs* 2006; 20(9):697-712
786. Robles E, Miller FB, Gilmore-Thomas KK, McMillan DE. Implementation of a clinic policy of client-regulated methadone dosing. *J Subst Abuse Treat* 2001; 20(3):225-30
787. Roncero AC, Saez FN, Castells C, X, Casas BM. [Morphine maintenance treatment in opiate dependent patients.]. *Rev Clin Esp* 2007; 207(4):194-6
788. Roozen HG, Boulogne JJ, van Tulder MW, van den Brink W, De Jong CA, Kerkhof AJ. A systematic review of the effectiveness of the community reinforcement approach in alcohol, cocaine and opioid addiction. *Drug Alcohol Depend* 2004; 74(1):1-13
789. Rosado J, Walsh SL, Bigelow GE, Strain EC. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone. *Drug Alcohol Depend* 2007;
790. Rosen D. Factors associated with illegal drug use among older methadone clients. *Gerontologist* 2004; 44(4):543-7
791. Rosenberg H, Melville J, McLean PC. Acceptability and availability of pharmacological interventions for substance misuse by British NHS treatment services. *Addiction* 2002; 97(1):59-66
792. Rosenblum A, Joseph H, Fong C, Kipnis S, Cleland C, Portenoy RK. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. *JAMA* 2003; 289(18):2370-8
793. Ross J, Darke S. The nature of benzodiazepine dependence among heroin users in Sydney, Australia. *Addiction* 2000; 95(12):1785-93
794. Rothman RB, Gorelick DA, Heishman SJ, Eichmiller PR, Hill BH, Norbeck J, Liberto JG. An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence. *J Subst Abuse Treat* 2000; 18(3):277-81
795. Rounsaville BJ, Kosten TR. Treatment for opioid dependence: quality and access. *JAMA* 2000; 283(10):1337-9
796. Routhier DD, Katz KD, Brooks DE. QTc prolongation and torsades de pointes associated with methadone therapy. *J Emerg Med* 2007; 32(3):275-8
797. Roy J, Lin X. Analysis of multivariate longitudinal outcomes with nonignorable dropouts and missing covariates: changes in methadone treatment practices. *Journal-of-the-American-Statistical-Association* 2002; 97(457):40-52
798. Sabatowski R, Berghaus G, Strumpf M, Radbruch L. Opioid und Fahrsicherheit - Ein unlösbares Problem? [Opioids and driving ability -- a problem unsolved?]. *Dtsch Med Wochenschr* 2003; 128(7):337-41

799. Salman R, Tuna S, Lessing A. Handbuch interkulturelle Suchthilfe. Giessen: Psychosozial Verlag; 1999.
800. Salman R, Tuna S. Kultursensible Suchthilfe mit Migranten. In: Hagemann T, Salman R, editors. Transkulturelle Psychiatrie. Psychiatrieverlag; 2001. p. 343.
801. Samer CF, Piguët V, Dayer P, Desmeules JA. Polymorphisme génétique et interactions médicamenteuses: leur importance dans le traitement de la douleur [Genetic polymorphism and drug interactions: their importance in the treatment of pain]. *Can J Anaesth* 2005; 52(8):806-21
802. Sanchez-Carbonell X, Vilaregut A. A 10-year follow-up study on the health status of heroin addicts based on official registers. *Addiction* 2001; 96(12):1777-86
803. Sanchez Hernandez AM, tienza Fernandez F, renal Maiz A, Gonzalez Torrecilla E, Puchol Calderon A, mendral Garrote J. Torsade de pointes durante el tratamiento con metadona [Torsades de pointes during methadone treatment]. *Rev Esp Cardiol* 2005; 58(10):1230-2
804. Schackman BR, Merrill JO, McCarty D, Levi J, Lubinski C. Overcoming Policy and Financing Barriers to Integrated Buprenorphine and HIV Primary Care. *Clin Infect Dis* 2006; 43 Suppl 4:S247-S253
805. Schaefer M, Heinz A, Backmund M. Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules? *Addiction* 2004; 99(9):1167-75
806. Scherbaum N, Specka M, Hauptmann G, Gastpar M. Senkt die Methadonsubstitutionsbehandlung die Mortalität Opiatabhängiger? [Does maintenance treatment reduce the mortality rate of opioid addicts?]. *Fortschr Neurol Psychiatr* 2002; 70(9):455-61
807. Scherbaum N, Kluwig J, Meiering C, Gastpar M. Use of illegally acquired medical opioids by opiate-dependent patients in detoxification treatment. *Eur Addict Res* 2005; 11(4):193-6
808. Schifano F, Zamparutti G, Zambello F, Oyefeso A, Deluca P, Balestrieri M, Little D, Ghodse AH. Review of deaths related to analgesic- and cough suppressant-opioids; England and Wales 1996-2002. *Pharmacopsychiatry* 2006; 39(5):185-91
809. Schiff M, el Bassel N, Engstrom M, Gilbert L. Psychological distress and intimate physical and sexual abuse among women in methadone maintenance treatment programs. *Social-service-review* 2002; 76(2):302-20
810. Schiff M, Levit S, Moreno RC. Retention and illicit drug use among methadone patients in Israel: A gender comparison. *Addict Behav* 2007;
811. Schlegel-Zawadzka M, Szpanowska-Wohn A, Kolarzyk E. Nutritional preferences of opiate addicted patients during the methadone maintenance treatment. *Asia Pac J Clin Nutr* 2004; 13(Suppl):S156
812. Schmidt N, Sittl R, Brune K, Geisslinger G. Rapid determination of methadone in plasma, cerebrospinal fluid, and urine by gas chromatography and its application to routine drug monitoring. *Pharm Res* 1993; 10(3):441-4
813. Schmittner J, Krantz MJ. QTc prolongation among hospitalized patients receiving methadone. *Arch Intern Med* 2006; 166(20):2289-90
814. Schmitz JM, Rhoades HM, Elk R, Creson D, Hussein I, Grabowski J. Medication take-home doses and contingency management. *Exp Clin Psychopharmacol* 1998; 6(2):162-8
815. Scholz M. Managing constipation that's opioid-induced. *RN* 2000; 63(6):103

816. Schottenfeld RS, Pakes JR, Kosten TR. Prognostic factors in Buprenorphine- versus methadone-maintained patients. *The Journal of nervous and mental disease* 1998; 186:35-43
817. Schottenfeld RS, Pakes J, O'Connor P, Chawarski M, Oliveto A, Kosten TR. Thrice-weekly versus daily buprenorphine maintenance. *Biol Psychiatry* 2000; 47(12):1072-9
818. Schottenfeld RS, Chawarski MC, Fiellin D. Abstinence achievement during opioid maintenance treatment: when to shift gears? Sixty Eight Annual Scientific Meeting of the College on Problems of Drug Dependence 2005;
819. Schug SA, Zech D, Grond S. Adverse effects of systemic opioid analgesics. *Drug Saf* 1992; 7(3):200-13
820. Schurks M, Overlack M, Bonnet U. Naltrexone treatment of combined alcohol and opioid dependence: deterioration of co-morbid major depression. *Pharmacopsychiatry* 2005; 38(2):100-2
821. Schuster CR. History and current perspectives on the use of drug formulations to decrease the abuse of prescription drugs. *Drug Alcohol Depend* 2006; 83 Suppl 1:S8-S14
822. Schwartz RP, Brooner RK, Montoya ID, Currens M, Hayes M. A 12-year follow-up of a methadone medical maintenance program. *Am J Addict* 1999; 8(4):293-9
823. Schwartz RP, Highfield DA, Jaffe JH, Brady JV, Butler CB, Rouse CO, Callaman JM, O'Grady KE, Battjes RJ. A randomized controlled trial of interim methadone maintenance. *Arch Gen Psychiatry* 2006; 63(1):102-9
824. Schwarzer A, Nauck F, Klaschik E. Stark wirksame Opioidanalgetika und Obstipation. [Strong opioids and constipation]. *Schmerz* 2005; 19(3):214-9
825. Scimeca MM, Savage SR, Portenoy R, Lowinson J. Treatment of pain in methadone-maintained patients. *Mt Sinai J Med* 2000; 67(5-6):412-22
826. Sees KL, Delucchi KL, Masson C, Rosen A, Clark HW, Robillard H, Banys P, Hall SM. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. *JAMA* 2000; 283(10):1303-10
827. Seifert J, Metzner C, Paetzold W, Borsutzky M, Passie T, Rollnik J, Wiese B, Emrich HM, Schneider U. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone. *Pharmacopsychiatry* 2002; 35:159-64
828. Seifert J, Metzner C, Paetzold W, Borsutzky M, Ohlmeier M, Passie T, Hauser U, Becker H, Wiese B, Emrich H, Schneider U. Mood and affect during detoxification of opiate addicts: a comparison of buprenorphine versus methadone. *Addict Biol* 2005; 10(2):157-64
829. Seivewright N, Fiellin DA. Community treatment of drug misuse: more than methadone. *Addiction* 2001; 96(2):342-3
830. Seivewright N, Iqbal MZ. Prescribing to drug misusers in practice—often effective, but rarely straightforward. *Addict Biol* 2002; 7(3):269-77
831. Seivewright N. Methadone treatment outcomes appear mainly unaffected by cannabis use. *Addiction* 2003; 98(3):251-2
832. Sell L, Farrell M, Robson P. Prescription of diamorphine, dipipanone and cocaine in England and Wales. *Drug Alcohol Rev* 1997; 16(3):221-6
833. Sell L, Zador D. Patients prescribed injectable heroin or methadone - their opinions and experiences of treatment. *Addiction* 2004; 99(4):442-9

834. Settertobulte W. Gesundheitliche Lage und Risikoverhalten bei Jugendlichen aus Migrantenfamilien. In: Marschalck P, Wiedl KH, editors. Migration und Krankheit. Osnabrück: Universitätsverlag Rasch; 2001. p. 171-88.
835. Seymour A, Black M, Jay J, Cooper G, Weir C, Oliver J. The role of methadone in drug-related deaths in the west of Scotland. *Addiction* 2003; 98(7):995-1002
836. Shah N, Lathrop SL, Landen MG. Unintentional methadone-related overdose death in New Mexico (USA) and implications for surveillance, 1998-2002. *Addiction* 2005; 100(2):176-88
837. Shanahan MD, Doran CM, Digiusto E, Bell J, Lintzeris N, White J, Ali R, Saunders JB, Mattick RP, Gilmour S. A cost-effectiveness analysis of heroin detoxification methods in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). *Addict Behav* 2006; 31(3):371-87
838. Sheerin IG, Green FT, Sellman JD. What is the cost-effectiveness of hepatitis C treatment for injecting drug users on methadone maintenance in New Zealand? *Drug Alcohol Rev* 2004; 23(3):261-72
839. Shelton MJ, Cloen D, DiFrancesco R, Berenson CS, Esch A, de Caprariis PJ, Palic B, Schur JL, Bugge CJ, Ljungqvist A, Espinosa O, Hewitt RG. The effects of once-daily saquinavir/minidose ritonavir on the pharmacokinetics of methadone. *J Clin Pharmacol* 2004; 44(3):293-304
840. Sheridan J, Wheeler A, Walters C. Health problems and help-seeking activities of methadone maintenance clients at Auckland Methadone Service (AMS): potential for community pharmacy service expansion? *Harm Reduct J* 2005; 2:25
841. Shoptaw S, Rotheram-Fuller E, Yang X, Frosch D, Nahom D, Jarvik ME, Rawson RA, Ling W. Smoking cessation in methadone maintenance. *Addiction* 2002; 97(10):1317-28
842. Silverman K, Higgins ST, Brooner RK, Montoya ID, Cone EJ, Schuster CR, Preston KL. Sustained cocaine abstinence in methadone maintenance patients through voucher-based reinforcement therapy. *Arch Gen Psychiatry* 1996; 53(5):409-15
843. Silverman K, Robles E, Mudric T, Bigelow GE, Stitzer ML. A randomized trial of long-term reinforcement of cocaine abstinence in methadone-maintained patients who inject drugs. *Journal-of-consulting-and-clinical-psychology* 2004; 72(5):839-54
844. Simoens S, Matheson C, Bond C, Inkster K, Ludbrook A. The effectiveness of community maintenance with methadone or buprenorphine for treating opiate dependence. *Br J Gen Pract* 2005; 55(511):139-46
845. Simpson DD, Joe GW, Greener JM, Rowan-Szal GA. Modeling year 1 outcomes with treatment process and post-treatment social influences. *Subst Use Misuse* 2000; 35(12-14):1911-30
846. Singhal A, Tripathi BM, Pal HR, Jena R, Jain R. Subjective effects of additional doses of buprenorphine in patients on buprenorphine maintenance. *Addict Behav* 2006;
847. Skjervold B, Bathen J, Spigset O. Methadone and the QT Interval: Relations to the Serum Concentrations of Methadone and Its Enantiomers (R)-Methadone and (S)-Methadone. *J Clin Psychopharmacol* 2006; 26(6):687-9
848. Skogstad M, Pettersen RB. [Maintenance treatment with methadone--an alternative]. *Tidsskr Nor Laegeforen* 1991; 111(25):3094-5
849. Smit C, Lindenburg K, Geskus RB, Brinkman K, Coutinho RA, Prins M. Highly active antiretroviral therapy (HAART) among HIV-infected drug users: a prospective cohort study of sexual risk and injecting behaviour. *Addiction* 2006; 101(3):433-40

850. Smith DE, Moser C, Wesson DR, Apter M, Buxton ME, Davison JV, Orgel M, Buffum J. A clinical guide to the diagnosis and treatment of heroin-related sexual dysfunction. *J Psychoactive Drugs* 1982; 14(1-2):91-9
851. Smith MT. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. *Clin Exp Pharmacol Physiol* 2000; 27(7):524-8
852. Smith PF, Kearney BP, Liaw S, Cloen D, Bullock JM, Haas CE, Yale K, Booker BM, Berenson CS, Coakley DF, Flaherty JF. Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R-, and S-methadone. *Pharmacotherapy* 2004; 24(8):970-7
853. Soares BGO, Lima MS, Lima RA, Farrell M. Dopamine agonists for cocaine dependence. Soares BGO, Lima MS, Lima Reisser A, Farrell M Dopamine agonists for cocaine dependence *The Cochrane Database of Systematic Reviews : Reviews* 2003 Issue 2 John Wiley & Sons, Ltd Chichester, UK DOI : 10.1002/14651858.CD003352.2003;
854. Sobel BF, Sigmon SC, Walsh SL, Johnson RE, Liebson IA, Nuwayser ES, Kerrigan JH, Bigelow GE. Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification. *Drug Alcohol Depend* 2004; 73(1):11-22
855. Sorensen JL, Haug NA, Delucchi KL, Gruber V, Kletter E, Batki SL, Tulskey JP, Barnett P, Hall S. Voucher reinforcement improves medication adherence in HIV-positive methadone patients: A randomized trial. *Drug Alcohol Depend* 2006;
856. Soriano V, Miro JM, Garcia-Samaniego J, Torre-Cisneros J, Nunez M, del RJ, Martin-Carbonero L, Castilla J, Iribarren JA, Quereda C, Santin M, Gonzalez J, Arribas JR, Santos I, Hernandez-Quero J, Ortega E, Asensi V, del Pozo MA, Berenguer J, Tural C, Clotet B, Leal M, Mallolas J, Sanchez-Tapias JM, Moreno S, Gatell JM, Tellez MJ, Rubio R, Ledesma E, Domingo P, Barreiro P, Pedreira J, Romero M, Gonzalez-Lahoz J, Lissen E. Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations. *J Viral Hepat* 2004; 11(1):2-17
857. Soyka M, Hock B, Kagerer S, Lehnert R, Limmer C, Kuefner H. Less impairment on one portion of a driving-relevant psychomotor battery in buprenorphine-maintained than in methadone-maintained patients: results of a randomized clinical trial. *J Clin Psychopharmacol* 2005; 25(5):490-3
858. Soyka M, Penning R, Wittchen U. Fatal poisoning in methadone and buprenorphine treated patients – are there differences? *Pharmacopsychiatry* 2006; 39(3):85-7
859. Soyka M, Apelt SM, Lieb M, Wittchen HU. One-year Mortality Rates of Patients Receiving Methadone and Buprenorphine Maintenance Therapy: A Nationally Representative Cohort Study in 2694 Patients. *J Clin Psychopharmacol* 2006; 26(6):657-60
860. Specka M, Finkbeiner T, Lodemann E, Leifert K, Kluwig J, Gastpar M. Cognitive-motor performance of methadone-maintained patients. *Eur Addict Res* 2000; 6(1):8-19
861. Speed S, Janikiewicz SM. A comparison of levels of satisfaction of stable drug users treated in general practice and an outpatient (community based) drug treatment service. *Health Soc Care Community* 2000; 8(6):436-42
862. Spencer JD, Latt N, Beeby PJ, Collins E, Saunders JB, McCaughan GW, Cossart YE. Transmission of hepatitis C virus to infants of human immunodeficiency virus-negative intravenous drug-using mothers: rate of infection and assessment of risk factors for transmission. *J Viral Hepat* 1997; 4(6):395-409
863. Srivastava A, Kahan M. Methadone induction doses: are our current practices safe? *J Addict Dis* 2006; 25(3):5-13

864. Staedt J, Wassmuth F, Stoppe G, Hajak G, Rodenbeck A, Poser W, Ruther E. Effects of chronic treatment with methadone and naltrexone on sleep in addicts. *Eur Arch Psychiatry Clin Neurosci* 1996; 246(6):305-9
865. Stallard P, Thomason J, Churchyard S. The mental health of young people attending a Youth Offending Team: a descriptive study. *J Adolesc* 2003; 26(1):33-43
866. Stancliff S, Myers JE, Steiner S, Drucker E. Beliefs about methadone in an inner-city methadone clinic. *J Urban Health* 2002; 79(4):571-8
867. Steffen T, Blattler R, Gutzwiller F, Zwahlen M. HIV and hepatitis virus infections among injecting drug users in a medically controlled heroin prescription programme. *Eur J Public Health* 2001; 11(4):425-30
868. Stein MD, Maksad J, Clarke J. Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. *Drug Alcohol Depend* 2001; 61(3):211-5
869. Stein MD, Herman DS, Bishop S, Lassar JA, Weinstock M, Anthony J, Anderson BJ. Sleep disturbances among methadone maintained patients. *J Subst Abuse Treat* 2004; 26(3):175-80
870. Stewart D, Gossop M, Marsden J, Strang J. Variation between and within drug treatment modalities: data from the National Treatment Outcome Research Study (UK). *Eur Addict Res* 2000; 6(3):106-14
871. Sticherling C, Schaer BA, Ammann P, Maeder M, Osswald S. Methadone-induced Torsade de pointes tachycardias. *Swiss Med Wkly* 2005; 135(19-20):282-5
872. Stimmel B. Methadone and affairs of the heart and of the brain. *J Addict Dis* 2003; 22(3):1-5
873. Stitzer ML, Iguchi MY, Felch LJ. Contingent take-home incentive: effects on drug use of methadone maintenance patients. *J Consult Clin Psychol* 1992; 60(6):927-34
874. Stock C, Shum JH. Bupreorphine: a new pharmacotherapy for opioid addictions treatment. *J Pain Palliat Care Pharmacother* 2004; 18(3):35-54
875. Stocker H, Kruse G, Kreckel P, Herzmann C, Arasteh K, Claus J, Jessen H, Cordes C, Hintsche B, Schlote F, Schneider L, Kurowski M. Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients. *Antimicrob Agents Chemother* 2004; 48(11):4148-53
876. Stohler R, Nordt C, Falcato L, Dürsteler-MacFarland KM, Rössler W. Wie effektiv sind Methadonbehandlungen in Privatpraxen? [Is methadone maintenance provided by private practitioners effective?]. *Soz Präventivmed* 2004; 49(4):276-80
877. Stone E, Fletcher K. User views on supervised methadone consumption. *Addict Biol* 2003; 8(1):45-8
878. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. *Hepatology* 2004; 39(4):1147-71
879. Strain EC, Preston KL, Liebson IA, Bigelow GE. Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers. *J Pharmacol Exp Ther* 1992; 261(3):985-93
880. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Comparison of buprenorphine and methadone in the treatment of opioid dependence. *Am J Psychiatry* 1994; 151(7):1025-30
881. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users. *Psychopharmacology (Berl)* 1994; 116(4):401-6

882. Strain EC, Bigelow GE, Liebson IA, Stitzer ML. Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. *JAMA : the journal of the American Medical Association* 1999; 281:1000-5
883. Strang J, Sheridan J. Methadone prescribing to opiate addicts by private doctors: comparison with NHS practice in south east England. *Addiction* 2001; 96(4):567-76
884. Strang J, Sheridan J, Hunt C, Kerr B, Gerada C, Pringle M. The prescribing of methadone and other opioids to addicts: national survey of GPs in England and Wales. *Br J Gen Pract* 2005; 55(515):444-51
885. Strauss SM, Astone JM, Des J, Hagan H. Integrating hepatitis C services into existing HIV services: the experiences of a sample of U.S. drug treatment units. *AIDS Patient Care STDS* 2005; 19(2):78-88
886. Strike CJ, Urbanoski K, Fischer B, Marsh DC, Millson M. Policy changes and the methadone maintenance treatment system for opioid dependence in Ontario, 1996 to 2001. *J Addict Dis* 2005; 24(1):39-51
887. Sulkowski M, Wright T, Rossi S, Arora S, Lamb M, Wang K, Gries JM, Yalamanchili S. Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. *Clin Pharmacol Ther* 2005; 77(3):214-24
888. Sullivan LE, Tetrault J, Bangalore D, Fiellin DA. Training HIV Physicians to Prescribe Buprenorphine for Opioid Dependence. *Subst Abus* 2006; 27(3):13-8
889. Sullivan LE, Barry D, Moore BA, Chawarski MC, Tetrault JM, Pantaloni MV, O'Connor PG, Schottenfeld RS, Fiellin DA. A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care. *Clin Infect Dis* 2006; 43 Suppl 4:S184-S190
890. Sullivan LE, Bruce RD, Haltiwanger D, Lucas GM, Eldred L, Finkelstein R, Fiellin DA. Initial Strategies for Integrating Buprenorphine into HIV Care Settings in the United States. *Clin Infect Dis* 2006; 43 Suppl 4:S191-S196
891. Suzuki S, Carlos MP, Chuang LF, Torres JV, Doi RH, Chuang RY. Methadone induces CCR5 and promotes AIDS virus infection. *FEBS Lett* 2002; 519(1-3):173-7
892. Sylvestre DL. Treating hepatitis C in methadone maintenance patients: an interim analysis. *Drug Alcohol Depend* 2002; 67(2):117-23
893. Sylvestre DL, Litwin AH, Clements BJ, Gourevitch MN. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. *J Subst Abuse Treat* 2005; 29(3):159-65
894. Takehana H, Izumi T. [Alcoholic heart disease]. *Nippon Rinsho* 2000; 58(1):151-6
895. Tamargo J. Drug-induced torsade de pointes: from molecular biology to bedside. *Jpn J Pharmacol* 2000; 83(1):1-19
896. Tegeder I, Geisslinger G, Lötsch J. Einsatz von Opioiden bei Leber- oder Niereninsuffizienz [Therapy with opioids in liver or renal failure]. *Schmerz* 1999; 13(3):183-95
897. Teichtahl H, Wang D, Cunningham D, Quinnell T, Tran H, Kronborg I, Drummer OH. Ventilatory responses to hypoxia and hypercapnia in stable methadone maintenance treatment patients. *Chest* 2005; 128(3):1339-47
898. Teplin D, Raz B, Daiter J, Varenbut M, Plater-Zyberk C. Screening for alcohol use patterns among methadone maintenance patients. *Am J Drug Alcohol Abuse* 2007; 33(1):179-83

899. Termorshuizen F, Krol A, Prins M, Geskus R, Van den BW, van Ameijden EJ. Prediction of relapse to frequent heroin use and the role of methadone prescription: an analysis of the Amsterdam Cohort Study among drug users. *Drug Alcohol Depend* 2005; 79(2):231-40
900. Theis JG, Selby P, Ikizler Y, Koren G. Current management of the neonatal abstinence syndrome: a critical analysis of the evidence (Structured abstract). *Biology of the Neonate* 1997; 71:345-56
901. Thomas BL. Letter: Methadone-associated gynecomastia. *N Engl J Med* 1976; 294(3):169
902. Threlkeld M, Parran TV, Adelman CA, Grey SF, Yu J. Tramadol versus Buprenorphine for the Management of Acute Heroin Withdrawal: A Retrospective Matched Cohort Controlled Study. *Am J Addict* 2006; 15(2):186-91
903. Tilson HA, Rech RH, Stolman S. Hyperalgesia during withdrawal as a means of measuring the degree of dependence in morphine dependent rats. *Psychopharmacologia* 1973; 28(3):287-300
904. Tomasino V, Swanson AJ, Nolan J, Shuman HI. The Key Extended Entry Program (KEEP): a methadone treatment program for opiate-dependent inmates. *Mt Sinai J Med* 2001; 68(1):14-20
905. Torrens M, San L, Martinez A, Castillo C, Domingo-Salvany A, Alonso J. Use of the Nottingham Health Profile for measuring health status of patients in methadone maintenance treatment. *Addiction* 1997; 92(6):707-16
906. Torrens M, Domingo-Salvany A, Alonso J, Castillo C, San L. Methadone and quality of life. *Lancet* 1999; 353(9158):1101
907. Torrens M, Fonseca F, Mateu G, Farre M. Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis. *Drug Alcohol Depend* 2005; 78(1):1-22
908. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H, Jr., Passet S, De PJ, Duff F, Schrenk UM, Dieterich DT. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. *N Engl J Med* 2004; 351(5):438-50
909. Tossonian HK, Raffa JD, Grebely J, Trotter B, Viljoen M, Mead A, Khara M, McLean M, Duncan F, Fraser C, Devlaming S, Conway B. Methadone Dosing Strategies in HIV-Infected Injection Drug Users Enrolled in a Directly Observed Therapy Program. *J Acquir Immune Defic Syndr* 2007;
910. Tracqui A, Tournoud C, Flesch F, Kopferschmitt J, Kintz P, Deveaux M, Ghysel MH, Marquet P, Pepin G, Petit G, Jaeger A, Ludes B. Intoxications aiguës par traitement. 29 observations cliniques - 20 cas mortels [Acute poisoning during substitution therapy based on high-dosage buprenorphine. 29 clinical cases - 20 fatal cases]. *Presse Med* 1998; 27(12):557-61
911. Tzschentke TM. Behavioral pharmacology of buprenorphine, with a focus on preclinical models of reward and addiction. *Psychopharmacology (Berl)* 2002; 161(1):1-16
912. Tzschentke TM. Reassessment of buprenorphine in conditioned place preference: temporal and pharmacological considerations. *Psychopharmacology (Berl)* 2004; 172(1):58-67
913. Uchtenhagen A, Ladjovic T, Rehm J. WHO Guidelines for psychosocially assisted pharmacological treatment of persons dependent on opioids. Research Institute for Public Health and Addiction at Zurich University; Centre for Addiction and Mental Health Toronto; 2005.
914. Uehlinger C, Deglon J, Livoti S, Petitjean S, Waldvogel D, Ladewig D. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Swiss multicentre study. *Eur Addict Res* 1998; 4 Suppl 1:13-8

915. Uehlinger C, Crettol S, Chassot P, Brocard M, Koeb L, Brawand-Amey M, Eap CB. Increased (R)-Methadone Plasma Concentrations by Quetiapine in Cytochrome P450s and ABCB1 Genotyped Patients. *J Clin Psychopharmacol* 2007; 27(3):273-8
916. Umbricht A, Huestis MA, Cone EJ, Preston KL. Effects of high-dose intravenous buprenorphine in experienced opioid abusers. *J Clin Psychopharmacol* 2004; 24(5):479-87
917. Umehara K, Shimokawa Y, Miyamoto G. Inhibition of human drug metabolizing cytochrome P450 by buprenorphine. *Biol Pharm Bull* 2002; 25(5):682-5
918. Unglaub W, Loncarek E, Wismath M, Johann M, Wodarz N, Klein H. Ergebnisse der Substitutionsbehandlung in einer psychiatrischen Klinikambulanz [Outcome of a substitution therapy program in an outpatient treatment setting of a psychiatric hospital]. *Psychiatr Prax* 2004; 31(Suppl1):S26-S28
919. Vader JP, Hämmig R, Besson J, Eastus C, Eggenberger C, Burnand B. Angemessenheit der Methadon-Substitutionsbehandlung bei Opiatabhängigkeit.: Bundesamt für Gesundheit; 2001.
920. Vader JP, Hämmig R, Besson J, Eastus C, Eggenberger C, Burnand B. Appropriateness of methadone maintenance treatment for opiate addiction: evaluation by an expert panel. *Soz Präventivmed* 2003; 48(Suppl1):S1-S14
921. Valenciano M, Emmanuelli J, Lert F. Unsafe injecting practices among attendees of syringe exchange programmes in France. *Addiction* 2001; 96(4):597-606
922. van Ameijden EJ, Langendam MW, Coutinho RA. Dose-effect relationship between overdose mortality and prescribed methadone dosage in low-threshold maintenance programs. *Addict Behav* 1999; 24(4):559-63
923. van Asten L, Zangerle R, Hernandez A, I, Boufassa F, Broers B, Brettle RP, Roy RJ, McMenamin J, Coutinho RA, Prins M. Do HIV disease progression and HAART response vary among injecting drug users in Europe? *Eur J Epidemiol* 2005; 20(9):795-804
924. van Beusekom I, Iguchi MY. A Review of Recent Advances in Knowledge About Methadone Maintenance Treatment. RAND Corporation Europe; 2001.
925. Van den BW, Haasen C. Evidenced-based treatment of opioid-dependent patients. *Can J Psychiatry* 2006; 51(10):635-46
926. Van Der Laan JW, Krajnc EI, Krajnc-Franken MA, Van LH. Immunotoxicological screening of morphine and methadone in an extended 28 day study in rats. *Int J Immunopharmacol* 1995; 17(6):535-43
927. Van Der Laan JW, Timmerman H, Van LH. Comparison of the in vivo effects of morphine and methadone on natural killer cell activity in spleen, peritoneal cavity, and lungs in rats. *Int J Immunopharmacol* 1996; 18(6-7):401-7
928. van Dorp E, Yassen A, Sarton E, Romberg R, Olofsen E, Teppema L, Danhof M, Dahan A. Naloxone reversal of buprenorphine-induced respiratory depression. *Anesthesiology* 2006; 105(1):51-7
929. van Haastrecht HJ, Bax JS, van den Hoek AA. High rates of drug use, but low rates of HIV risk behaviours among injecting drug users during incarceration in Dutch prisons. *Addiction* 1998; 93(9):1417-25
930. van Limbeck J, Wounters L, Kaplan CD, Geerlings PJ, van Alem V. Prevalence of psychopathology in drugaddicted Dutch. *J Subst Abuse Treat* 1992; 9:4352

931. Van Thiel DH, Anantharaju A, Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. *Am J Gastroenterol* 2003; 98(10):2281-8
932. Vasilev GN, Alexieva DZ, Pavlova RZ. Safety and efficacy of oral slow release morphine for maintenance treatment in heroin addicts: a 6-month open noncomparative study. *Eur Addict Res* 2006; 12(2):53-60
933. Vazquez V, Gury C, Laqueille X. Méthadone : de la pharmacocinétique à la pharmacologie clinique. [Methadone: from pharmacokinetic profile to clinical pharmacology]. *Encephale* 2006; 32(4 Pt 1):478-86
934. Ventegodt S, Merrick J. Psychoactive drugs and quality of life. *ScientificWorldJournal* 2003; 3:694-706
935. Verdejo A, Toribio I, Orozco C, Puente KL, Perez-Garcia M. Neuropsychological functioning in methadone maintenance patients versus abstinent heroin abusers. *Drug Alcohol Depend* 2005; 78(3):283-8
936. Verrando R, Robaey G, Mathei C, Buntinx F. Methadone and buprenorphine maintenance therapies for patients with hepatitis C virus infected after intravenous drug use. *Acta Gastroenterol Belg* 2005; 68(1):81-5
937. Verster A, Buning E. Richtlijnen zur Methadonsubstitution. Amsterdam: Euromethworks; 2000.
938. Verthein U, Ullmann R, Lachmann A, Düring A, Koch B, Meyer-Thompson HG, Schmidt R, Reimer J, Haasen C. The effects of racemic D,L-methadone and L-methadone in substituted patients—a randomized controlled study. *Drug Alcohol Depend* 2005; 80(2):267-71
939. Vigezzi P, Guglielmino L, Marzorati P, Silenzio R, De CM, Corrado F, Cocchi L, Cozzolino E. Multimodal drug addiction treatment: a field comparison of methadone and buprenorphine among heroin- and cocaine-dependent patients. *J Subst Abuse Treat* 2006; 31(1):3-7
940. Vignau J, Brunelle E. Differences between general practitioner- and addiction centre-prescribed buprenorphine substitution therapy in France. Preliminary results. *Eur Addict Res* 1998; 4 Suppl 1:24-8
941. Villa A, Foresti V, Confalonieri F. Autonomic neuropathy and prolongation of QT interval in human immunodeficiency virus infection. *Clin Auton Res* 1995; 5(1):48-52
942. Villafranca SW, McKellar JD, Trafton JA, Humphreys K. Predictors of retention in methadone programs: A signal detection analysis. *Drug Alcohol Depend* 2005;
943. Vlahov D, O'Driscoll P, Mehta SH, Ompad DC, Gern R, Galai N, Kirk GD. Risk factors for methadone outside treatment programs: implications for HIV treatment among injection drug users. *Addiction* 2007; 102(5):771-7
944. Vodoz JF, Jaquier F, Lamy O. Torsade de pointe: un effet secondaire grave et méconnu chez le toxicomane sous méthadone [Torsade de Pointe: a serious and unknown adverse effect in a patient taking methadone]. *Schweiz Rundsch Med Prax* 2003; 92(41):1748-50
945. Vormfelde SV, Poser W. Death attributed to methadone. *Pharmacopsychiatry* 2001; 34(6):217-22
946. Waldrop-Valverde D, Ownby RL, Wilkie FL, Mack A, Kumar M, Metsch L. Neurocognitive Aspects of Medication Adherence in HIV-Positive Injecting Drug Users. *AIDS Behav* 2006; .
947. Waldvogel D, Figner B, Eich D. Illicit methadone injecting during methadone maintenance treatment in a specialised out-patient clinic. *Swiss Med Wkly* 2005; 135(43-44):644-6

948. Walker DJ, Zacny JP. Subjective, psychomotor, and analgesic effects of oral codeine and morphine in healthy volunteers. *Psychopharmacology (Berl)* 1998; 140(2):191-201
949. Walker DJ, Zacny JP. Subjective, psychomotor, and physiological effects of cumulative doses of opioid mu agonists in healthy volunteers. *J Pharmacol Exp Ther* 1999; 289(3):1454-64
950. Walker DJ, Zacny JP, Galva KE, Lichtor JL. Subjective, psychomotor, and physiological effects of cumulative doses of mixed-action opioids in healthy volunteers. *Psychopharmacology (Berl)* 2001; 155(4):362-71
951. Wall TL, Sorensen JL, Batki SL, Delucchi KL, London JA, Chesney MA. Adherence to zidovudine (AZT) among HIV-infected methadone patients: a pilot study of supervised therapy and dispensing compared to usual care. *Drug Alcohol Depend* 1995; 37(3):261-9
952. Wallen MC, Lorman WJ, Gosciniak JL. Combined buprenorphine and clonidine for short-term opiate detoxification: patient perspectives. *J Addict Dis* 2006; 25(1):23-31
953. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. *Clin Pharmacol Ther* 1994; 55(5):569-80
954. Walsh SL, June HL, Schuh KJ, Preston KL, Bigelow GE, Stitzer ML. Effects of buprenorphine and methadone in methadone-maintained subjects. *Psychopharmacology (Berl)* 1995; 119(3):268-76
955. Walsh SL, Preston KL, Bigelow GE, Stitzer ML. Acute administration of buprenorphine in humans: partial agonist and blockade effects. *J Pharmacol Exp Ther* 1995; 274(1):361-72
956. Walsh SL, Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. *Drug Alcohol Depend* 2003; 70(2 Suppl):S13-S27
957. Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL. Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb1a gene knockout mice. *Psychopharmacology (Berl)* 2004; 173(1-2):132-8
958. Ward J, Mattick RP, Hall W, Darke S. The effectiveness and safety of methadone maintenance. *Addiction* 1996; 91(11):1727-9
959. Ward J, Mattick RP, Hall W. *Methadone Maintenance Treatment and Other Opioid Replacement Therapies*. Amsterdam: Harwood Academic Publishers; 1998.
960. Warren E, Viney R, Shearer J, Shanahan M, Wodak A, Dolan K. Value for money in drug treatment: economic evaluation of prison methadone. *Drug Alcohol Depend* 2006;
961. Weatherburn D, Lind B. The impact of law enforcement activity on a heroin market. *Addiction* 1997; 92(5):557-69
962. Weatherburn D, Lind B. Street-level drug law enforcement and entry into methadone maintenance treatment. *Addiction* 2001; 96(4):577-87
963. Weber JC, Kopferschmitt J. Les traitements de substitution chez le toxicomane [Substitution therapy of drug addicts]. *Presse Med* 1998; 27(39):2088-99
964. Weig W. Migration und seelische Gesundheit. *IMIS-Beiträge* 1998; (8):31-44
965. Weinberg DS, Inturrisi CE, Reidenberg B, Moulin DE, Nip TJ, Wallenstein S, Houde RW, Foley KM. Sublingual absorption of selected opioid analgesics. *Clin Pharmacol Ther* 1988; 44(3):335-42
966. Weinstein SP, Gottheil E, Sterling RC, DeMaria PA, Jr. Long-term methadone maintenance treatment: some clinical examples. *J Subst Abuse Treat* 1993; 10(3):277-81

967. Wells R, Lemak CH, D'Aunno TA. Factors associated with interorganizational relationships among outpatient drug treatment organizations 1990-2000. *Health Serv Res* 2005; 40(5 Pt 1):1356-78
968. Welp EAE, Bosman I, Langendam MW, Totte M, Maes RAA, Ameijden EJC. Amount of self-reported illicit drug use compared to quantitative hair test results in community-recruited young drug users in Amsterdam. *Addiction* 2003; 98(7):987-94
969. Wesson DR. Buprenorphine in the treatment of opiate dependence: its pharmacology and social context of use in the U.S. *J Psychoactive Drugs* 2004; Suppl 2:119-28
970. Westermeyer J, Berger LJ. "World Traveler" addicts in Asia: I. Demographic and clinical description. *Am J Drug Alcohol Abuse* 1977; 4(4):479-93
971. White JM, Danz C, Kneebone J, La Vincente SF, Newcombe DA, Ali RL. Relationship between LAAM-methadone preference and treatment outcomes. *Drug Alcohol Depend* 2002; 66(3):295-301
972. White JM. Pleasure into pain: the consequences of long-term opioid use. *Addict Behav* 2004; 29(7):1311-24
973. Wichers MC, Koek GH, Robaey G, Praamstra AJ, Maes M. Early increase in vegetative symptoms predicts IFN-alpha-induced cognitive-depressive changes. *Psychol Med* 2005; 35(3):433-41
974. Wilczek H, Stepan J. [Bone metabolism in individuals dependent on heroin and after methadone administration]. *Cas Lek Cesk* 2003; 142(10):606-8
975. Wilkerson D, Migas N, Slaven T. Outcome-oriented standards and performance indicators for substance dependency rehabilitation programs. *Subst Use Misuse* 2000; 35(12-14):1679-703
976. Winslow M, Ng WL, Mythily S, Song G, Yiong HC. Socio-demographic profile and help-seeking behaviour of buprenorphine abusers in singapore. *Ann Acad Med Singapore* 2006; 35(7):451-6
977. Wittchen HU, Perkonigg A, Reed V. Comorbidity of Mental Disorders and Substance Use Disorders. *Eur Addict Res* 1996; 2:36-47
978. Wittchen HU, Apelt SM, Buhringer G, Gastpar M, Backmund M, Golz J, Kraus MR, Tretter F, Klotsche J, Siegert J, Pittrow D, Soyka M. Buprenorphine and methadone in the treatment of opioid dependence: methods and design of the COBRA study. *Int J Methods Psychiatr Res* 2005; 14(1):14-28
979. Wojnar-Horton RE, Kristensen JH, Yapp P, Ilett KF, Dusci LJ, Hackett LP. Methadone distribution and excretion into breast milk of clients in a methadone maintenance programme. *Br J Clin Pharmacol* 1997; 44(6):543-7
980. Wolff K, Rostami-Hodjegan A, Hay AWM, Raistrick D, Tucker G. Population-based pharmacokinetic approach for methadone monitoring of opiate addicts: potential clinical utility. *Addiction* 2000; 95(12):1771-83
981. Wolff K, Boys A, Rostami-Hodjegan A, Hay A, Raistrick D. Changes to methadone clearance during pregnancy. *Eur J Clin Pharmacol* 2005; 61(10):763-8
982. Wong SH, Wagner MA, Jentzen JM, Schur C, Bjerke J, Gock SB, Chang CC. Pharmacogenomics as an aspect of molecular autopsy for forensic pathology/toxicology: does genotyping CYP 2D6 serve as an adjunct for certifying methadone toxicity? *J Forensic Sci* 2003; 48(6):1406-15
983. Woulde TA, Roberts AB, Pryor JE, Bagnall C, Gunn TR. The effect of methadone treatment on the quantity and quality of human fetal movement. *Neurotoxicol Teratol* 2004; 26(1):23-34

984. Wu E, El-Bassel N, Gilbert L, Piff J, Sanders G. Sociodemographic disparities in supplemental service utilization among male methadone patients. *J Subst Abuse Treat* 2004; 26(3):197-202
985. Yaffe GJ, Strelinger RW, Parwatikar S. Physical symptom complaints of patients on methadone maintenance. *Proc Natl Conf Methadone Treat* 1973; 1:507-14
986. Yassen A, Olofsen E, Romberg R, Sarton E, Danhof M, Dahan A. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers. *Anesthesiology* 2006; 104(6):1232-42
987. Yeo AK, Chan CY, Chia KH. Complications relating to intravenous buprenorphine abuse: a single institution case series. *Ann Acad Med Singapore* 2006; 35(7):487-91
988. Yuan CS, Foss JF, O'Connor M, Moss J, Roizen MF. Gut motility and transit changes in patients receiving long-term methadone maintenance. *J Clin Pharmacol* 1998; 38(10):931-5
989. Yuan CS, Foss JF, O'Connor M, Osinski J, Karrison T, Moss J, Roizen MF. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. *JAMA* 2000; 283(3):367-72
990. Yuan CS, Foss JF, O'Connor M, Osinski J, Karrison T, Moss J, Roizen MF. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. *JAMA : the journal of the American Medical Association* 2000; 283:367-72
991. Zacny JP, Lichtor JL, Thapar P, Coalson DW, Flemming D, Thompson WK. Comparing the subjective, psychomotor and physiological effects of intravenous butorphanol and morphine in healthy volunteers. *J Pharmacol Exp Ther* 1994; 270(2):579-88
992. Zacny JP, Lichtor JL, Flemming D, Coalson DW, Thompson WK. A dose-response analysis of the subjective, psychomotor and physiological effects of intravenous morphine in healthy volunteers. *J Pharmacol Exp Ther* 1994; 268(1):1-9
993. Zacny JP, Conley K, Marks S. Comparing the subjective, psychomotor and physiological effects of intravenous nalbuphine and morphine in healthy volunteers. *J Pharmacol Exp Ther* 1997; 280(3):1159-69
994. Zacny JP, Hill JL, Black ML, Sadeghi P. Comparing the subjective, psychomotor and physiological effects of intravenous pentazocine and morphine in normal volunteers. *J Pharmacol Exp Ther* 1998; 286(3):1197-207
995. Zacny JP. Morphine responses in humans: a retrospective analysis of sex differences. *Drug Alcohol Depend* 2001; 63(1):23-8
996. Zacny JP. Characterizing the subjective, psychomotor, and physiological effects of a hydrocodone combination product (Hycodan) in non-drug-abusing volunteers. *Psychopharmacology (Berl)* 2003; 165(2):146-56
997. Zacny JP, Gutierrez S. Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-drug-abusing volunteers. *Psychopharmacology (Berl)* 2003; 170(3):242-54
998. Zacny JP. Profiling the subjective, psychomotor, and physiological effects of tramadol in recreational drug users. *Drug Alcohol Depend* 2005; 80(2):273-8
999. Zador D, Sunjic S. Deaths in methadone maintenance treatment in New South Wales, Australia 1990-1995. *Addiction* 2000; 95(1):77-84
1000. Zador D. Injectable opiate maintenance in the UK: Is it good clinical practice? *Addiction* 2001; 96(4):547-53

1001. Zador DA, Sunjic SD. Methadone-related deaths and mortality rate during induction into methadone maintenance, New South Wales, 1996. *Drug Alcohol Rev* 2002; 21(2):131-6
1002. Zajicova A, Wilczek H, Holan V. The alterations of immunological reactivity in heroin addicts and their normalization in patients maintained on methadone. *Folia Biol (Praha)* 2004; 50(1):24-8
1003. Zanis DA, McLellan AT, Belding MA, Moyer G. A comparison of three methods of measuring the type and quantity of services provided during substance abuse treatment. *Drug Alcohol Depend* 1997; 49(1):25-32
1004. Zaric GS, Barnett PG, Brandeau ML. HIV transmission and the cost-effectiveness of methadone maintenance. *Am J Public Health* 2000; 90(7):1100-11
1005. Zarkin GA, Dunlap LJ. Implications of managed care for methadone treatment. Findings from five case studies in New York State. *J Subst Abuse Treat* 1999; 17(1-2):25-35
1006. Zeldman A, Ryan RM, Fiscella K. Motivation, autonomy support, and entity beliefs: their role in methadone maintenance treatment. *Journal-of-social-and-clinical-psychology* 2004; 23(5):675-96
1007. Zentralvorstand FMH. Guideline für Guidelines. SAEZ 1999; 80(9):581-5
http://www.fmh.ch/d/31/obj_794/Guidelines99.htm
1008. Zhang W, Ramamoorthy Y, Tyndale RF, Sellers EM. Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. *Drug Metab Dispos* 2003; 31(6):768-72
1009. Zhang Z, Friedmann PD, Gerstein DR. Does retention matter? Treatment duration and improvement in drug use. *Addiction* 2003; 98(5):673-84
1010. Zharikova OL, Deshmukh SV, Kumar M, Vargas R, Nanovskaya TN, Hankins GD, Ahmed MS. The effect of opiates on the activity of human placental aromatase/CYP19. *Biochem Pharmacol* 2006;
1011. Zimmer-Hofler D, Dobler-Mikola A. Swiss heroin-addicted females. Career and social adjustment. *J Subst Abuse Treat* 1992; 9(2):159-70
1012. Zimmermann C, Seccareccia D, Booth CM, Cottrell W. Rotation to methadone after opioid dose escalation: How should individualization of dosing occur? *J Pain Palliat Care Pharmacother* 2005; 19(2):25-31
1013. Zylberberg H, Fontaine H, Correias JM, Carnot F, Brechot C, Pol S. Dilated bile duct in patients receiving narcotic substitution: an early report. *J Clin Gastroenterol* 2000; 31(2):159-61